ࡱ>  beYZ[\]^_`a bjbj ;$k 1<<vIdIH"J"J"J6J6J6J8nJ$Q6J`z>W"`]^___hC[L _______$\dgZ`"JO__OO`"J"J__`OF"J_"J__DO__Q%uFIJ_`0`JhghgHhg"J%"`=OOOOOOO``OOO`OOOOhgOOOOOOOOO< "Error*" DOCPROPERTY "DM_emea_doc_ref_id" \* MERGEFORMAT EMA/164014/2018 \* MERGEFORMAT EMA/164014/2018 Rev.2.0.1 accompanying GVP Module V Rev.2 Human Medicines Evaluation Guidance on the format of the risk management plan (RMP) in the EU in integrated format General consideration and guidance This guidance should be read in conjunction with GVP module V. According to GVP module V, the aim of a risk management plan (RMP) is to document the risk management system considered necessary to identify, characterise and minimise the important risks of a medicinal product. To this end, the RMP contains: the identification or characterisation of the safety profile of the medicinal product, with emphasis on important identified and important potential risks and missing information, and also on which safety concerns need to be managed proactively or further studied (the safety specification); the planning of pharmacovigilance activities to characterise and quantify clinically relevant risks and to identify new adverse reactions (the pharmacovigilance plan); the planning and implementation of risk minimisation measures, including the evaluation of the effectiveness of these activities (the risk minimisation plan). Throughout this document, please be as concise as possible and ensure the content is scientifically based and that it does not include any element of a promotional nature. Consider which information will add value to the readers understanding of the safety profile of the medicinal product and how best to interpret and manage the important identified and potential risks as well as the uncertainties surrounding the information available. Please focus the document accordingly. Tabulation of any data is encouraged if it aids the presentation. The applicant/marketing authorisation holder should include links or references to the relevant part of the eCTD dossier of the supporting documents or PSURs, when applicable. Throughout the RMP template, eCTD data/submissions should be read as eCTD or CTD data/submission, corresponding to the type of submission to the competent authority. Specific requirements for different types of initial marketing authorisation applications are described within each section of the template. The examples provided in each Module/Section represent only guidance for writing the RMP and should not be regarded as directions in a defined scenario. Each RMP should be based on the safety data of the medicinal product. Checklist for writing or assessing an RMP The following general points need to be considered when writing or reviewing an RMP for a medicinal product. The checklist is meant to provide further guidance and is not part of the RMP; therefore, it should not be included in the documents submitted for assessment: Part II: Safety specification Have all appropriate parts of the safety specification been included? Have all appropriate data been reviewed when compiling the safety specification, e.g. are there important (outstanding) issues which have not been discussed in the safety specification? If parts of the target population have not been studied, have appropriate safety concerns in relation to potential risks and missing information been included? Have limitations in the safety database (e.g. related to the size of the study population, study inclusion and exclusion criteria) been considered and what are the implications of such limitations on the safety profile of the medicinal product? Has reference been made to populations likely to be exposed during the intended or expected use of the medicinal product in the medical practice? Does the safety specification provide a true reflection of the safety concerns (e.g. important identified risks, important potential risks and/or missing information) with the medicinal product? For generic or hybrid applications, have all safety concerns from the latest version of the RMP for the reference medicinal product or from a list of safety concerns published on the CMDh website been included in the safety specification? If not, has appropriate justification been provided and has the applicant proposed a list of safety concerns? If no information on the safety profile of the reference medicinal product is available (no RMP or no CMDh list for the substance), has the safety profile been drafted considering all available relevant information (e.g. public assessment documents for the reference medicinal product, literature, applicants own trial data)? Part III: Pharmacovigilance plan Are all safety concerns from the safety specification covered in the pharmacovigilance plan? Are routine pharmacovigilance activities adequate or are additional pharmacovigilance activities necessary? Are the activities in the pharmacovigilance plan clearly defined, described and suitable for identifying or characterising risks or providing missing information? Are the safety studies that have been imposed by a competent authority as conditions clearly identified? If there are safety concerns derived from medication errors, does the RMP include appropriate proposals to monitor the correct use of the product? Are the proposed additional studies necessary, feasible, non-promotional and able to provide the required further characterisation of the risk(s) and address the scientific questions? Are timelines and milestones appropriate and feasible for the proposed actions, including those for the submission of results? Part IV: Plans for post-authorisation efficacy studies Have all post-authorisation safety studies (PAES), either as conditions of the marketing authorisation or as specific obligations, been included? Part V: Risk minimisation measures Are routine risk minimisation measures sufficient or is there a need identified for additional risk minimisation activities? Have additional risk minimisation activities been suggested and, if so, are these sufficiently justified and risk-proportionate? Is implementation feasible in all Member States? Have criteria for effectiveness of additional risk minimisation activities been defined a priori? Are the methods for evaluating the effectiveness of risk minimisation activities well described and appropriate? Part VI: Summary of the risk management plan Is it a true representation of the RMP? Have the facts been presented appropriately without any elements of promotional nature? EU Risk Management Plan for (INN or common name) RMP version to be assessed as part of this application: RMP Version number: An RMP should be assigned a new RMP version number and a date each time the RMP is updated and submitted for assessment (e.g. versions 0.1, 0.2, 0.3 etc. for an initial submission of an RMP; versions 1.1, 1.2, etc. and 2.1, 2.2 etc. for RMP updates post-authorisation). The version number of the RMP version agreed at the time of the competent authority opinion should be the same as the one provided with the last eCTD submission in the procedure (most often with the closing sequence). It is advisable to use major version numbers for final approved RMP versions (e.g. version 1.0 at the end of the initial marketing authorisation application; 2.0, 3.0, etc. for post-authorisation updates). Data lock point for this RMP: It is recommended that the Data Lock Point (DLP) should not be more than 6 months before the RMP sign-off date. For initial marketing authorisation applications it usually reflects the DLP of the Clinical Safety Summary. Date of final sign-off: The date of sign-off is the date when the draft RMP was considered finalised and ready for submission to the regulatory agency. Rationale for submitting an updated RMP: Summary of significant changes in this RMP: This section is applicable for post-authorisation RMP updates when a different RMP version is still under assessment with another procedure. If two or more parallel procedures contain RMP submissions, to facilitate assessment, it is usually advised to submit a common consolidated version of the RMP; the supporting Word version of the RMP included with the submission should include track changes (colour coded for each procedure), so that changes related to each procedure can be easily identified. This will also facilitate the finalisation of the RMP for each procedure. Where the submission of a common, consolidated RMP version is not practical, distinct RMP documents may be submitted with each procedure (Word versions should also include tracked changes, per procedure). For further guidance please refer to European Medicines Agency post-authorisation procedural advice for users of the centralised procedure. The best regulatory path for the RMP update in case of multiple procedures potentially impacting on the RMP content should be discussed with the competent authority before submissions. RMP Version number: Submitted on: Procedure number: ,
This section is not required for initial marketing authorisation applications. There can only be ONE currently approved RMP for a product(s). If several updates to the RMP are submitted during the course of a procedure, the version considered as the current approved RMP for future updates and track-changes purposes shall be the one mentioned in the Opinion documents (most often same version is submitted with the closing sequence of the procedure). Version number: Approved with procedure: Date of approval (opinion date):
QPPV name: The QPPVs actual signature or the evidence that the RMP was reviewed and approved by the QPPV should be included in the finalised approved version of RMP. In the case the option of oversight declaration has been selected and no signature has been submitted, the MAH should have the actual signature in their system, either in pen on paper, digital signature attached to the RMP document or any other electronic system of document management. For eCTD submission, this would be the RMP with the last eCTD sequence of the procedure (usually the closing sequence). Select one of the options: QPPV signature: Or QPPV oversight declaration: QPPV. The electronic signature is available on file.> Table of content  TOC \o "1-3" \h \z \u  HYPERLINK \l "_Toc528579154" Table of content  PAGEREF _Toc528579154 \h 6  HYPERLINK \l "_Toc528579155" Part I: Product(s) Overview  PAGEREF _Toc528579155 \h 8  HYPERLINK \l "_Toc528579156" Part II: Module SI - Epidemiology of the indication(s) and target population(s)  PAGEREF _Toc528579156 \h 10  HYPERLINK \l "_Toc528579157" Part II: Module SII - Non-clinical part of the safety specification  PAGEREF _Toc528579157 \h 12  HYPERLINK \l "_Toc528579158" Part II: Module SIII - Clinical trial exposure  PAGEREF _Toc528579158 \h 13  HYPERLINK \l "_Toc528579159" Part II: Module SIV - Populations not studied in clinical trials  PAGEREF _Toc528579159 \h 15  HYPERLINK \l "_Toc528579160" SIV.1 Exclusion criteria in pivotal clinical studies within the development programme  PAGEREF _Toc528579160 \h 16  HYPERLINK \l "_Toc528579161" SIV.2 Limitations to detect adverse reactions in clinical trial development programmes  PAGEREF _Toc528579161 \h 16  HYPERLINK \l "_Toc528579162" SIV.3 Limitations in respect to populations typically under-represented in clinical trial development programmes  PAGEREF _Toc528579162 \h 16  HYPERLINK \l "_Toc528579163" Part II: Module SV - Post-authorisation experience  PAGEREF _Toc528579163 \h 17  HYPERLINK \l "_Toc528579164" SV.1 Post-authorisation exposure  PAGEREF _Toc528579164 \h 18  HYPERLINK \l "_Toc528579165" Part II: Module SVI - Additional EU requirements for the safety specification  PAGEREF _Toc528579165 \h 19  HYPERLINK \l "_Toc528579166" Part II: Module SVII - Identified and potential risks  PAGEREF _Toc528579166 \h 19  HYPERLINK \l "_Toc528579167" SVII.1 Identification of safety concerns in the initial RMP submission  PAGEREF _Toc528579167 \h 21  HYPERLINK \l "_Toc528579168" SVII.2 New safety concerns and reclassification with a submission of an updated RMP  PAGEREF _Toc528579168 \h 26  HYPERLINK \l "_Toc528579169" SVII.3 Details of important identified risks, important potential risks, and missing information  PAGEREF _Toc528579169 \h 27  HYPERLINK \l "_Toc528579170" Part II: Module SVIII - Summary of the safety concerns  PAGEREF _Toc528579170 \h 28  HYPERLINK \l "_Toc528579171" Part III: Pharmacovigilance Plan (including post-authorisation safety studies)  PAGEREF _Toc528579171 \h 29  HYPERLINK \l "_Toc528579172" III.1 Routine pharmacovigilance activities  PAGEREF _Toc528579172 \h 29  HYPERLINK \l "_Toc528579173" III.2 Additional pharmacovigilance activities  PAGEREF _Toc528579173 \h 30  HYPERLINK \l "_Toc528579174" III.3 Summary Table of additional Pharmacovigilance activities  PAGEREF _Toc528579174 \h 31  HYPERLINK \l "_Toc528579175" Part IV: Plans for post-authorisation efficacy studies  PAGEREF _Toc528579175 \h 33  HYPERLINK \l "_Toc528579176" Part V: Risk minimisation measures (including evaluation of the effectiveness of risk minimisation activities)  PAGEREF _Toc528579176 \h 34  HYPERLINK \l "_Toc528579177" V.1. Routine Risk Minimisation Measures  PAGEREF _Toc528579177 \h 35  HYPERLINK \l "_Toc528579178" V.2. Additional Risk Minimisation Measures  PAGEREF _Toc528579178 \h 36  HYPERLINK \l "_Toc528579179" V.3 Summary of risk minimisation measures  PAGEREF _Toc528579179 \h 38  HYPERLINK \l "_Toc528579180" Part VI: Summary of the risk management plan  PAGEREF _Toc528579180 \h 40  HYPERLINK \l "_Toc528579181" II.A List of important risks and missing information  PAGEREF _Toc528579181 \h 42  HYPERLINK \l "_Toc528579182" II.B Summary of important risks  PAGEREF _Toc528579182 \h 43  HYPERLINK \l "_Toc528579183" II.C Post-authorisation development plan  PAGEREF _Toc528579183 \h 44  HYPERLINK \l "_Toc528579184" II.C.1 Studies which are conditions of the marketing authorisation  PAGEREF _Toc528579184 \h 44  HYPERLINK \l "_Toc528579185" II.C.2 Other studies in post-authorisation development plan  PAGEREF _Toc528579185 \h 44  HYPERLINK \l "_Toc528579186" Part VII: Annexes  PAGEREF _Toc528579186 \h 45  HYPERLINK \l "_Toc528579187" Annex 1 EudraVigilance Interface  PAGEREF _Toc528579187 \h 45  HYPERLINK \l "_Toc528579188" Annex 2 Tabulated summary of planned, ongoing, and completed pharmacovigilance study programme  PAGEREF _Toc528579188 \h 45  HYPERLINK \l "_Toc528579189" Annex 3 - Protocols for proposed, on-going and completed studies in the pharmacovigilance plan  PAGEREF _Toc528579189 \h 46  HYPERLINK \l "_Toc528579190" Annex 4 - Specific adverse drug reaction follow-up forms  PAGEREF _Toc528579190 \h 47  HYPERLINK \l "_Toc528579191" Annex 5 - Protocols for proposed and on-going studies in RMP part IV  PAGEREF _Toc528579191 \h 47  HYPERLINK \l "_Toc528579192" Annex 6 - Details of proposed additional risk minimisation activities (if applicable)  PAGEREF _Toc528579192 \h 47  HYPERLINK \l "_Toc528579193" Annex 7 - Other supporting data (including referenced material)  PAGEREF _Toc528579193 \h 51  HYPERLINK \l "_Toc528579194" Annex 8 Summary of changes to the risk management plan over time  PAGEREF _Toc528579194 \h 51  Part I: Product(s) Overview Table Part I.1 Product(s) Overview Unless significantly different for each product, the following table is expected to be completed only once for each substance. Active substance(s) (INN or common name)Pharmacotherapeutic group(s) (ATC Code)Marketing Authorisation Name of the marketing authorisation applicant for initial marketing authorisation applications. For mutual recognition/ decentralised procedures applications include also information on expected future marketing authorisation holders in the reference member state, if this information is known at the time of the application.Medicinal products to which this RMP refersIndicate total number of products to which the RMP refers <#>Invented name(s) in the European Economic Area (EEA)For decentralised/mutual recognition products include only the invented name(s) in the reference member state.Marketing authorisation procedure  Brief description of the product Chemical classSummary of mode of actionImportant information about its composition (e.g. origin of active substance for biologicals, relevant adjuvants or residues for vaccines)Hyperlink to the Product InformationInclude a link or reference to the proposed PI in the eCTD sequence. If no updated PI is submitted with the procedure, the link should direct to the latest approved PI.Indication(s) in the EEA Current: For initial marketing authorisation applications, this section refers to the indication proposed by the applicant. For post-authorisation procedures, it refers to the indication that is currently approved. Proposed (if applicable): For post-authorisation procedures, e.g. if the RMP is submitted with an extension/restriction of indicationDosage in the EEA Current: For initial marketing authorisation applications, this section refers to the posology proposed by the applicant. For post-authorisation procedures, it refers to the posology currently approved. Summarise information only related to the main population; not a duplication of all dosages/dosage adjustments for the sub-populations listed in SmPC section 4.2.Proposed (if applicable): Summarise information only related to the main population; not a duplication of all dosages/dosage adjustments for the sub-populations listed in SmPC section 4.2.Pharmaceutical form(s) and strengths Current (if applicable):Proposed (if applicable):Is/will the product be subject to additional monitoring in the EU? Yes/No At initial marketing authorisation application conclusion or with RMP updates Part II: Safety specification For full initial marketing authorisation applications, all modules in Part II should be submitted. The requirements for other types of initial marketing authorisation applications are provided in section V.C.1.1 of the GVP Module V. If a reference medicinal product is authorised, please check if it has an RMP/summary for the RMP published on the EMA and/or national competent authorities website or whether the safety concerns for a substance/reference product are published on the CMDh website. If the Applicant considers that the available evidence justifies the reclassification or removal of a safety concern, this should be discussed. Similarly, if the Applicant has identified a new safety concern specific to the product (e.g. risks associated with a new formulation, route of administration or new excipient; or a new safety concern raised from any clinical data generated), this should be also discussed and the new safety concern detailed in Module SVII. Article 14(2) of Regulation (EC) No 1394/2007 provides for a specific framework for RMP for advanced therapy medicinal products (ATMP). The marketing authorisation applicants/holders should adapt the risk management plans of ATMP, considering and discussing the anticipated post-authorisation follow-up needs, focusing on particularities of these medicinal products. The specific RMP content requirements for ATMP should be discussed with the competent authority before the submission. Part II: Module SI - Epidemiology of the indication(s) and target population(s) This section should only contain data relevant for the identification of the safety concerns (see module SVII). Information on inter-regional (e.g. EU, US, Asia, Africa etc.) variations may be provided when relevant, but the focus should be on the European population. A brief summary of epidemiology is expected to be provided. This summary should provide an interpretive, high level overview of the information avoiding detailed discussion on specific epidemiology studies or published articles. When the medicinal product has/is expected to have several authorised indications, the data for the different indications should be integrated where this is sensible from a clinical perspective. When there are clinically relevant differences in user characteristics between the authorised indications, separate sections are, however, expected for each authorised indication (e.g. Crohns disease and rheumatoid arthritis; multiple sclerosis and hairy cell leukaemia). This module may not be applicable or have a reduced content for RMPs submitted with initial marketing authorisation applications involving: Generic medicinal products; Fixed combination medicinal products which do not contain a new active substance; Well established medicinal use medicinal products; Biosimilar medicinal products. For hybrid medicinal products, the requirements are based on risk proportionality principle, addressing the differences with the originator product. Incidence: Prevalence: Demographics of the population in the indication (when relevant for assessment of safety and risk management) and risk factors for the disease: The main existing treatment options: summarise the standard of care, with the view of the expected safety profile and outcome in the absence of treatment with the medicinal product Natural history of the indicated condition in the population, including mortality and morbidity: Discuss the possible stages of disease progression to be treated and applied to the natural history of the indication in the (untreated) population. This section should also describe concisely the relevant adverse events to be anticipated in the (untreated) targeted population in EU, their frequency and their characteristics. Important co-morbidities: The risks of the medicinal product are evaluated based on the characteristics of the medicinal product (e.g. documented in clinical trials) and the context of use: expected co-morbidities and co-medications in the target population. This section should include, where clinically relevant, diseases distinct from the indication that occur frequently in patients with the indicated condition (e.g. hypertension is a co-morbidity for hyperlipidaemia); a simple list is sufficient. For guidance on when information should be provided on co-morbidities in the target population, please consider the following examples: If the target population for a medicinal product is men with prostate cancer, the target population is likely to be men over the age of 50 years, and they have an increased risk for myocardial infarction. Patients with psoriasis are at an increased risk of depression and suicidal ideation and behaviour. Part II: Module SII - Non-clinical part of the safety specification This module should present a high-level summary of the significant non-clinical safety findings. The topics should normally include, but do not need to be limited to: Key safety findings from non-clinical studies and relevance to human usage: (for each safety finding) Toxicity key issues identified from acute or repeat-dose toxicity studies reproductive/developmental toxicity genotoxicity carcinogenicity Safety pharmacology as applicable cardiovascular system, including potential effect on the QT interval nervous system etc. Other toxicity-related information or data as applicable What constitutes an important non-clinical safety finding will depend upon the medicinal product, the target population and experience with other similar compounds or therapies in the same class. Normally, significant areas of toxicity (by target organ system) and the relevance of the findings to the use in humans should be discussed. Also, quality aspects, if relevant to safety (e.g. genotoxic impurities), should be discussed. If a medicinal product is intended for use in women of childbearing age, data on the reproductive/developmental toxicity should be explicitly mentioned and the implications for use in this population should be discussed. Based on these discussions, the applicant should comment if there are any findings in the non-clinical testing warrant inclusion among the summary of safety concerns; i.e. being an important identified risk, important potential risk, or if a non-clinical study is missing information. Where studies do not raise concerns in relation to human safety, these should be mentioned, if relevant, to the target population (e.g. no signs of reproductive or developmental toxicity if the medicinal product is intended for use in women of childbearing age). For full initial marketing authorisation applications where the Applicant generated no non-clinical data, relevant data available from bibliographical sources should be presented. Where the non-clinical safety finding is not considered relevant for human beings, the provision of a brief explanation is required, and the safety finding is not expected to be carried forward to SVII and SVIII as a risk. If, based on the assessment of the non-clinical or clinical data, additional non-clinical studies are considered warranted, this should be briefly discussed here. In the Post-authorisation phase, this section would only be expected to be updated when new non-clinical data impact the list of safety concerns. Safety concerns identified on the basis of non-clinical data which are no longer relevant and/or have not been confirmed when sufficient relevant post-marketing experience and evidence are gathered can be removed from the list of safety concerns. This module may not be applicable or have a reduced content for RMPs submitted with initial marketing authorisation applications involving: Generic medicinal products; Hybrid medicinal products; Well established medicinal use medicinal products. For fixed combination medicinal products with a new active substance, the focus of this module should be on the data generated for the new active substance. For fixed combination medicinal products with no new active substance, the module should contain information on the new non-clinical data generated, if any. Part II: Module SIII - Clinical trial exposure In this module, in order to assess the limitations of the human safety database, summary information on the clinical trial exposure should be provided in an appropriate format (e.g. tables/graphs) at time of submission of the initial RMP or when there is a major update due to new exposure data from clinical studies (e.g. in a new indication). The content of this section should be assessed for relevance over time and, in the absence of new significant clinical trial exposure data, this section does not need to be updated. Data should be pooled and not shown per individual trial unless there are clearly relevant and duly justified reasons why some data cannot be pooled or combined. If the RMP includes more than one medicinal product, the total population table should be provided for each medicinal product as well as a table that combines the information on total patients exposed for all medicinal products, as appropriate. The cumulative exposure data in this module (including cumulative data per indication, treatment duration, patient population, formulation), when presented in an aggregated form, would not be deemed to be commercially confidential and thus would not be redacted in case of an access to document request (unless a detailed justification is provided which demonstrate how the release of the data would undermine the commercial interests or competitive position of the company). The categories below are suggestions; tables/graphs should be tailored to the product according to the availability of data: Table SIII.1: Duration of exposure Cumulative for all indications (person time) Duration of exposurePatientsPerson timee.g. <1 m1 to <3 m3 to <6 me"6 m etc. Total person time<Indication>Duration of exposurePatientsPerson timee.g. <1 m1 to <3 m3 to <6 me"6 m etc. Total person time for indication Table SIII.2: Age group and gender When providing data by age group, the age group should be relevant to the target population; this should be reflected in the choice of age categories for this table. Paediatric data should be divided by age categories (e.g. ICH-E11); similarly, the data on older people should be stratified into age categories reflecting the target population (e.g. 65-74, 75-84 and 85 years and above). Age groupPatientsPerson timeMFMFe.g. Preterm newborn infantsTerm newborn infants (0 to 27 days)Infants and toddlers (28 days to 23 months)Children (2 to e.g. 11 years)Adolescents (e.g. 12 to 17 years)Adults (e.g. 18 to 64 years)Elderly people 65-74 years 75-84 years 85 + yearsTotalAge groupPatientsPerson timeMFMFAge group 1Age group 2 etc.TotalTable SIII.3: Dose Dose of exposurePatientsPerson timeDose level 1Dose level 2 etc.TotalDose of exposureDose level 1Dose level 2 etc.TotalOther stratifications should be provided where this adds meaningful information for risk management planning purposes (e.g. ethnic origin). Table SIII.4: Ethnic origin Ethnic originPatientsPerson timeEthnic origin 1Ethnic origin 2 etc.TotalThis module may not be applicable or have a reduced content for RMPs submitted with initial marketing authorisation applications involving: Generic medicinal products; Well established medicinal use medicinal products. For fixed combination medicinal products with a new active substance, the focus of this module should be on the data generated for the new active substance. For fixed combination medicinal products with no new active substance, the module should contain information on the new non-clinical data generated, if any. For hybrid medicinal products, the requirements are based on risk proportionality principle, addressing new data generated and the differences with the originator product. Part II: Module SIV - Populations not studied in clinical trials This module should discuss the populations which have not been studied or have only been studied to a limited degree in the pre-approval phase. The implications of this with respect to predicting the safety of the medicinal product in the marketplace should be explicitly discussed. Exclusion criteria from the clinical trial development programme should be included as missing information only when they are relevant for the approved and proposed indication (e.g. on-label). When such populations are proposed as missing information, RMP module SIV should then also include a discussion on the relevant subpopulations, including whether or not any use in populations excluded from the clinical trials (e.g. women of childbearing potential, older people) might be associated with additional risks of clinical significance in case the product is used in these populations. This module should discuss the limitations of the clinical trial population in relation to predicting the safety of the medicinal product(s) in real life use. If difficult to populate for e.g. for bibliographic applications or where the applicant does not have access to original trial data, the Applicant is encouraged to include any relevant data that the Applicant has access to, even if these are limited to the inclusion/exclusion criteria listed in published studies which are publicly available. This module may not be applicable or have a reduced content for RMPs submitted with initial marketing authorisation applications involving: Generic medicinal products; Hybrid medicinal products; Fixed combination medicinal products with no new active substance; Well established medicinal use medicinal products. For fixed combination medicinal products with a new active substance, the focus of this module should be on the data generated for the new active substance. SIV.1 Exclusion criteria in pivotal clinical studies within the development programme Discuss the important exclusion criteria in the pivotal clinical studies across the development programme. Reason for exclusion: Is it considered to be included as missing information?: / Rationale: (if not included as missing information) SIV.2 Limitations to detect adverse reactions in clinical trial development programmes It is assumed that the clinical trial development programme is unable to detect certain kinds of adverse reactions. In these circumstances, please add a simple statement indicating the particular limitations of the programme (choose options that apply): , < adverse reactions with a long latency>, or those caused by or . Or, if this assumption is not correct, briefly discuss the level of detection for the clinical trial programme conducted. SIV.3 Limitations in respect to populations typically under-represented in clinical trial development programmes This section aims to present the size of the safety database in each of the populations that are under-represented. Some populations are often excluded or under-represented in clinical trials. For each of the line in the table below, indicate the information on the low exposure of or the lack thereof (e.g. the number of subjects included and total person years of follow-up in the clinical development programme) for the medicinal product(s) covered in this RMP, if available and as appropriate. Table SIV.2: Exposure of special populations included or not in clinical trial development programmes Type of special population Please indicate if included in pre-authorisation clinical development program: Exposure Total number of subjects and person time. Do not include clinical trials inclusion/exclusion criteria.Pregnant women In most cases, person time exposure data can be omitted for this populationBreastfeeding womenPatients with relevant comorbidities: Patients with hepatic impairment Patients with renal impairment Patients with cardiovascular impairment Immunocompromised patients Patients with a disease severity different from inclusion criteria in clinical trials The degree of impairment should be specified, if availablePopulation with relevant different ethnic originSubpopulations carrying relevant genetic polymorphisms Type of genetic polymorphism should be specified, if availableOther If applicable, other special population under-represented in clinical trials which are relevant for the targeted indication if the safety profile is expected to be different to the general population. Part II: Module SV - Post-authorisation experience This module is normally empty before the granting of the Marketing Authorisation unless post-marketing data are available from post-authorisation experience in other regions outside EU where the product is already authorised or from other authorised medicinal products containing the same active substance from the same marketing authorisation holder. This section should only provide an overview of exposure in the post-authorisation phase for risk management planning purposes. It is not the intention to duplicate post authorisation experience information from PSURs but to provide high-level information on the number of patients exposed post authorisation. A discussion on how the medicinal product is being used in practice and on-label and off-label use, including use in the special populations mentioned in RMP module SIV, can also be included when relevant for the risk identification discussion in module SVII. Where appropriate and relevant for the discussion in SVII, data on use in markets outside the EU from indications not authorised in EU should also be summarised, and the implications for the authorisation in the EU should be discussed. This module may not be applicable or have a reduced content in the same situations as Module SIV, described above. SV.1 Post-authorisation exposure When available, worldwide data on patients exposed post marketing should be provided. For post-marketing RMP updates, this section should be updated only when the cumulative post-marketing exposure changes to a degree where the considerations on the risk evaluation need also to be updated (e.g. population exposed in a new indication). Details and methods used to calculate person- and person-time exposure should be briefly presented; however, this section is not intended to duplicate the information already available in the PSUR and should only be presented as an overview. The standard method to calculate exposure based on the posology of the product and/or treatment cycles and sales and global exposure data presented in an aggregated form would not be deemed to be commercially confidential and thus would not be redacted in case of a access to document request (unless a detailed justification is provided which demonstrate how the release of the data would undermine the commercial interests or competitive position of the company). The redaction would be accepted for data pertaining to national exposure data, if proposed. SV.1.1 Method used to calculate exposure If different methods have been used to calculate exposure for some tables, this section should be repeated before each of the relevant table(s). SV.1.2 Exposure It is acknowledged that post-marketing data will most likely not be available by age group or by gender but, when available, this should be provided. Total exposure and exposure by indication should always be presented. Table SV.1: Exposure table by indication, , , The categories provided may follow template from GVP Module VII Periodic safety update report, and the PSUR table(s) can be reused in this RMP module. Other relevant variables should be used if relevant for the risk identification discussion, e.g. duration of treatment. If possible, use in the EU should be broken down by country or sales area. Exposure from areas outside of the EU for indications different than those approved or proposed in the EU should be presented as a separate section in the table, if exposure in such patients is relevant for the safety discussion for the EU indication. IndicationSexAge (years)DoseFormulationRegionMaleFemalee.g. 2 to d"16e.g. >16 to 65e.g. >65e.g. unknowne.g. <40e.g. Unknowne.g. Intravenouse.g. Orale.g. EU countrye.g. Non EU countrye.g. OtherOverall<Indication1><Indication2>Part II: Module SVI - Additional EU requirements for the safety specification Potential for misuse for illegal purposes Discuss the potential for misuse for illegal purposes, e.g. as a recreational drug or to facilitate assault. Discuss the means of limiting this in the risk minimisation plan where appropriate, e.g. limited pack size, controlled access programme, special medical prescription etc. This module may not be applicable or have a reduced content in the same situations as Modules SIV-SV, described above. Part II: Module SVII - Identified and potential risks The safety profile of the product should be concisely presented, as it is known at the time of the RMP data lock point. Relevant information for the identification of important identified and important potential risks and any relevant updates on missing information should be discussed (see GVP Module V section V.A.1). If they have not already been provided in the previous sections, provide appropriate eCTD links or references to the primary data informing the discussion here. The identification of the important identified and important potential risks in this section to be addressed in the RMP should not be a copy paste of tables or lists of adverse reactions from clinical trials or of sections 4.4 and 4.8 of the SmPC, as the safety concerns to be included in this section of the RMP should be considered important (see GVP Module V section V.A.1). For RMPs including multiple substances and/or medicinal products and where there may be significant differences in the important identified and important potential risks or missing information for different substances/ medicinal products, it is appropriate to make it clear which safety concerns relate to which substance/ medicinal product. Categories to be considered include safety concerns relating to the active substance, safety concerns related to a specific formulation or route of administration and safety concerns associated with a switch to non-prescription status. Exceptionally, if agreed with the competent authority and where needed for risk management planning purposes, the safety specification may include additional elements if they are resulting in important identified risk, important potential risk or missing information such as: The disposal of the product where it might pose a particular risk because of remaining active substance (e.g. patches); Innovative pharmaceutical forms (e.g. to contain a higher percentage of active substance which reduces the dose burden for patient and related side effects; long-term delivery gastric-resident dosage forms for ultra-long-acting drug delivery may improve patients adherence to treatment and to reduce the gastro-intestinal side effect); Use with a medical device and risks associated with the medical device; Quality aspects relevant in relation to the safety of the product and not adequately addressed at time of marketing authorisation (e.g. investigation of other methods to improve the quality/composition of the product to address adverse events related to it). See GVP Module V section V.B.5.8. for the safety topics derived from specific situations/data sources which are thought to be of particular interest to be discussed in module SVII when they lead to risks of the medicinal product, as appropriate. Advanced therapy medicinal products (ATMP): Article 14(2) of Regulation (EC) No 1394/2007 provides for a specific framework for RMP for advanced therapy medicinal products (ATMP). The marketing authorisation applicants/holders should adapt the risk management plans of ATMP, considering and discussing the anticipated post-authorisation follow-up needs, focusing on particularities of these medicinal products. The specific RMP content requirements for ATMP should be discussed with the competent authority before the submission. Further guidance on the safety and efficacy follow-up and risk management requirements for ATMP is provided on the Agency website. See the Guideline on Safety and Efficacy Follow-up Risk Management of Advanced Therapy Medicinal Products for risks to be considered in drafting the safety specification. For hybrid medicinal products, the requirements are based on risk proportionality principle, addressing the differences with the originator product. Generic medicinal products and fixed combination medicinal products with no new active substance This module is applicable for all initial marketing authorisation applications except for applications for generic medicinal products and fixed combination medicinal products with no new active substance, if there is a RMP available for the reference medicinal product or when the reference medicinal product does not have an RMP but the safety concerns of the substance are published on the CMDh website. In case a reference medicinal product has published RMP/summary of the RMP on the EMA and/or national competent authorities website or the safety concerns for a substance/reference product are published on the CMDh website, than the safety concerns should be based on it. If discrepancies exist between approved RMPs and/or lists of safety concerns for the same active substance, then the applicant is expected to propose and justify the most appropriate safety specification for their medicinal product. Exceptionally, the applicant for a new generic medicinal product may add, reclassify or remove safety concerns compared with the safety profile of the reference product if this is appropriately justified. In case of any changes to the already included information in the published CMDh list, the marketing authorisation holder should provide the information to CMDh using the instructions on their website once the RMP is approved. In very exceptional circumstances, if Module SVII is not applicable and a change in the safety specification is proposed, include the following: with a submission of this RMP in comparison with the reference medicinal product published on website>: Please consider that the text in this section will be included verbatim in the RMP public summary. < is a new > < previously classified as is to be reclassified as or > SVII.1 Identification of safety concerns in the initial RMP submission This section is expected to be submitted only for initial marketing authorisation applications, locked and not change after the approval of the initial RMP. Whether a risk is considered identified risk or potential risk would depend on the strength of evidence supporting the causal association with the medicinal product. From the identified risks of the medicinal product, the RMP should address only the risks that are an undesirable clinical outcome and for which there is sufficient scientific evidence that they are caused by the medicinal product. Risks for adverse reactions may be identified from multiple sources such as non-clinical findings confirmed by clinical data; clinical trials, epidemiological studies, spontaneously reported data and published literature, for example: An adverse reaction recorded in a well-designed randomised clinical trial in excess of the placebo comparator would generally be considered as an identified risk if the criterion on clinical outcome is also fulfilled; For some adverse reactions (e.g. laboratory abnormalities), the identified risk may be the clinical outcome of the adverse reaction, if these have been observed (e.g. associated with such laboratory abnormality). For example: the identified risk of bleeding due to abnormal INR range/thrombocytopenia, the identified risk of infection due to neutropenia, the identified risk of hypotension/ lipothymia/ renal failure due to adverse reactions such as dehydration as a consequence of vomiting and/or diarrhoea, the identified risk of cardiac arrhythmia due to coronary vasospasm or Torsade de Pointes due to QTc prolongation. From the potential risks of the medicinal product, the RMP should address only the risks with undesirable clinical outcomes and for which there is scientific evidence to suspect the possibility of a causal relationship with the medicinal product, but where there is currently insufficient evidence to conclude that this association is causal. For example: Where the supposition is based on more than theoretical considerations, may include signals that have been evaluated with an indeterminate outcome (i.e. which can be neither refuted nor confirmed), a class effect plausible also for a new medicinal product, findings from non-clinical studies which have not been observed in clinical studies, or undesirable clinical outcomes observed in clinical trials or epidemiological studies for which there is not yet enough evidence to support a causal relation (e.g. due to low number of events or unexpected incidence rates in comparator groups). SVII.1.1. Risks not considered important for inclusion in the list of safety concerns in the RMP Not all adverse reactions are necessarily considered a risk for the medicinal product in a given therapeutic context and not all risks qualify as important to be included in the list of safety concerns for the purpose of risk management planning (see GVP Module V section V.A.1). For example: Transient low-grade headache is an adverse reaction listed in section 4.8 of the SmPC, but it is not associated to a relevant risk. Reversible alopecia, itchy rash or transient reduced fertility of a medicinal product indicated for the treatment of life-threating oncologic diseases are risks that could have an impact on the quality of life. However, the clinical impact of these risks on patients is considered minimal in relation to the severity of the indication treated and these risks should therefore not be classified as important. The risk of irreversible reduction of fertility is not considered important for a medicinal product almost exclusively used in a patient population aged > 60 years given the therapeutic context. Some risks are already well-known to health professionals and do not require additional pharmacovigilance activities or additional risk minimisation measures. For example, in cases where health professionals are already aware of the risk of anaphylactic reactions and have the appropriate measures in place as part of clinical practice, anaphylactic reactions may not need to be included as an important risk. Reason for not including an identified or potential risk in the list of safety concerns in the RMP: The justification for non-inclusion should be provided. The reasons can be grouped as described in examples below. Information on seriousness, frequency, or adherence to standard clinical practice (in each EU Member state where the product is already authorised) should be provided to support the proposed classification, as appropriate: SVII.1.2. Risks considered important for inclusion in the list of safety concerns in the RMP For risks included in the list of safety concerns of the medicinal product(s) for the purpose of risk management planning, the scientific evidence that has led to the inclusion should be briefly discussed. Further details on the safety concerns should be provided in section SVII.3. Important risks to be included in the RMP are those risks which are already characterised and confirmed to have an impact on the risk-benefit balance of the medicinal product or those that, when further characterised and if confirmed to be associated with the medicinal product, would have an impact on the risk-benefit balance. These risks would usually warrant further evaluation as part of the pharmacovigilance plan or risk minimisation activities, either routine or additional. : Examples of important identified risks are: If an adverse reaction which is an important identified risk for an active comparator occurs at a similar or higher frequency with the new medicinal product in a clinical trial, this suggests that the adverse reaction may also be an important identified risk for the new medicinal product. For a medicinal product on the market for years, drug-induced liver injury was identified as a new adverse reaction after a referral procedure and considered to have a major impact on the benefit risk. Warnings in section 4.4. of the SmPC have been implemented and the recommendation to perform regular liver function tests have been added to the SmPC as a precautionary measure in the post-marketing period.  Hepatotoxicity or a similar term should be classified as an important identified risk. Neutropenia of e" grade 3 and serious infections with fatal outcome were observed in clinical trials prior marketing authorisation of an oral first-in-class medication. Regular blood counts are recommended, according to the SmPC, to minimise the risk of serious infections. As oral medications are very likely to be used in an out-of-hospital setting and it is unclear whether this risk minimisation will be effective, serious infections should be included as an important identified risk. Cardiac disorders with life-threating outcome were identified as being causally related to a medicinal product in clinical trials prior marketing authorisation. However, an accurate estimation of frequency was not possible from clinical trial data as the clinical trial population was too small and, therefore, a PASS investigating frequency of the risk was imposed. Cardiac disorders should be classified as an important identified risk. If a serious adverse reaction was identified in clinical trials (e.g. Stevens Johnson Syndrome) and, at the time of the initial marketing authorisation application, the incidence is considered acceptable for a positive risk-benefit balance, routine pharmacovigilance activities could be considered sufficient to monitor this risk assuming that the event is appropriately managed by health professionals in clinical practice. The periodic risk-benefit evaluation (e.g. PSUR) will therefore discuss the findings from spontaneous reporting and provide an evaluation on whether the frequency of the event is higher than expected. However, if a signal is raised following the use in clinical practice, the identified risk would be considered as an important identified risk and additional pharmacovigilance activities should be considered to provide an accurate estimate of the frequency and inform the risk-benefit evaluation. Risk-benefit impact: present the reasons for this classification, consider seriousness, frequency and severity as determinants, e.g.: Serious adverse reactions (as described in GVP Annex I Definitions) that result in death, are life-threatening, result in persistent or significant disability or incapacity, or are a congenital anomaly/birth defect, if not prevented or managed appropriately; Common adverse reactions that are so severe (Grade 3-4) that it may lead to a serious outcome, discontinuing the treatment and/or reducing the efficacy of the medicinal product, if not managed appropriately, even if the adverse reaction is not serious; Severe adverse reactions occurring with high frequency in the targeted population that could have a severe impact on the patient (e.g. depression could significantly impact the quality of life and it could also lead to the potential risk of suicide, therefore, it could be classified as in important identified risk). : Examples of important potential risks are: QTc prolongation is a known adverse reaction of another medicinal product of the same class, observed in clinical trials and included in section 4.8 of the SmPC; however, no events of Torsade de Pointes have been observed in the clinical development programme or the magnitude of QTc prolongation is lower than normally associated with Torsade de pointes. Consequently, Torsade de pointes would be an important potential risk; When neutropenia is a listed adverse reaction, serious infections can still be classified as an important potential risk even if there is not yet enough clinical evidence of serious infections associated with neutropenia. When there is a high likelihood of off-label use and a safety issue has been identified as derived from such use, if this risk is not already an important identified or potential risk for the target population (GVP Module V Section V.B.5.8.), the specific risk should be included as an important potential risk. Whenever possible, its name should be specific. For example, severe bleeding [in off-label paediatric use] should be used rather than the unspecific term off-label use in children if bleeding is not already included as an important identified or potential risk. Other unspecific terms for which reference should be made to the particular risk, when possible, are long-term use or medication error. A treatment has been proven effective only in adults (e.g. because the disease is very rare in children and, therefore, data in children could not be gathered and the medicinal product is likely to be ineffective or unsafe in this population). However, a high risk of off-label use in children related to the absence of effective and safe treatments in this patient population has been identified post-marketing. The potential safety harm to children resulted from the likely off-label use should be discussed in the RMP, a safety concern in the form of an important potential risk related to the specific safety concern should be considered, and paediatric post-marketing safety studies may therefore be a suitable pharmacovigilance activity, despite the restricted indication in adults. In animal studies, carcinogenicity was observed at clinically relevant exposures of a new medicinal product or the occurrence of secondary malignancy in humans after exposure is plausible based on the mechanistic properties of the medicinal product. However, the study observation period was too short or the study population was too small to establish a causal relation. Secondary malignancies should be considered to be added as an important potential risk. Based on the characteristics and the mechanistic properties of a medicinal product, abuse of a medicinal product is possible and would lead to significant consequences such as addiction and death from overdosing. Nevertheless, abuse has not yet been observed. Risk from abuse/misuse should be listed as an important potential risk. Risk-benefit impact: present the reasons for this classification, consider seriousness, frequency and severity as determinants; consider potential risks when, if confirmed in well-designed post-marketing studies, they would be classified as important identified risk due to the risk-benefit impact. : Missing information for the purpose of the risk management planning refers to gaps in knowledge about the safety of a medicinal product for certain anticipated utilisation or for use in particular patient populations within the approved indication, for which there is insufficient medicinal product exposure to determine whether the safety profile differs from that characterised so far (see GVP Module V section V.A.1). For example: Use in subpopulations not studied (e.g. exclusion of a subpopulation from clinical studies) but within the approved indication: the absence of data itself does not automatically constitute a safety concern; instead, a scientific rationale for anticipating a different safety profile in the particular subpopulation /use is needed for the inclusion of that subpopulation as missing information, or that further data collection is warranted of another reason e.g.: Patients with severe renal impairment were excluded from clinical trials, and the medicinal product is not contraindicated in this population; if the pharmacokinetic profile may be different in the excluded population (based on knowledge of the pharmacokinetic profile or the known mechanism of action) further data collection/ studies in such population are considered warranted. The safety concern should be classified as missing information use in patients with renal impairment; A medicinal product is initially approved for treatment of adults and, subsequently, it is approved for treatment of the same disease in children based on a small clinical study in children (e.g. deferred paediatric development for selected age groups/indications). The approval is justified based on an extrapolation to the adult experience, both in terms of efficacy and safety. There are no specific safety concerns in children, as compared to the adult population. However, long-term safety data have not been studied at all in this population. In such case, long term safety in children may be included as missing information. As limited data have been available at the time of marketing authorisation, a paediatric PASS should be considered as a suitable method of collecting post-approval safety data in children. In principle, the safety concern derived from the specific situations/data sources described in GVP Module V Section V.B.5.8. should be specified rather than using the unspecific term (off-label use; medication error) if possible. For instance: When a certain population has explicitly been excluded from the approved indication, but off-label use in this population is anticipated and a specific safety concern is associated with off-label use, then this specific safety issue should also be discussed in the RMP and considered to be added as a safety concern. e.g. cardiac safety in patients with prior significant cardiac history. When there are potential risks related to cumulative or long-term exposure, e.g.: for a medicinal product, ototoxicity after long term use is a concern based on theoretical considerations, non-clinical data, and/or class effects, but long-term data is missing. There has been little or no long-term use of the medicine in clinical development. The particular concern of ototoxicity should be included in the RMP as a potential risk and long-term use should be added as missing information. Risk-benefit impact: what are the reasons for this classification; what is the data that is still required to be gathered post-authorisation. SVII.2 New safety concerns and reclassification with a submission of an updated RMP This section applies to RMP updates after the granting of the marketing authorisation. When an important identified or potential risk or missing information is re-classified or removed, a justification should be provided in this RMP section, with appropriate reference to the safety data. The information included in this section may take the form of a statement describing a previous regulatory request, with a reference to the procedure where such request was formulated. < is a new > < previously classified as is to be reclassified as or > Reasons for the reclassification/removal/addition to the list of safety concerns: For new proposals from the marketing authorisation holder: Discuss briefly the level of scientific evidence that has led to this re-classification/removal, e.g. consider also seriousness and frequency as determinants (see examples in SVII.1). Further details on the safety concerns should be provided in section SVII.3, if applicable. or Include procedure number and link/reference to the procedure submission where such request was formulated. Further details on the safety concerns should be provided in section SVII.3, if applicable. SVII.3 Details of important identified risks, important potential risks, and missing information This section applies to all stages of the product life cycle. Data should be provided considering all possible sources, e.g. clinical trials from the current application (or from the originator, in case of hybrids or generics); literature, post-marketing data, etc. Do not cross reference other applications. SVII.3.1. Presentation of important identified risks and important potential risks : (using MedDRA terms when appropriate. Generally, only one MedDRA PT or SMQ is expected. Use verbatim if no MedDRA term adequately captures the given term. This list should not include the extensive list of PTs/LLTs used for MAH signal detection) Potential mechanisms: Provide plausible biological mechanisms on how the administration of the medicinal product could lead to the event. Evidence source(s) and strength of evidence: Provide a brief summary of the main reasons for considering the risk as an important identified or important potential risk. Please consider that this text will be included verbatim in the RMP public summary. Characterisation of the risk: Describe the frequency, absolute risk, relative risk, severity, reversibility, long-term outcomes, and impact on quality of life, as applicable. For frequency, state clearly: Frequency parameter used e.g. incidence or reporting rates; Confidence intervals; Data source e.g. randomised clinical trial population, epidemiological study, post-marketing reporting data. For important identified risks incidence should be presented for the whole population and relevant subpopulation with differences discussed, if appropriate. Risk factors and risk groups: Describe patient factors, dose-related, at risk period, additive or synergistic factors. Please consider that this text will be included verbatim in the RMP public summary. Preventability: Provide data on predictability of a risk, factors that could increase the risk of an adverse reaction and how to minimise these, possibility of detection at an early stage which could mitigate seriousness. When additional risk minimisation measures are proposed or are in place, make reference to the specific section in Part V where the measures are being described. Impact on the risk-benefit balance of the product: Describe the actual impact and the expected impact on the risk-benefit balance if the risk is further characterised (e.g. via pharmacovigilance plan and/or risk minimisation measures in place). It is expected that these new data confirms the presumed concerns (i.e. risk is minimised)? Public health impact: The purpose is to estimate how many events of a specific AE (safety concern) are to be expected in post-marketing. Where available, describe the absolute risk (incidence rate) in relation to the size of the target population and consequently actual number of individuals affected or describe the overall outcome expected on the population level. SVII.3.2. Presentation of the missing information Include only the missing information which has been selected to be part of the list of safety concerns. : (using MedDRA terms when appropriate or population name. Generally, only one MedDRA PT or SMQ is expected. Use verbatim if no MedDRA term adequately captures the given term. This list is not meant to refer to the list of terms to be used when querying the MAH database) Evidence source: Describe any evidence that the safety profile is expected to be different from that in the general target population. Select from following options: Population in need of further characterisation: If risks cannot be defined based on available evidence Or Anticipated risk/consequence of the missing information: Describe the risk anticipated in the population not studied. Describe the population followed up for further characterisation. Part II: Module SVIII - Summary of the safety concerns A summary of the safety concerns identified in previous Module SVII of Part II should be provided. The summary should be provided for each medicinal product included in the RMP, if the list of safety concerns is different for different medicinal products. This module is applicable for all initial marketing authorisation applications. Table SVIII.1: Summary of safety concerns Summary of safety concernsImportant identified risksImportant potential risksMissing information Part III: Pharmacovigilance Plan (including post-authorisation safety studies) The Pharmacovigilance plan should provide details of pharmacovigilance activities/studies intended to identify and/or further characterise safety concerns and studies measuring the effectiveness of risk minimisation measures where such studies are required. This part is applicable for all initial marketing authorisation applications. III.1 Routine pharmacovigilance activities Routine pharmacovigilance is the primary/minimum set of activities required to fulfil the legal requirements for pharmacovigilance contained in Directive 2001/83/EC and Regulation (EC) No 726/2004. The Pharmacovigilance System Master File describing these activities is not required to be repeated in the RMP. Signal detection, which is part of routine pharmacovigilance, will be an important element in identifying new risks for all medicinal products but should not be discussed here. For well characterised safety concerns, routine pharmacovigilance may be sufficient. Part III.1 should only include a brief description of the routine pharmacovigilance activities beyond adverse reaction reporting and signal detection (see examples in the GVP Module V, section V.B.6.1.). In general terms, activities which are mandatory for all products and included in the pharmacovigilance system master file do not need to be included here. Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Specific adverse reaction follow-up questionnaires for : Provide the purpose and a description of the materials used when specific questionnaires to obtain structured information on reported suspected adverse reactions of special interest are required. Describe by type of activity and not by safety concern. The forms should be provided in Annex 4 of the RMP. Other forms of routine pharmacovigilance activities for : This includes the description of following activities including objectives and milestones, e.g. enhanced passive surveillance high level description, observed versus expected analyses, cumulative reviews of adverse events of interest. Describe by type of activity and not by safety concern. III.2 Additional pharmacovigilance activities The Applicant/Marketing authorisation holder should describe additional pharmacovigilance activities such as non-clinical, clinical or epidemiological (non-interventional or interventional) studies, and explain why they are needed. e.g.: Long-term follow-up extensions of ongoing clinical trial(s); Cohort studies to provide additional characterisation of the long term safety of the medicinal product; Further effort to evaluate the missing data. For generic medicinal products, the pharmacovigilance plan will reflect their outstanding needs for pharmacovigilance investigations at the time of their approval. Studies in the pharmacovigilance plan should relate to the safety concerns identified in the safety specification irrespective of whether the studies are to identify and characterise important risks/missing information, or to assess the effectiveness of additional risk minimisation activities using behavioural or safety outcome indicators. Tabulated summary of on-going and completed pharmacovigilance study programme should be provided in Annex 2. Protocols for studies in the pharmacovigilance plan should be provided in Annex 3 of the RMP until completion of the study and submission to the competent authorities of the final study report. When any doubt exists about the need for additional pharmacovigilance activities, consultation with a competent authority should be considered. Further guidance on the conduct of post-authorisation safety studies (PASS) is provided in the GVP Module VIII. For all safety studies imposed as condition of the marketing authorisation (category 1), as specific obligations in the context of a marketing authorisation under exceptional circumstances or conditional marketing authorisation (category 2), or required by the competent authority (category 3) complete the following summary. This should not be a duplication of the protocol synopsis, but it should be detailed enough to be able to inform what the study will add to further characterise the safety profile of the product. It should be also consistent with the study description provided in table III.3 and should include: summary Study short name and title: e.g. EPI-PM-006 - Medicinal Product observational cohort safety study in immunocompromised patients Please consider that the text of the study title will be included verbatim in the RMP public summary. Rationale and study objectives: Indicate the rationale for conducting the study (include also all the safety concerns addressed). Present briefly the study objectives. Please consider that the text in this section will be included verbatim in the RMP public summary. Study design: State the study design. e.g. randomised clinical trial extension, observational chart-review, cohort study, self-controlled case series Study population: Present briefly the population included in the study, in line with the inclusion and exclusion criteria. Milestones: Include all requested milestones for reporting to the regulatory authorities (e.g. protocol submission, interim reports, and final report submission) as well as major milestones from study protocol (e.g. registration in the EU PAS register, start/end of data collection, interim progress reports, final study report completion, date of publication). III.3 Summary Table of additional Pharmacovigilance activities This section should be a complete overview of all on-going and planned categories 1-3 safety studies included in the Pharmacovigilance Plan, regardless of whether they were designed to assess the safety of the medicinal product, or the effectiveness of the risk minimisation measures. Information on the study population should be part of the information provided in the study objectives as indicated in the example tabulation e.g. to evaluate the long term safety of adult/ paediatric/ adolescent/ elderly/ very elderly patients with Type 1 diabetes. Clear milestones and due dates should be provided (e.g. submission of final study report by 31/01/2018). Submission of interim results or other intermediate milestones (e.g. submission of a draft protocol) is not expected unless explicitly requested by the competent authority; such request would need to be documented in the RMP and the relevant intermediate milestones/due dates added. Final report due dates should be provided for all studies included in the table below. This date should be in accordance with Annex IID/IIE conditions for studies category 1 and 2, respectively. If a study aims to evaluate the effectiveness of risk minimisation measures, this needs to be made explicit in the study summary of objectives. Table Part III.1: On-going and planned additional pharmacovigilance activities Examples of activities are provided in green in the table, to guide on the level of the detail expected. Not all milestones are applicable for all studies, and not all products will have studies from all categories. Do not include empty rows if no study is planned for a Category. Study (study short name, and title) Status (planned/on-going)Summary of objectivesSafety concerns addressed (list)Milestones (required by regulators)Due dates (in DD/MM/YYYY format)Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation (key to benefit risk)LE observational cohort safety study (study LE123) PlannedTo evaluate over a minimum of 1 year the incidence of all-cause mortality and adverse events of special interest in patients with lupus erythematosus. - serious infections (including non-serious and serious opportunistic infections and PML) - malignancies (including non-melanoma skin cancer) - serious infusion - hypersensitivity reactions - serious psychiatric events (mood disorders, anxiety and suicide).Protocol submission 31/01/2019 Final report31/12/2018Long-term safety registry (Study REG4321) PlannedTo evaluate the incidence of all-cause mortality and adverse events of special interest in patients with systemic lupus erythematosus, using data from a long-term safety registry where all patients are followed for a minimum of 5 years, - serious infections (including opportunistic infections and PML) - selected serious psychiatric events - malignancies (including non-melanoma skin cancer).Protocol submission28/02/2017Final report30/10/2023Category 2 Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances (key to benefit risk)Long term safety PASS EPIOA005 On-goingPrimary To further evaluate the long-term safety profile of in the treatment of patients with <> when used under conditions of routine clinical care Secondary To further evaluate the long-term effectiveness of <> in the treatment of patients with <> when used under conditions of routine clinical care To quantify discontinuation of treatment due to adverse events or due to lack of or loss of therapeutic response. To further elucidate the risk of abnormal liver function tests and hepatitis- Long term safety - Use in populations not studied in clinical trials: pregnancy and lactation, elderly, children under 14 years of age, hepatic impairment, renal impairmentAnnual reports To be submitted with annual re-assessmentsCategory 3 - Required additional pharmacovigilance activities (by the competent authority)Post-marketing multi-centre registry study REGAR02 On-goingTo investigate the association between the induced QTc prolongation and possible predictive factors, and estimate the incidence of treatment-emergent adverse events of special interest. The study will also monitor the patterns of drug utilisation for .- Cardiac riskAnnual update Progress reports on enrolment and intermediate analysis results will be provided yearly.Final report31/03/2020Drug utilisation study for DUS-01 PlannedTo document the real-life use of the product and to monitor off-label use. To measure the effectiveness of routine risk minimisation measures, e.g. the compliance with the SmPC recommendations on dose reduction in renal impaired patients. To measure the effectiveness of the educational materials, i.e. the off-label use in paediatric population.- Safety in renal impaired patients -Off-label use in paediatric population Final report31/01/2019Post-approval safety surveillance program for lot-specific adverse events Q-450-E01 PlannedTo evaluate any potential change in the frequency of hypersensitivity, immunogenicity or lack of drug effect events.Changes in the frequency of hypersensitivity and immunogenicity events with the altered manufacturing processFinal report2 years following the expiry of the first released finished batch 31/01/2020Data collection from participation in the registry PlannedTo monitor the treatment safety of - Inhibitor development - Thromboembolic events - Serious allergic reactions or anaphylaxisRegular updates Data will be reviewed on an on-going basis as a part of signal detection and reported within PSURs, when available. Part IV: Plans for post-authorisation efficacy studies Include a list of the planned and on-going imposed post-authorisation efficacy studies, i.e. imposed by the competent authority as a condition of marketing authorisation or which are Specific Obligations in the context of conditional marketing authorisation or marketing authorisation under exceptional circumstances. Protocol(s) should be provided in Annex 5. If not such studies are required, this part may be left empty. Table Part IV.1: Planned and on-going post-authorisation efficacy studies that are conditions of the marketing authorisation or that are specific obligations. Examples of activities are provided in green in the table, to guide on the level of the detail expected. Not all milestones are applicable for all studies. Submission of intermediate milestones imposed by the competent authority should be included. Final study report due dates should always be included in accordance with Annex II conditions. Please consider that text from the table below will be included verbatim in the RMP public summary. Study (study short name and title), Status (planned, on-going)Summary of objectivesEfficacy uncertainties addressedMilestonesDue Date (in DD/MM/YYYY format)Efficacy studies which are conditions of the marketing authorisation Extension of clinical trial for (SUMACI) (on-going)To examine the 5-year efficacy and safety of , compared with reference treatment, in patients who received study treatment in the pivotal sponsored study for treatment of <>.Long term efficacy and safetyFinal report30/06/2022 Efficacy studies which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstancesExternal natural history controlled, open-label interventional study to assess the efficacy and safety of in the treatment of , including long-term treatment (CLINI-EXT-05) On-goingTo further investigate the benefits of in the treatment of <>,Long-term efficacyProtocol submission 28/02/2017 Interim reports To be submitted with annual re-assessmentFinal report31/12/2022A global, prospective, non-interventional, observational study in the treatment of (AXAB-9001) OngoingTo provide a report of descriptive data on 1000 patients including 200 patients treated with Long term efficacy and safetyFinal report30/06/2019Part V: Risk minimisation measures (including evaluation of the effectiveness of risk minimisation activities) This part is applicable for all initial marketing authorisation applications. Risk Minimisation Plan For initial marketing authorisation applications for generic, hybrid medicinal products and fixed combination product with no new active substance, if the medicinal product does not have additional risk minimisation activities, the following statement may be sufficient and sections V.1 V.3 may not be applicable: However, if new important risks have been identified for the submitted product, the risk minimisation activities for such safety concerns should be presented in Part V, following the same requirements as for a full marketing authorisation application. If the originator medicinal product does have additional risk minimisation activities, a full Part V is required for these medicinal products. Further guidance on risk minimisation measures can be found in GVP Module XVI and GVP Module XVI Addendum I Educational materials. V.1. Routine Risk Minimisation Measures Include all safety concerns from Part II: Module SVIII. This section may not be applicable for initial marketing authorisation applications for generic, hybrid medicinal products and fixed combination product with no new active substance, where the originator product does not have additional risk minimisation activities. Table Part V.1: Description of routine risk minimisation measures by safety concern Safety concernRoutine risk minimisation activities Please provide the following information, as applicable:  Provide only reference to SmPC/PL section(s) (do not copy the complete SmPC/PL wording): e.g. e.g. Include the specific clinical measures/monitoring information for healthcare professionals in SmPC or patients in PL: e.g. e.g. e.g. when the amount of medicine in a pack helps ensuring that the medicinal product is used correctly. e.g. restricted medical prescription, special medical prescription, categorisation at member states level etc. V.2. Additional Risk Minimisation Measures This section should present the additional risk minimisation measures. The proposed draft key messages of additional risk minimisation activities should be provided in the RMP Annex 6. For medicinal products approved non-centrally, in situations where the need for additional risk minimisation may vary across member states, the RMP can reflect that the need for (and content of) additional risk minimisation can be agreed at national level. This section may not be applicable for initial marketing authorisation applications for generic, hybrid medicinal products and fixed combination medicinal product with no new active substance, where the originator medicinal product does not have additional risk minimisation activities. Select from following options: Statement that there is no need for additional risk minimisation activities Or Further extensive guidance on additional risk minimisation measures and on monitoring the effectiveness of risk minimisation activities is provided in GVP Module XVI, but examples of the materials most frequently used are included below: Healthcare Professional and Patient/Carer Guide The term guide can refer to any descriptive material that educates Healthcare Professional and/or patients/caregivers about specific risks, and/or their early symptoms, and/or the best course of action to be taken when these appear beyond the recommendation contained in the Product Information. A guide may also aim to raise awareness about an on-going (imposed) registry/study, as well as about the general value of reporting adverse events. Terms such as brochure, leaflet should be avoided and the term guide should be used instead. Healthcare Professional training material In case of complex medicinal products, guides may be supplemented with training materials. They are commonly used to train Healthcare Professional when new complicated administration procedures (e.g. intra-vitreal injections, imaging diagnostics, ATMPs, etc.) are introduced or diagnostic products are first authorised, in order to minimise the potential risks associated with performing such procedures. Prescriber checklist Used to facilitate patient selection when initiating therapy or repeat prescription is issued, as appropriate. The checklist should remind prescribers of e.g. a restricted indication, contraindications, warnings and precautions needed for the use of a medicinal product particularly relating to important safety concerns in the SmPC and to facilitate the need for examination of specific aspects of the patients health before initiating treatment and/or during continuous monitoring as appropriate. Patient diary It is generally requested to record information on the recommended treatment (e.g. date and/or outcome of specific tests needed) to facilitate regular monitoring of the patients health status with respect to the medicinal product related safety concerns or particular signs and symptoms that can be discussed with the Healthcare Professionals. It is useful for the patient to read about precautions needed to minimise important risks. Patient alert card The aim of this tool should be to ensure that special information regarding the patients current therapy and its important risks (e.g. potential life-threatening interactions with other therapies) is held by the patient at all times and reaches the relevant healthcare professional as appropriate. The information should be kept to the minimum necessary to convey the key minimisation message(s) and the required mitigating action, in any circumstances, including emergency. Ability to carry with ease (e.g. can be fitted in a wallet) should be a key feature of this tool. Pregnancy prevention programmes A pregnancy prevention programme (PPP) is a set of interventions aiming to minimise pregnancy exposure during treatment with a medicinal product with known or potential teratogenic effects. The scope of such a programme is to ensure that female patients are not pregnant when starting therapy or do not become pregnant during the course and/or soon after stopping the therapy. It could also target male patients when use of a medicinal product by the biological father might have a negative effect on the pregnancy outcome. A PPP combines the use of educational tools with interventions to control appropriately access to the medicine. Therefore, the following elements should be considered individually and/or in combination in the development of a PPP. Educational tools targeting healthcare professionals and patients to inform on the teratogenic risk and required actions to minimise this risk e.g. guidance on the need to use more than one method of contraception and guidance on different types of contraceptives; information included for the patient on how long to avoid pregnancy after treatment is stopped; information for when the male partner is treated; Controlled access at prescribing or dispensing level to ensure that a pregnancy test is carried out and negative results are verified by the healthcare professional before prescription or dispensing of the medicinal product; Prescription limited to a maximum of 30 days supply; Counselling in the event of inadvertent pregnancy and evaluation of the outcome of any accidental pregnancy. Objectives: Include objectives including a list of risks addressed. Rationale for the additional risk minimisation activity: Include justification on why the particular additional risk minimisation is considered needed. Target audience and planned distribution path: Include very brief summary of planned communication plan. Plans to evaluate the effectiveness of the interventions and criteria for success: Specify how effectiveness will be measured and provide the criteria for judging success. Milestones for reporting should be included when effectiveness is evaluated using only routine pharmacovigilance activities. Include justification when an additional risk minimisation activity is proposed to be removed from the RMP. V.3 Summary of risk minimisation measures Table Part V.3: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern Include all safety concerns from Part II: Module SVIII. Examples below are provided in green in the table, to guide on the level of detail expected. For clarity, a further summary of pharmacovigilance activities should also be included for clarity. Although the title of the section makes reference to the risk minimisation activities, to facilitate the drafting and the publication of the RMP summary, as well as to have an overview of risk management activities in the RMP, the table also includes pharmacovigilance activities. Please consider that text from the table below will be included verbatim in the RMP public summary. This section may not be applicable for initial marketing authorisation applications for generic, hybrid medicinal products and fixed combination product with no new active substance, where the originator medicinal product does not have additional risk minimisation activities. Safety concernRisk minimisation measuresPharmacovigilance activities Provide only reference to SmPC/PL section (do not copy the complete SmPC/PL wording) e.g.: e.g. Include only a list of elements from the PhV Plan above  Part VI: Summary of the risk management plan A separate RMP Part VI should be provided for each product in the RMP, but applicants may use the same RMP part VI if the relevant sections of the summary apply to all products with the same active substance. As it is a stand-alone document, do not include any references to other parts of eCTD dossier or other medicinal products published RMP summaries. This section should be submitted for all initial marketing authorisation applications and all post-authorisation RMP updates. When submitting the RMP summary for publication, do not include the title Part VI: summary of the risk management plan. Instead, start on Summary of risk management plan for (). The exact layout of the template can be found on the following page. Summary of risk management plan for () This summary should be updated to reflect any important change to the RMP and be consistent with other RMP parts/modules. This is a summary of the risk management plan (RMP) for . The RMP details important risks of , , and how more information will be obtained about 's risks and uncertainties (missing information). 's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how should be used. For centrally authorised medicinal product only: should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR)>. Important new concerns or changes to the current ones will be included in updates of 's RMP. I. The medicine and what it is used for is authorised for (see SmPC for the full indication). It contains as the active substance and it is given by . For centrally authorised medicinal product only: s benefits can be found in s EPAR, including in its plain-language summary, available on the EMA website, under the medicines webpage . The link to the EPAR summary will be provided to the applicant as part of the cover letter in the CHMP opinion package. MAHs should use the same link for updates related to post-authorisation procedures. II. Risks associated with the medicine and activities to minimise or further characterise the risks Important risks of , together with measures to minimise such risks and the proposed studies for learning more about 's risks, are outlined below. Measures to minimise the risks identified for medicinal products can be: Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals; Important advice on the medicines packaging; The authorised pack size the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly; The medicines legal status the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks. Together, these measures constitute routine risk minimisation measures. Include the sentence below, if the RMP (Part V.2) includes additional risk minimisation measures: , these measures are supplemented with additional risk minimisation measures mentioned under relevant important risks, below>. In addition to these measures, information about adverse reactions is collected continuously and regularly analysed <, including PSUR assessment - include PSUR statement only if product has PSUR requirements> so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities. Include the sentence below, if the RMP does contain missing information in the summary of safety concerns: is not yet available, it is listed under missing information below>. II.A List of important risks and missing information Important risks of are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely . Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of . Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine); List of important risks and missing information (from Part II: Module SVIII)Important identified risks<>Important potential risks<>Missing information<>II.B Summary of important risks If Module SVII is not applicable (see Part II Module SVII requirements) and the reference medicinal product does not have additional risk minimisation activities and no additional pharmacovigilance activities are requested, include only this statement: If Module SVII is applicable (see Part II Module SVII requirements) or the reference medicinal product has additional risk minimisation activities or additional pharmacovigilance activities, provide the following information for each risk/ missing information: Module SVII is applicable: risk > or Evidence for linking the risk to the medicine Delete this row for tables summarising missing informationUse text from RMP Part II SVII.3.1 under Evidence source(s) and strength of evidence or the corresponding SVII Justification of with a submission of this RMP in comparison with the reference medicinal product published on website if SVII.3.1. is not applicableRisk factors and risk groups Delete this row for tables summarising missing informationUse text from RMP Part II SVII.3.1 under Risk factors and risk groups if RMP Part II SVII.3.1 is not applicableRisk minimisation measures Use text from table Part V.3. Use text from table Part V.3. Additional pharmacovigilance activities This row should be removed in case there are no additional pharmacovigilance activitiesAdditional pharmacovigilance activities: Use study short name from table Part V.3. See section II.C of this summary for an overview of the post-authorisation development plan. Module SVII is not applicable but there are additional risk minimisation activities or additional pharmacovigilance activities: risk 2> or Fill this table for each risk that have corresponding additional risk minimisation activities or additional pharmacovigilance activitiesRisk minimisation measures This row should be removed if RMP Part V.3 is not applicable Use text from table Part V.3 Use text from table Part V.3. Additional pharmacovigilance activities This row should be removed in case there are no additional pharmacovigilance activitiesAdditional pharmacovigilance activities: Use study short name from table Part V.3 or from Table Part III.2 if Part V.3 is not applicable. See section II.C of this summary for an overview of the post-authorisation development plan. II.C Post-authorisation development plan II.C.1 Studies which are conditions of the marketing authorisation Include studies category 1 and 2 from Table Part III.1: On-going and planned additional pharmacovigilance activities. Include all studies from Table Part IV.1: Planned and on-going post-authorisation efficacy studies which are a condition of the marketing authorisation or which are a specific obligation. Include text from Part III.2 and/or Part IV. Purpose of the study: Include text from Part III.2 Rationale and study objectives and/or Part IV Summary of objectives. .> II.C.2 Other studies in post-authorisation development plan Include category 3 studies from Table Part III.3: On-going and planned additional pharmacovigilance activities. Include text from Part III.2. Purpose of the study: Include text from Part III.2 Rationale and study objectives. .> Part VII: Annexes For generic (Article 10 (1)) and hybrid (Article 10 (3)) medicinal products, the same requirements as for initial marketing authorisation application for a new active substance apply. For annexes 4 and 6, materials should be kept as similar as possible with the originator product in order to deliver a consistent message. Therefore, marketing authorisation holders are strongly encouraged to share the content of their material(s) upon request from other marketing authorisation holders. Table of contents TOC \o "1-3" \h \z \u  Include TOC of Annexes (it is predefined and not considered as confidential information). Annex 1 EudraVigilance Interface Annex 1 of the RMP is not required to be submitted in eCTD; the electronic file should be submitted in accordance to GVP Module V section V.C.2 and the guidance on the website. Leave Annex 1 empty. Annex 2 Tabulated summary of planned, ongoing, and completed pharmacovigilance study programme List all studies included in the Pharmacovigilance Plan (current or in previously approved RMP versions). Table 1 Annex II: Planned and on-going studies Study Include study short name, title and category number Summary of objectivesSafety concerns addressedProtocol link Milestones Include link or reference to full protocol (included in RMP Annex 3 or eCTD). Include planned submission dates of interim and final study report requested by the Competent Authorities.e.g.: LE observational cohort safety study (study LE123) Category 1e.g. To evaluate over a minimum of 1 year the incidence of all-cause mortality and adverse events of special interest in patients with lupus erythematosus.e.g.: - serious infections (including non-serious and serious opportunistic infections and PML) - malignancies (including non-melanoma skin cancer) - serious infusion - hypersensitivity reactions - serious psychiatric events (mood disorders, anxiety and suicide).Link to protocol Interim results:31 December 2016 Final study report submission: 15 July 2020 Table 2 Annex II: Completed studies Study Include study short name, title and category number Summary of objectives Safety concerns addressedDate of Final Study Report submission Link to report Include date of report submission or state the reason for not submitting the results. Include link or reference to full Final Study report (included in eCTD).e.g.: An open-label, multicentre evaluation of the long-term safety and efficacy of drug A in the prevention and treatment of bleeding episodes in previously untreated patients with acquired haemophilia A A123 Category 2e.g. To evaluate the long-term safety in subjects with acquired haemophilia Ae.g. - Long-term safety - Safety profile in patients e" 75 years27 May 2015 Link to final study reportAnnex 3 - Protocols for proposed, on-going and completed studies in the pharmacovigilance plan Annex 3 should include protocols of imposed studies (categories 1 and 2) and protocols for those required studies (category 3). Protocols of studies not imposed or not required should not be included. This annex may include the electronic links or references to other modules of the eCTD dossier where the protocols are included, instead of the full protocol documents. Table of contents Include ToC Part A: Requested protocols of studies in the Pharmacovigilance Plan, submitted for regulatory review with this updated version of the RMP If protocols have been requested to be submitted for review by the competent authority, and the marketing authorisation holder choses to submit for assessment a study protocol within the same procedure as the RMP submission, part A should include this protocol; alternatively the protocol might be reviewed in a stand-alone procedure, and once agreed, included in the RMP annex 3 part C. When a protocol not yet approved is submitted to address a request for supplementary information, a track changes version of any updated protocol and an executive summary of how outstanding points have been addressed should be always submitted (e.g. in the cover letter of the procedure). Part B: Requested amendments of previously approved protocols of studies in the Pharmacovigilance Plan, submitted for regulatory review with this updated version of the RMP If protocol amendments have been requested to be submitted for review by the competent authority, and the marketing authorisation holder choses to submit for assessment the study protocol amendment within the same procedure as the RMP submission, part B should include the updated protocol; alternatively the protocol amendment might be reviewed in a stand-alone procedure, and once agreed, included in the RMP annex 3 part C. Once approved, protocols from parts A or B should be moved to part C, with the next warranted RMP update. Part C: Previously agreed protocols for on-going studies and final protocols not reviewed by the competent authority This section should include: The final approved protocols for studies included in the Pharmacovigilance Plan (current or in previously approved RMP versions). They should be accompanied by the name of the procedure when the protocol was approved and date of the procedure outcome. The protocols not reviewed or not approved for category 3 studies, for information only. Protocols of completed studies should be removed from this annex once the final study reports are submitted to the competent authority for assessment. Approved protocols: Final protocols not reviewed or not approved: Annex 4 - Specific adverse drug reaction follow-up forms Table of contents Follow-up forms Provide the specific adverse drug reaction follow-up forms in full. Annex 5 - Protocols for proposed and on-going studies in RMP part IV This section should include links or references to other parts of the eCTD dossier, where the protocol for an imposed efficacy study was submitted. This information is meant to facilitate the assessment by maintaining an overview of the post-authorisation efficacy and safety development plans. Annex 6 - Details of proposed additional risk minimisation activities (if applicable) key messages of the additional risk minimisation measures Example: Key messages are included before initial approval of the product (D1- D181) for review and assessment. For Centrally Authorised Products, the PRAC, CHMP (or CAT, if applicable) and EMA will review and agree a final version that will be included in Annex II of the marketing authorisation. If the product requires a revision of the key messages post-marketing, an amended set of key messages can be proposed for assessment in Annex 6 by the Marketing authorisation holder (tracked changes). In exceptional situations, it may be possible to tailor the key elements within the RMP to specific national situations or treatment behaviours/guidelines, i.e. some key elements may be unique for some EU Member States. However, it should be kept in mind that key elements considered applicable for all Member States will be included in Annex II of the marketing authorisation (for centrally authorised products) or as a condition of the marketing authorisation for DCP/MRP and purely national products. The following text can be directly adapted into the final annex II: Prior to the of in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority. The programme is aimed at The MAH shall ensure that in each Member State where is marketed, all who are expected to have access to/are provided with the following educational : Physician educational material: In addition to the Summary of Product Characteristics select all tools that apply: Based on the choice on the above listing, select all relevant elements and edit as required. Guide for healthcare professionals:
and the importance of contributing to such a study> Healthcare professionals training material: , including the approved indication according to the SmPC> > For diagnostic products, select additional information: use, interpretation errors, safety information and the results of clinical trials informing on the diagnostic use of > Prescriber checklist: risks of and the measures to minimise them> Patient alert card: > That treatment may increase the risk of: Signs or symptoms of the safety concern and when to seek attention from a healthcare professional Contact details of the prescriber The patient information pack: Patient information leaflet In addition to the patient information leaflet select all that applies: Based on the choice on the above listing, select all relevant elements and edit as required. The suggested key elements are not strictly supposed to be used only for the related specific tool (see example below): Patient/carer guide: risks(s) associated with the use of namely: and the risks associated with its use, namely: > sign and symptoms of the risk of > Patient diary: to facilitate regular monitoring of the patients health status to product related or > associated with the use of > For pregnancy-related risks, select additional information: in case of pregnancy> Annex 7 - Other supporting data (including referenced material) Only key literature referenced in the RMP should be included in the format of electronic links or references if already included in other modules of the dossier. Annex 8 Summary of changes to the risk management plan over time A list of all significant changes to the Risk Management Plan over time VersionApproval date ProcedureChange   dd/mm/yyyyAdd high level description of major changes: Important Identified/Potential Risk/Missing information 1: Added/ Removed/ Reclassified Study 1: Added as a new safety concern has been identified and need to be further characterised Due date postponed due to difficulties with patient recruitment Removed as study has been completed and obligation has been fulfilled Additional risk minimisation 1: Added/ Modified to increase the patients awareness on the signs and symptoms relevant to the early recognition of increased plasma levels in patients with specific polymorphism Added to inform the healthcare professionals about the new available information regarding heart failure Annex 4: Specific adverse drug reaction follow up forms 1 added   available on EMA website  HYPERLINK "http://www.ema.europa.eu" http://www.ema.europa.eu  QPPV name will not be redacted in case of an access to documents request; see HMA/EMA Guidance document on the identification of commercially confidential information and personal data within the structure of the marketing-authorisation application; available on EMA website  HYPERLINK "http://www.ema.europa.eu" http://www.ema.europa.eu   HYPERLINK "http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124" http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124   HYPERLINK "http://www.hma.eu/464.html" http://www.hma.eu/464.html  Same principle applied as in EMEA/743133/2009: HMA/EMA Recommendations on the handling of requests for access to Periodic Safety Update Reports (PSURs); available on EMA website  HYPERLINK "http://www.ema.europa.eu" http://www.ema.europa.eu   HYPERLINK "http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000429.jsp&mid=WC0b01ac0580029590" http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000429.jsp&mid=WC0b01ac0580029590  EMEA/743133/2009: HMA/EMA Recommendations on the handling of requests for access to Periodic Safety Update Reports (PSURs); available on EMA website  HYPERLINK "http://www.ema.europa.eu" http://www.ema.europa.eu  available on EMA website  HYPERLINK "http://www.ema.europa.eu" http://www.ema.europa.eu  See  HYPERLINK "http://www.ema.europa.eu" www.ema.europa.eu; further ATMP-specific guidance is being developed  EMEA/149995/2008; available on EMA website  HYPERLINK "http://www.ema.europa.eu" http://www.ema.europa.eu   HYPERLINK "http://www.hma.eu/464.html" http://www.hma.eu/464.html   HYPERLINK "http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124" http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124   HYPERLINK "http://www.hma.eu/464.html" http://www.hma.eu/464.html   HYPERLINK "http://www.hma.eu/464.html" http://www.hma.eu/464.html  Changes are considered important if they relate to the following: new safety concerns or important changes/removal to a known safety concerns, major changes to the pharmacovigilance plan (e.g. addition of new studies or completion of ongoing studies), any additional risk minimisation measure which is added or removed, routine risk minimisation activities recommending specific clinical measures to address the risk.   HYPERLINK "http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000683.jsp&mid=WC0b01ac058067a113" http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000683.jsp&mid=WC0b01ac058067a113      IF  STYLEREF "Doc title (Agency)" \* MERGEFORMAT HIXYef    ! j k l 轴|xqbh>>h}d6B*^Jph3f h&hHh' h&hqp h&hh&hqpaJh&hSaJh&haJ h naJh&h.FaJh&hKNaJh&h-BaJh1GmHnHuh1Ghv?jhv?Uh&htaJjh&htUaJ h&hth n" k l 7 Z=HUss  & F^gdgd!UgdqVgd*^gd  & FgdgdHgd gdvegdH@ hgdqp@ @ l x - L 6 7 q z ЦЦЗЗЋЗЗ|mm|a|a|ahM<6B*^Jph3fh>>h-6B*^Jph3fh>>ht#6B*^Jph3fh|e6B*^Jph3fh>>hH6B*^Jph3fh'6B*^Jph3fh>>hve6B*^Jph3fh>>hB6B*^Jph3fh>>h6B*^Jph3fh>>h856B*^Jph3fh>>h56B*^Jph3f ?AHRZx1<XYZ^_ghiʾ⯠⯔vi\iOBOih>>hHCJOJQJh>>h$TCJOJQJh>>hCJOJQJh>>hCJOJQJh>>hve6B*^Jph3fh>>h 6B*^Jph3fh~m6B*^Jph3fh>>h&LM6B*^Jph3fh>>hhL6B*^Jph3fhr{6B*^Jph3fh|e6B*^Jph3fh& 6B*^Jph3fh>>h6B*^Jph3fh>>hp56B*^Jph3f ' <=x 濲{q{g{g{]{N{ghFh_hCJOJQJ^JhV@CJOJQJh|eCJOJQJh2]?CJOJQJhFhCJOJQJhveCJOJQJ^Jh>>hHCJOJQJ^Jh>>h;;CJOJQJ^Jh>>h;;CJOJQJh>>hHCJOJQJh>>hgCJOJQJh>>hvCJOJQJh>>hCJOJQJh>>hKCJOJQJ 4AGHV^ufWfK<h>>h{CJOJQJ^Jh@[CJOJQJ^Jh>>hKCJOJQJ^Jh>>h*CJOJQJ^Jh>>h%2CJOJQJ^Jh>>hCJOJQJ^Jh>>hK5CJOJQJ^JhF5CJOJQJ^Jh>>h5CJOJQJ^J hqVhqVh*^CJOJQJ^JhCJOJQJ^JhFhCJOJQJh|eCJOJQJhCJOJQJ 3RSTUrsrs;oy(ʻ|pdXh: CJOJQJ^Jh+fCJOJQJ^JhCJOJQJ^Jh+yPCJOJQJ^Jh}CJOJQJ^JhaICJOJQJ^JhCJOJQJ^Jh>>h ]CJOJQJ^Jh>>hCJOJQJ^Jh>>h*CJOJQJ^Jh@[CJOJQJ^Jh>>h{CJOJQJ^Jh|eCJOJQJ^Js]"B,A !_!!gd!U  & F^gdg.  & F^gdk  & F^gd}Mgd>>  & F^gd(+?@AJT\]`~ JM!"~+岦妚厂vgggh>>h ]CJOJQJ^JhLf0CJOJQJ^JhCJOJQJ^JhFCJOJQJ^Jhb8CJOJQJ^JhCJOJQJ^Jh>>hFhCJOJQJ^JhCJOJQJ^JhkACJOJQJ^JhCJOJQJ^Jh>>hCJOJQJ^Jhe CJOJQJ^J(+- 12j@ABF_3ʻʬʻʻ呅ymaRyyhkhCJOJQJ^JhkCJOJQJ^JhCJOJQJ^Jh&8CJOJQJ^Jh>h ]CJOJQJ^Jh>>hCJOJQJ^JhzmNCJOJQJ^J 3H_z{+,klt@ A !!;!ʾ񲦚ph>>hg.CJOJQJ^JhV@CJOJQJ^Jh>>hV@CJOJQJ^JhCJOJQJ^Jh"=CJOJQJ^Jh(]CJOJQJ^Jh2]?CJOJQJ^JhCJOJQJ^Jh>>h ]CJOJQJ^JhkCJOJQJ^Jh>>hCJOJQJ^J);!K!W!]!^!_!`!!!!!!!!"2"="G"Y"v"|"""""""""" # ##(#,#N#a#t#ȾҜ~~o~~o~o~~o~```h,ht6B*^Jph3fh,hZX6B*^Jph3fh,ho6B*^Jph3fh,h6B*^Jph3f h&hoh&ho5h&h5h&hoCJaJh>>hve5CJh>>h5CJ h&hh ]CJOJQJ^Jh>>hCJOJQJ^JhICJOJQJ^J%!!!!#$$T%%%i&&H'o'')++,5,,,%.N..S^Sgd&`gd6: ndgdl5/gdgd&gd t#######$4$G$Y$x$$$$$$$$$$"%+%,%I%S%T%%%%%%%%&&g&Ŷ⶧⛶|x|te|eh)h6B*^Jph3fhoh)hh,6B*^Jph3fh,h)6B*^Jph3fh6:6B*^Jph3fh,hfa_6B*^Jph3fh,h6B*^Jph3f h&ho h&hh,ho6B*^Jph3fh,hZX6B*^Jph3fh,ha/6B*^Jph3f$g&h&i&&&&&&&&&&' ' '6'E'F'G'H'I'йkWJ;7hhl5/hj CJOJQJaJhl5/hB*^Jph'h$B*CJOJPJQJ^JaJph-hl5/hB*CJOJPJQJ^JaJph-hl5/hl5/B*CJOJPJQJ^JaJph'hB*CJOJPJQJ^JaJphhCJOJQJaJ-h&hB*CJOJPJQJ^JaJph h&ho h&h+h hZT h&h h)h)h.6B*^Jph3fI'm'n'o'''''''(((()))))* *$*8*{*~***++ + ++߲ߦߚߋߋߋߋߋ||j|^h6B*^Jph3f"jh6B*H*U^Jph3fh,hj6B*^Jph3fh,hC6B*^Jph3fh,6B*^Jph3fhv6B*^Jph3fh,h%6B*^Jph3fh,haE6B*^Jph3fh,h=6B*^Jph3fh,h6B*^Jph3f h,hash h,h++++++,,2,4,5,6,[,\,],j,,,,,,,,,,,,,,--".#.񽹲rcTh,h$/6B*^Jph3fh,h6B*^Jph3fh,h;x6B*^Jph3fh,hn$k6B*^Jph3fhZT6B*^Jph3fh,hZP6B*^Jph3f h&hU h,hUhh&has5 h&has h&hh,h%6B*^Jph3fh,h6B*^Jph3fh,h+w6B*^Jph3f #.$.%.M.N.f.g...........V/X/Y/e/p///y00000 1 111۴񤘌teVRhh,hKX=6B*^Jph3fh,h>h&6B*^Jph3fh6:6B*^Jph3fhm6B*^Jph3fh6B*^Jph3fhO6B*^Jph3fhPv6B*^Jph3fh&#jh0J&6B*U^Jph3f h&h\' h&h0 h&hU h&hh,hn$k6B*^Jph3fh,h6B*^Jph3f ...Y/0 11 111`22Q33J44g566+77 88#99^:K ^KK  I$a$gdbgd&S^Sgd,111 1%1/1:1<1=1>1A1L1Q1w1{11111111111111 2 222+2,2-2.2»л´­עxoko[xjh{h-jp0JtUh-jph{h-jp0Jtjh{h-jp0JtUh&hmH nH u jhhUmH nH u h&hRh h&h, h&hC@ h&h\' h&h h&hi F h&hc1 h&hh,hKX=6B*^Jph3fh,h6B*^Jph3fh&#.2>2?2@2Z2[2\2]2^2_2`2a2b2~22222222222222222222.3/303J3K3L3N3O3P3Q3R3S3o3p3ξξξjqh-jpUjh{h-jp0JtUjwh-jpUjh{h-jp0JtUh-jph#h-jp5OJPJQJ^Jjh{h-jp0JtUj}h-jpUjh-jpU h-jph{h-jp0Jt.p3q3r33333333333333333'4(4)4C4D4E4G4H4I4J4K4L4h4i4j4k4444444444Խ٩ٙԌ٩|oj_h-jpUjh{h-jp0JtUjeh-jpUjh{h-jp0JtUh-jph#h-jp5OJPJQJ^Jjkh-jpUjh-jpU h-jph{h-jp0Jtjh{h-jp0JtUjh{h-jp0JtU+4444444444D5E5F5`5a5b5d5e5f5g5h5i55555555555555566666 6ٲ٭نٲ٭yjSh-jpUjh{h-jp0JtUjYh-jpUjh-jpU h-jp$h#h-jpCJOJPJQJ^JaJjh{h-jp0JtUh-jph{h-jp0Jtjh{h-jp0JtUh#h-jp5OJPJQJ^J) 6!6"6'6(666666666666666667 7 7$7%7&7(7)7*7+7,7-7I7J7K7L7l7m7n77٦ٖy٦ij h{h-jp0JtUh#h-jp5OJPJQJ^JjG h-jpUjh{h-jp0JtUh-jpjMh-jpUjh-jpU h-jp$h#h-jpCJOJPJQJ^JaJh{h-jp0Jtjh{h-jp0JtUjh{h-jp0JtU(7777777777777777888888 8!8"8>8?8@8A8v8w8x888888888888׻׻׊׻z׻m׊׻j5 h-jpUj h{h-jp0JtUh#h-jp5OJPJQJ^Jj; h-jpUj h{h-jp0JtUh-jph{h-jp0Jt$h#h-jpCJOJPJQJ^JaJjh{h-jp0JtU h-jpjh-jpUjA h-jpU*88888999999 9!9"9#9$9%9A9B9C9D9J9K9999999999999999999;:<:=:W:٦ٖ٦yjh{h-jp0JtUj)h-jpUj h{h-jp0JtUh-jpj/ h-jpUjh-jpU h-jp$h#h-jpCJOJPJQJ^JaJh{h-jp0Jtjh{h-jp0JtUj h{h-jp0JtU,W:X:Y:[:\:]:^:_:`:|:}:~::::::::::::::::::G;H;I;c;d;e;g;h;i;j;k;l;;;׻׻׊׻z׻m׊׻jh-jpUjh{h-jp0JtUh#h-jp5OJPJQJ^Jjh-jpUjh{h-jp0JtUh-jph{h-jp0Jt$h#h-jpCJOJPJQJ^JaJjh{h-jp0JtU h-jpjh-jpUj#h-jpU*^::j;;I<<E==b>>=??%@@@zAANBBXCCvDDEFFF+ & Fgd_ZJK -KK I;;;;;;;;;;;;;;;;;;;;;;;&<'<(<B<C<D<F<G<H<I<J<K<g<h<i<j<o<p<<<<<٦ٖ٦yjh{h-jp0JtUj h-jpUjh{h-jp0JtUh-jpjh-jpUjh-jpU h-jp$h#h-jpCJOJPJQJ^JaJh{h-jp0Jtjh{h-jp0JtUjh{h-jp0JtU,<<<<<<<<<<<<<"=#=$=>=?=@=B=C=D=E=F=G=c=d=e=f=============>>׻׻׊׻z׻m׊׻jh-jpUj|h{h-jp0JtUh#h-jp5OJPJQJ^Jjh-jpUjh{h-jp0JtUh-jph{h-jp0Jt$h#h-jpCJOJPJQJ^JaJjh{h-jp0JtU h-jpjh-jpUjh-jpU*>>>?>@>A>[>\>]>_>`>a>b>c>d>>>>>>>>>>>>>>>>>>>>>>>???6?7?8?Խ٦ٖԉ٦y٪ljh-jpUjjh{h-jp0JtUjh-jpUjph{h-jp0JtUh-jp$h#h-jpCJOJPJQJ^JaJjh-jpUjh-jpU h-jph{h-jp0Jtjh{h-jp0JtUjvh{h-jp0JtU*8?:?;????[?\?]?^?????????????????@@@@@ @"@#@$@%@&@'@C@D@E@dzdžyijXh{h-jp0JtUjh-jpUj^h{h-jp0JtUh#h-jp5OJPJQJ^Jjh-jpUjdh{h-jp0JtUh-jph{h-jp0Jt$h#h-jpCJOJPJQJ^JaJjh{h-jp0JtUjh-jpU h-jp)E@F@e@f@g@@@@@@@@@@@@@@@@@@@@@@@@@@AAAAWAXAYAsAtAuAwAxAyAzA{A|AAA|jh-jpUjLh{h-jp0JtUjh-jpUjRh{h-jp0JtUh-jp$h#h-jpCJOJPJQJ^JaJjh-jpUjh-jpU h-jph{h-jp0Jtjh{h-jp0JtU/AAAAAAAAAAAAAAAABBBB+B,B-BGBHBIBKBLBMBNBOBPBlBmBnBùìùȕȅùxùhȕXj: h{h-jp0JtUh#h-jp5OJPJQJ^Jjh-jpUj@h{h-jp0JtUh-jp$h#h-jpCJOJPJQJ^JaJjh-jpUjh-jpU h-jph{h-jp0Jt h{h-jp0JtPJmHnHtHjh{h-jp0JtUjFh{h-jp0JtU"nBoBBBBBBBBBBBBBBBBB5C6C7CQCRCSCUCVCWCXCYCZCvCwCxCyCCCCCCCCCCCCCDD|j"h-jpUj."h{h-jp0JtUj!h-jpUj4!h{h-jp0JtUh-jp$h#h-jpCJOJPJQJ^JaJj h-jpUjh-jpU h-jph{h-jp0Jtjh{h-jp0JtU/DDDSDTDUDoDpDqDsDtDuDvDwDxDDDDDDDDDDDDDDDDEEEEEtEuEvEEEEEEԽ٦ٖԉ٦ylj%h-jpUj%h{h-jp0JtUj$h-jpUj"$h{h-jp0JtUh-jp$h#h-jpCJOJPJQJ^JaJj#h-jpUjh-jpU h-jph{h-jp0Jtjh{h-jp0JtUj(#h{h-jp0JtU*EEEEEEEEEEEEFFFFFFFFF8F9F:F;F}F~FFFFFFFFFFFFFFֽֽ֖~wpip h_Zhqp h_Zh h&hjh_ZhUj'h-jpUj'h{h-jp0JtUj&h-jpUjh-jpU h-jpj&h{h-jp0JtUh-jph{h-jp0Jt$h#h-jpCJOJPJQJ^JaJjh{h-jp0JtU'FFFFFFFFGGaGbGvGwGGGGGGGGGGGGGGGGGGGGDHɽɶppppah~h6B*^Jph3f0hDmhxf5B*PJ^JmH nHphsH tHhDmh<5hSV h~hK6B*PJ^Jph3fhDmhK5hDmh5 hh- hC6B*^Jph3fh1:6B*^Jph3fh6B*^Jph3fhKh hhk hhh_ZhH5!FFbGwGGGGGGqzkd ($$Ifl0 $ : t0G%644 la$If $IfgdKgdkGGGEH+I|vm $IfgdK$If $Ifgdxfzkd($$Ifl0 $ : t0G%644 laDHEHHHHH*I+I,IWIXIIIIIIIIJ1J9J:JⲮphWIW8 h~hl6B*PJ^Jph3fhXE6B*PJ^Jph3f h~h6B*PJ^Jph3fhDmhH5h~hbt6B*^Jph3f hChhl6B*^Jph3fh6B*^Jph3fhDmhl5hDmh5hSV h~hK6B*PJ^Jph3fhXE6B*^Jph3f$h~h6B*^JmHph3fsHh~h6B*^Jph3fh~hK6B*^Jph3f+I,IXIII|vv$If $Ifgdxfzkd()$$Ifl0 $ : t0G%644 laIII;Jv $IfgdXE$Ifzkd)$$Ifl0 $ : t0G%644 la:J;JMXMYMZM|MMMȺ֜~ziXG6 h~h6B*PJ^Jph3f h~h<6B*PJ^Jph3f hmhnK6B*PJ^Jph3f hmh6B*PJ^Jph3fh}hDmhHPJnH tH hSVh_Zh}6B*ph3fh5h6B*ph3f hmh Y6B*PJ^Jph3fhm6B*PJ^Jph3fh Y6B*PJ^Jph3fh6B*PJ^Jph3fhHQU6B*PJ^Jph3f hDmh hDmhMYMM}ww$If$If{kd(.$$Ifl40 $` : t0G%644 laMMMMMMMMMMMMMMMNNNNNNпvhWF5 h~h6;6B*PJ^Jph3f h~h6B*PJ^Jph3f h~h6B*PJ^Jph3fhC6B*PJ^Jph3fhm6B*PJ^Jph3fh6B*PJ^Jph3f hDmh=/hC hDmh hDmhHhDmhH5hDmh5hSV h~hHQU6B*PJ^Jph3f h~h"6B*PJ^Jph3fhe]6B*PJ^Jph3f h~h,6B*PJ^Jph3fMMMMMNHO}}tkb $IfgdC $Ifgd6; $Ifgd=/$If{kd.$$Ifl40 $ : t0G%644 laNNNN6OFOGOHOIOJOcOdOyOOOOOOPPPP,P-P.PFPGPHPIPbPcPпЮ~пЮog_XXMh~hHPJ^J hDmhHhDmhH5hDmh5h~hHB*PJ^Jph3f hDmh=/ hDmhhDmhHPJnH tH hSV h~hC6B*PJ^Jph3f h~h6B*PJ^Jph3f h~h=6B*PJ^Jph3f h~h6B*PJ^Jph3f h~h6;6B*PJ^Jph3fhe]6B*PJ^Jph3fHOIOJOdOP}tk $Ifgd6; $Ifgd$If{kd\/$$Ifl40 $` : t0G%644 laPP-P.PGP}}}$If{kd/$$Ifl4C0 $ : t0G%644 laGPHPIPcP}w$If$If{kd0$$Ifl490 $` : t0G%644 lacPdPPPQzqq $Ifgd\ $Ifgd_{kd'1$$Ifl4.0 $ : t0G%644 lacPdPxP{PPPPPQQQQ Q!Q"Q3QVQWQ]QpQ R R1R;R=RcRfRRž|rhaWMrMhCJOJQJhICJOJQJ h+fh2djhSCJOJQJhe]CJOJQJhZTCJOJQJh~hCJOJQJh&hr5CJaJh&hK]45CJaJh&h5CJaJ h&h hDmhz h~h6B*PJ^Jph3f hDmh_ hDmhhDmh_5hDmh#h5hDmh5hSVQQQ"Q RTV%WWY{vqld_ZgdRgd~$a$gdegdTOUgd.gd#s`gdAGgd4a'zkd1$$Ifl0 $ : t0G%644 la RRRRRRRRRSSSS^SySSSTTBTXTYTTTTTTTCVHVV߻ȊqaqUqh6B*^Jph3fh6B*^JmHph3fsHhwh6B*^Jph3fh.CJOJQJh]%CJOJQJh~huCJOJQJh~hq$CJOJQJh~hfCJOJQJh~hrCJOJQJhe]CJOJQJhfJhCJOJQJhCJOJQJjhH*UhhDhCJOJQJVVV!W$W%WWWMX{XXXXYYYYNZVZZZ[ZcZdZmZZZZӿӵӵӵxjxjx\xNhH>|6B*^JaJph3fhB6B*^JaJph3fh6B*^JaJph3f hmh6B*^JaJph3fh6B*^JaJph3f h~h6B*^JaJph3fh~hRCJOJQJhfgCJOJQJhCJOJQJh~mCJOJQJh~hCJOJQJ h&hHhQ] h&hKT h&h h#s`h2djZZZZZZZZZ&[*[+[?[j[k[u[v[w[x[[[[[[[žylbXlbKh~hrECJOJQJhCJOJQJhCJOJQJh~h;CJOJQJh~hT'CJOJQJhZTCJOJQJhM<CJOJQJh~h-CJOJQJh-CJOJQJh~hCJOJQJ h}MhRh(6B*^JaJph3f hmh6B*^JaJph3fhH>|6B*^JaJph3fhTOU6B*^JaJph3fYZw[[[\9\\\\\]^^6`P`9a.bbccc.dd & Fgd  & Fgd  & Fgdgdegde & F gdgd~gdB[[[[[[\\\$\.\6\7\8\9\\\i\m\\\\\\\\\\\\\ŸܫšŇŇŇš~rfZSLS hmhjE hmhh&h@$<5CJaJh&h :5CJaJh&hH5CJaJh5CJaJh-hCJOJQJh~h.CJOJQJh-CJOJQJh~hUT<CJOJQJh~h CJOJQJhCJOJQJh~h;CJOJQJhCJOJQJh~hCJOJQJh~h+ICJOJQJ\\\\\=]>]@]A]F]L]N]\]i]j]]]]]]]]]]j^n^^^^^^^^^^듄xib^bh@$< hmhA~hmh :6B*^Jph3fh6B*^Jph3fhmh@$<6B*^Jph3fhmh\hmh%6B*^Jph3f hmhhhmhh6B*^Jph3fhmh,[6B*^Jph3f hmh!F hmh,[ hmhcq hmhr[ hmhq hmh hmh :"^8_9_b_________```$`5`6`N`O`P`a`k```aa8a9aʻ񻝻廎ymamamUmIhnF6B*^Jph3fh@6B*^Jph3fhc*6B*^Jph3fh6B*^Jph3f h@$<h : h@$<hcq h@$<hhmh :6B*^Jph3fhmhtE6B*^Jph3fhmhrEn6B*^Jph3fhmhq 6B*^Jph3fhT6B*^Jph3fhmh 6B*^Jph3fh6B*^Jph3fhmh6B*^Jph3f9a>aFaaaaaabbb-b.bbbFcMcPcQccccccʻuiZK<h hh6B*^Jph3fhNUh6B*^Jph3fhh6B*^Jph3fh|6B*^Jph3fhmha6B*^Jph3fhmh|6B*^Jph3fhmh :6B*ph3fha6B*^Jph3fhmh6B*^Jph3fhmh!F6B*^Jph3fh@$<6B*^Jph3fhmhu6B*^Jph3fhnF6B*^Jph3fhmh6B*^Jph3fcccc-d.dKdVdedqddddddddde e e"e;efCf|f'j/kklfmn{oooo!qgd  & F gdgdgdegdggd.sG & F7^7`gd8Ggd.sgd!eeeeeeeeeeeee f"f.f/f=f>fBfCfmf{f|fffHgIggghh1h;hhhiBiԿ髜~tttjt~h4/CJOJQJhVCJOJQJhLgCJOJQJhghCJOJQJ h!h.sh(#h6B*^Jph3fh&h5h$_1h.s5nH tH (h(#h6B*PJ^JnH ph3ftH h$_1h5nH tH h5nH tH h.sh hBhh.snH tH %BiNiiiii&j'j5jfjjjjjjjjjjjjjjj+k.k/k3k8kdkkk˴˧˚ˍˀvi_Uh8CJOJQJh|CJOJQJhmh^CJOJQJhUCJOJQJhmhEICJOJQJhmh0cCJOJQJhmh&LMCJOJQJhmhuCJOJQJhmhinCJOJQJh!CJOJQJhmhCJOJQJhgCJOJQJhVCJOJQJhLgCJOJQJhlGCJOJQJkkkkk6l:lll4m=m>memfmmmmmmmmmmmqnnnnnnnnnnnnoo*o.o/o¸zmchCJOJQJh& hCJOJQJhmh0cCJOJQJhmhCJOJQJh7CJOJQJhmhu"CJOJQJhmh%KCJOJQJhCJOJQJhmhKCJOJQJhVCJOJQJhmhHCJOJQJhmhCJOJQJhmhCJOJQJ&/oKoooyozo{o|ooooooooooopp q!q%qQqRqZq[qqq`sasssssstttpt齶zzpchmhhCJOJQJhvCJOJQJhmhD]CJOJQJhmhCJOJQJho:CJOJQJh*GnCJOJQJ h&h h&h h&hh hVCJOJQJhmh CJOJQJhCJOJQJ hh hCJOJQJhmhCJOJQJ&!qRqasttvUwywwwwwwwmkdS2$$Ifl4$  t0644 lalf4yt8 G$Ifgdegdegde$a$gde ptztttttu u%uuu v v vvvvvvvv w,wSwTwUwxwywwwwwwwwȾ雎鎄wpipb[bpiWhSV h&hh h&hd$ h&h h&hhmh[yCJOJQJh}CJOJQJhmh`ECJOJQJhcRCJOJQJhmhCJOJQJjh0J&CJUh%CJOJQJh:CJOJQJhp;ZCJOJQJhmhkCJOJQJhmhCJOJQJh+:oCJOJQJ"wwwwwwwwwwwwwwwwwwwwwwwwwwwwxxxxxxx,x6x@xDxFxHxJxbxdxfxxϾϜϋϜzϜϾϜs h&hM hmhQV6B*^JaJph3f hmhin6B*^JaJph3f hmh6B*^JaJph3f hmhh6B*^JaJph3f hmhFp6B*^JaJph3f hmh6B*^JaJph3fhSV h&h h&h| hmh3 h&h-wwwwwlccc G$Ifgdekd3$$Ifl4Fu$f   I   t06    44 lalf4yt8wwwwwlccc G$Ifgdekd4$$Ifl4Fu$f  I  t06    44 lalf4yt8wwwwwlccc G$Ifgdekd5$$Ifl4Fu$f  I  t06    44 lalf4yt8wwxxxlccc G$Ifgdekd6$$Ifl4Fu$f  I  t06    44 lalf4yt8xxBxDxlcc G$Ifgdekd 7$$Ifl4Fu$f  I  t06    44 lalf4yt8DxFxHxv G$Ifgdekd 8$$Ifl40u$f   "    t0644 lalf4yt8HxJxdxfxmkd9$$Ifl4$  t0644 lalf4yt8 G$Ifgdemkd8$$Ifl4$  t0644 lalf4yt8fxxxxxxxxckd1:$$Ifl4Fu$f   I   t06    44 lalf4yt8 G$Ifgdexxxxxxxxxxxxxxxxxxxxyyy y y"y&y(y6y@yJyhylynypyyyzzzzb{ֳֳvjh}6B*^Jph3f#jh0J&6B*U^Jph3fhmh6B*^Jph3f h&h[y h&hC1 h&hh h&hM hmhQV6B*^JaJph3f h&hFph`hFpB*ph3f hmh6B*^JaJph3fhSV h&h| h&h h&h)xxxxxlccc G$Ifgdekd3;$$Ifl4Fu$f  I  t06    44 lalf4yt8xxyyylccc G$Ifgdekd5<$$Ifl4Fu$f  I  t06    44 lalf4yt8y y"y$y&ylccc G$Ifgdekd7=$$Ifl4Fu$f  I  t06    44 lalf4yt8&y(yjylylcc G$Ifgdekd9>$$Ifl4Fu$f  I  t06    44 lalf4yt8lynypyyc{m{v{{zzzqqq G$Ifgd`gdekd;?$$Ifl40u$f   "    t0644 lalf4yt8b{c{l{m{u{v{{{{{{{{{{{{{{{{{{{{{{||| |||&|'|+|,|9|=|M|N|R|S|[|_|o|p|t|u|||||||||||||||hmhu6B*^Jph3fhmhU?6B*^Jph3fhmh6B*^Jph3fhSV h&hh&hU?nH tH h&hnH tH hmhC16B*^Jph3f>{{{{{{{offfff G$Ifgd`kd@$$Ifl4F 1%      t06    44 layt8{{{{{{I;222 G$Ifgd`d$Ifgdmkd@$$Ifl4r  1%  [\\Z  t0644 layt8{{{{{{B4d$IfgdmkdA$$Iflr  1%  [\\Z  t0644 layt8 G$Ifgd`{{{{||B4d$IfgdmkdC$$Iflr  1%  [\\Z  t0644 layt8 G$Ifgd`|||| |'|B4d$IfgdmkdD$$Iflr  1%  [\\Z  t0644 layt8 G$Ifgd`'|(|)|*|+|,|BkdE$$Iflr  1%  [\\Z  t0644 layt8 G$Ifgd`,|N|O|P|Q|R| G$Ifgd`d$IfgdmR|S|p|q|r|s|K=444 G$Ifgd`d$IfgdmkdF$$Iflr  1%  [\\Z  t0644 layt8s|t|u||||B4d$IfgdmkdG$$Iflr  1%  [\\Z  t0644 layt8 G$Ifgd`||||||B4d$IfgdmkdH$$Iflr  1%  [\\Z  t0644 layt8 G$Ifgd`||||||B4d$IfgdmkdI$$Iflr  1%  [\\Z  t0644 layt8 G$Ifgd`||||||BkdJ$$Iflr  1%  [\\Z  t0644 layt8 G$Ifgd`|||||| G$Ifgd`d$Ifgdm||||||||||||||||}} }}}}}}}}}}}}}$}%})}*}:};}?}@}E}J}K}^}_}o}p}x}y}}}}}}}}}}ЫߠРߠhmhD56B*^Jph3fh&hD5nH tH  h&hhmhU?6B*^Jph3fhmh6B*^Jph3f h&hhnH tH h&hnH tH hSVh&hU?nH tH  h&hU?8|||||||KBBBBB G$Ifgd`kdK$$Iflr  1%  [\\Z  t0644 layt8|||KB G$Ifgd`kd L$$Iflr  1%   [ \ \ Z   t0644 layt8|||||&hkdM$$Ifl1%  t0644 layt8 G$Ifgd`hkd M$$Ifl1%  t0644 layt8|}}}}}}}}hkdHN$$IflF 1%      t06    44 layt8 G$Ifgd`}}%}&}'}(}K=444 G$Ifgd`d$Ifgdmkd;O$$Iflr  1%  [\\Z  t0644 layt8(})}*};}<}=}B4d$Ifgdmkd}?}@}F}G}H}I}Bkd=Q$$Iflr  1%  [\\Z  t0644 layt8 G$Ifgd`I}J}K}_}p}y}B=44 G$Ifgdegdekd>R$$Iflr  1%   [ \ \ Z   t0644 layt8 G$Ifgd`y}}}}}}fXd$Ifgdmkd?S$$IflF 1%      t06    44 layt8 G$Ifgde}}}}}oaXX G$Ifgded$Ifgdmkd6T$$IflF 1%    t06    44 layt8}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}~~~~~ ~ ~ ~~~~~~~~~~~~³³¤•||h&hnH tH  h&h h&hhweh6B*^Jph3fhwehu6B*^Jph3fhwehD56B*^Jph3fhweh6B*^Jph3fhnH tH h&hnH tH hSVh&hD5nH tH h&hD56nH tH 0}}}}}offf G$Ifgdekd-U$$IflF 1%    t06    44 layt8}}}}}offf G$Ifgdekd$V$$IflF 1%       t06    44 layt8}}}}}offf G$IfgdekdW$$IflF 1%    t06    44 layt8}}}}}offf G$IfgdekdX$$IflF 1%     t06    44 layt8}}}}}oaXX G$Ifgded$Ifgdwekd Y$$IflF 1%      t06    44 layt8}}~~~oaXX G$Ifgded$IfgdwekdZ$$IflF 1%    t06    44 layt8~~ ~ ~ ~offf G$IfgdekdZ$$IflF 1%    t06    44 layt8 ~ ~~~~~~ojjaaa G$Ifgdegdekd[$$IflF 1%       t06    44 layt8~~~~~~~~~~~~~~~ ,/0[`߀6ôè񛑛zzzph}CJOJQJhmhz`}CJOJQJhtqCJOJQJhCJOJQJhmhCJOJQJhwe6B*^Jph3fhweh6B*^Jph3fhweh6B*^Jph3fh&h6nH tH h&hnH tH hnH tH hSVh&hnH tH *~~~~~offf G$Ifgdekd\$$IflF 1%      t06    44 layt a~~~~~oaXX G$Ifgded$Ifgdwekd]$$IflF 1%    t06    44 layt a~~oaXX G$Ifgded$Ifgdwekd^$$IflF 1%    t06    44 layt aofff G$Ifgdekd_$$IflF 1%    t06    44 layt a 7*Fojbb]]UPgdJ$a$gdegdz`} & F gdgdtqkd`$$IflF 1%       t06    44 layt a67Zgk)*+EHU[ CEFă Z_9춬좕{nnan{nhweh}CJOJQJhweh(|jCJOJQJhwehuCJOJQJhwehCJOJQJhwehCJOJQJhgCJOJQJh.XCJOJQJhJhCJOJQJ h&h h&h[1 h&h h}Mhz`}h-hCJOJQJhCJOJQJhz`}CJOJQJ%9Dbwy&358RVZnɇ· ˾}pf\\R\\hCJOJQJhCJOJQJh{CJOJQJhwehf7CJOJQJhwehC1CJOJQJhwehuCJOJQJhweh/CJOJQJhweh WCJOJQJhwehCJOJQJhwehgCJOJQJh(CJOJQJh}CJOJQJhJCJOJQJhweh(|jCJOJQJhCJOJQJF6QɈf(4JÊv[ُ?[ $Ifgdegdgde6 ngdegd & F gdgdgde567<FPQRv}ȈɈFeflmȉщ҉'(34?鸱ҕ{qj`h&h>*\ h&h`h&h5\hwehBCJOJQJhwehtECJOJQJhwehtE>*CJOJQJ h&hB h&h h&hhhCJOJQJh=hCJOJQJhwehCJOJQJhCJOJQJhCJOJQJhwehCJOJQJ%?IJŠÊNJȊՊߊ).WZkȸ|uh[hNhhweh55CJOJQJhweh^CJOJQJhwehCJOJQJ h&h[1 h&hghKhQ h&hB h&hhKeh`5\hFhF\hF6B*\^Jph3fhweh6B*\^Jph3fh} h5\hy2h>*\hxshX[\hxsh\hKeh`>*\hKeh>*\kswx|ċ4Sj~滱検|tojbZRZMjRZ hl)\h>>h\h>>h\h;L2h\ hK\ hQ\h} h\hy2h\hxsh\hKeh \hKeh\hKeh\hweh.CJOJQJhCJOJQJh)CJOJQJh}CJOJQJhKCJOJQJhweh55CJOJQJhwehCJOJQJhwehCJOJQJՌ֌ߌ!"#(2JMtuv=Ǻ|||ohaTh<hCJOJQJ h&h[1 h&hhweh.CJOJQJhweh^CJOJQJhweh4v"CJOJQJhweh55CJOJQJhwehBCJOJQJh}CJOJQJhwehCJOJQJh,h.6h,hB6h,h\h,h\h!Uh\h!Uh\h>>h\=G[pv~ʎَގɏ̏׏؏ُ>?ܸܸvi_XTXM h&h(hY: h&hh:CJOJQJh9NLhGCJOJQJhKeCJOJQJh9NLh`(CJOJQJh9NLh7>CJOJQJhmbCJOJQJhjCJOJQJhY:CJOJQJh9NLh@=CJOJQJh`CJOJQJh9NLh55CJOJQJh9NLhCJOJQJh<hCJOJQJhCJOJQJ?YZ[knvאܐݐސ*ĵӦymaUFB; hKehhSVh9NLh6B*^Jph3fh6B*^Jph3fhB6B*^Jph3fh6B*^Jph3fh9NLhs6B*^Jph3fhy2hj5]hxsh5]hKehB5]h9NLh6B*^Jph3fhh6B*^Jph3fh9NLh6B*^Jph3fh9NLh6B*^Jph3fhy2h7>5]hxsh5]hKeh5][ސ+^e\S $Ifgde $Ifgd9NLkda$$Ifl40F%bb t0&44 laPf4pyt a $Ifgde $IfgdKe*+]^ '(6PQlm’Ò"#012̾{tmi_Rh9NLhBCJOJQJhCJOJQJhj hmh`( hmh h,hl h,hg h,h h>>h h>>h`(hx4 h} h hy2hl hxsh hKehB hKeh7> hmh@= hKehhSVh9NLh@=CJOJQJh9NLhCJOJQJhKeh hKeh@= ull $IfgdekdLb$$Ifl4"0F%b`b t0&44 laPf4pyt a (QmÒ1wnaaaaaXO $Ifgde $Ifgdj  & F $Ifgd $Ifgdekdb$$Ifl40F%b b t0&44 laPf4pyt a 12cwnn $Ifgdekdc$$Ifl40F%bb t0&44 laPf4pyt a2Ubcȓ͓Γ12?@AGHXCDEF{|ôssle[hE`<CJOJQJ h&h c h&hh9NLhCJOJQJh9NLh@=CJOJQJh9NLhCJOJQJ hKeh@= hxshBh6B*^Jph3fh9NLh6B*^Jph3fhj h} hB hy2h hxsh hKeh7hSVh hKehB hKeh hKehΓ@wne\ $Ifgde $Ifgdj $IfgdKekdd$$Ifl40F%bb t0&44 laPf4pyt a@AHDEwne\e $Ifgdj $Ifgde $Ifgdekdd$$Ifl40F%bb t0&44 laPf4pyt aEF|ݖvۜwojeee`[Vgd6gdegdE`<gdegd~~$a$gdekd>e$$Ifl40F%bb t0&44 laPf4pyt a ͕̕ӕԕvۖܖݖ "6ŗƗǗʗ˗̗¸®ܡ攇zm`mmSzh9NLhQVCJOJQJh9NLh55CJOJQJh9NLh@&1CJOJQJh9NLhvKCJOJQJh9NLhrOCJOJQJh9NLh[`CJOJQJh~~h~~CJOJQJhcCJOJQJhuFCJOJQJh~~hCJOJQJh9NLh} CJOJQJh} CJOJQJh9NLhCJOJQJh9NLh/??CJOJQJ >uv{| J؜ڜۜ)ȝ¸ٸٸ٫ٸقxkaWh%CJOJQJhcCJOJQJh9NLhCJOJQJhs{CJOJQJh+@FCJOJQJh+PCJOJQJ h&h c h&h$y h&hhE`<hE`<CJOJQJhCJOJQJhrOCJOJQJh9NLhrOCJOJQJh9NLhCJOJQJh9NLh cCJOJQJh9NLhXXCJOJQJ" 23ßğȟџӟԟڟ;?@PQVjuw»»uuhuh[h9NLhKoiCJOJQJh9NLh2~ CJOJQJhcCJOJQJh9NLhvKCJOJQJ h} h c h} hh9NLhSCJOJQJh9NLhQVCJOJQJ hy2h c hy2h hxshh9NLhZCJOJQJh9NLhY1vCJOJQJjhCJH*OJQJUh9NLhCJOJQJۜ 3ğԟ T_cot $$Ifa$gd9NLgd9NLgdegdeΠӠڠ۠YZ\`dnopϺxk_kUKUKUhCJOJQJhaCJOJQJjh0J&CJUh9NLh0CJOJQJh9NLh/CJOJQJh/CJOJQJh9NLhCJOJQJ h,h~vh,hIL\ h,hJh!UhIL\ h!UhJ h>>hJ h>>h lh>>hIL\ h>>h h} h hy2hJ"8 hxshh9NLhD5CJOJQJpqϡ 'Xdw{~¢ST^_bcnost߾ߴ짐yyyyyyub%h th/B*PJ^JnHphtHhSV-h&h/B*PJ^JmH nHphsH tH-h&hB*PJ^JmH nHphsH tHh9NLh9NLCJOJQJhmGwCJOJQJhQYCJOJQJhcCJOJQJh9NLhaCJOJQJh9NLhCJOJQJhaCJOJQJhCJOJQJ&kde$$Ifl4Fֈ 1%$$C$!$$$ t044 lap<:LfxȤ&(8:<>@BDFHJLFfTh $$Ifa$gd9NL $Ifgde8:JLdfvxƤȤ$&(6RTjln¥ĥ̥5~~wp h&hY h&h'h/B*PJ^JmH nHphsH tH-h&hTB*PJ^JmH nHphsH tH-h&hB*PJ^JmH nHphsH tHhSV h}Mh/CJOJQJmH sH  h}MhCJOJQJmH sH h9NLhCJOJQJh9NLh/CJOJQJ)LNPRTprtvxz|~FfqFfl $Ifgde¥ĥ6`x&ĭخP%gd & Fgdm & Fgdgdgdegde$a$gdeFfCv $Ifgde56_`!%wx~%&DŻܻܻ~m\K h9NLh(A6B*^JaJph3f h9NLhKoi6B*^JaJph3f h9NLh6B*^JaJph3f h9NLh'6B*^JaJph3f h9NLh6B*^JaJph3f h&hM h&hhhCJOJQJhCJOJQJhNCJOJQJh9NLhuCJOJQJh9NLhCJOJQJhxshN5hxsh5 h&h[1DT_cdefgɩ!+NT± ~m\K=\hg.6B*^JaJph3f hvhl6B*^JaJph3f hvh6B*^JaJph3f h9NLhT$6B*^JaJph3f h9NLhVG6B*^JaJph3f h9NLhI6B*^JaJph3f h9NLh\6B*^JaJph3f h9NLhl6B*^JaJph3f h9NLh6B*^JaJph3fh*o6B*^JaJph3fhXm6B*^JaJph3f h9NLh 6B*^JaJph3fTd٪*;^oz{~ͼͮ͝ތ~pbTEh9NLh6B*^Jph3fhh6B*^JaJph3fh*o6B*^JaJph3fh6B*^JaJph3fhXm6B*^JaJph3f hvhI6B*^JaJph3f hvhp6B*^JaJph3fhmGw6B*^JaJph3f hvh'6B*^JaJph3f hvh6B*^JaJph3f hvh6B*^JaJph3f hvh(A6B*^JaJph3f«ëƫ]gĬάíĭjkϮ׮خOPovȼwhYMh2-6B*^Jph3fhvh6B*^Jph3fhvhyW 6B*^Jph3fhI6B*^Jph3fhvh6B*^Jph3fh|h|6B*^Jph3fhL6B*^Jph3fh9NLh6B*^Jph3fh6B*^Jph3fh .h6B*ph3fhL6>*B*^Jph3fh6>*B*^Jph3fh9NLh6>*B*^Jph3fvBNm°ð2i|maRFR7h9NLh6B*^Jph3fh2-6B*^Jph3fh9NLh6B*^Jph3fh6B*^Jph3fhvh6B*^Jph3fhmGw6B*^Jph3fhvh6B*^Jph3fhmh6B*^Jph3fhmh6B*^Jph3fhmh2-6B*^Jph3fh36B*^Jph3fh~c56B*^Jph3fh-o"6B*^Jph3fhzA6B*^Jph3fhZi6B*^Jph3f Ȳ bgtuvwz{ͽrfTH9h9NLh6B*^Jph3fh{6B*^Jph3f#jh0J&6B*U^Jph3fh6B*^Jph3fh6B*^JmHph3fsHhwh6B*^Jph3fhmGwh6B*^Jph3fhmGw6>*B*^Jph3fh9NLh6>*B*^Jph3fhh6>*B*^Jph3fh|6B*^Jph3fhL6B*^Jph3fh9NLh6B*^Jph3fh6B*^Jph3f{$%)B)jlrvw̷зʻ~n__P__;__(h9NLh6B*PJ^JnHph3ftHh9 Uh6B*^Jph3fh9NLh6B*^Jph3fh|h|6>*B*^Jph3f#h|h6>*B*^JaJph3fh^\:h^\:6B*^Jph3fh6B*^Jph3fh^\:h6>*B*^Jph3fh^\:h6B*^Jph3f h|h|6B*^JaJph3f'jh0J&6B*U^JaJph3f h9NLh6B*^JaJph3f%dǽ*C+S & Fgd^ & Fgd^gdUcgd^6 ngdegde kdgd|gd|gd|6R :Rtǹȹ2῱vvvl__U_hLCJOJQJhV&hCJOJQJhr CJOJQJhfJhCJOJQJjhH*UhhDhCJOJQJhCJOJQJh{3]hCJOJQJh|6B*^JaJph3fhr 6B*^JaJph3f'jh0J&6B*U^JaJph3fh6B*^JaJph3f h9NLh6B*^JaJph3f!ں |}~67>@HIOScdĽƽǽ)ȾȰ՛j,h|h6B*CJOJQJ^JaJph3fh|h|>* hr >*h|hr >* hs3>*h|h>*hmFh|CJOJQJjh0J&CJU^Jh"CJOJQJhfJhCJOJQJh|CJOJQJhACJOJQJhCJOJQJhmFhCJOJQJ )*=>tucABCJrs{)*ijĪ}oao}P h^h6B*^JaJph3fh=s%6B*^JaJph3fh)6B*^JaJph3f h9NLh6B*^JaJph3f h&hT$ h&h& h&h l h&hhs3h)^J h|h6B*^JaJph3fh|h^J hh` hh| hhA hh,h|h|6B*CJOJQJ^JaJph3f*+<Hdey~4TX7mop毞{m{m{m{mm_{m{Q{m{h 6B*^JaJph3fhK6B*^JaJph3fh6B*^JaJph3f hhh6B*^JaJph3f#hTh6>*B*^JaJph3f h;h6B*^JaJph3fhUc6B*^Jph3fh :h6B*^Jph3fhush6B*^Jph3fhW%h6B*ph3fh6B*^Jph3fh^6B*^JaJph3fpy}~"~ae±~m_QmQmCh56B*^JaJph3fhK6B*^JaJph3fh6B*^JaJph3f hth6B*^JaJph3fhFh^6B*ph3fhh h6B*^Jph3fhK6B*ph3fhFh6B*ph3f hh h^6B*^JaJph3f hh h6B*^JaJph3f hhh6B*^JaJph3fh 6B*^JaJph3fh6B*^JaJph3fe'78\|ŷӦᕄsdREhh6B*ph3f#h h6>*B*^JaJph3fh6>*B*^JaJph3f h5h6B*^JaJph3f heHBh6B*^JaJph3f h.lh^6B*^JaJph3f h.lh6B*^JaJph3fh6B*^JaJph3fhK6B*^JaJph3fh56B*^JaJph3fh6B*^JaJph3f hh6B*^JaJph3f!"MinERSY;<AKõ}qbQGh&h5^J h9NLha6B*^JaJph3fhKMh^6B*^Jph3fhVp6B*^Jph3fh56B*^Jph3f h9NLh6B*^JaJph3fh9NLh6B*^Jph3fh6B*^Jph3fh^6B*^JaJph3fh6B*^JaJph3f h n<h6B*^JaJph3f heHBh6B*^JaJph3fh6h6B*ph3f ?DGQw ϾϾφxjYKh-6B*^JaJph3f hvh-6B*^JaJph3fh{6B*^JaJph3fhI9/6B*^JaJph3fh 6B*^JaJph3fhVp6B*^JaJph3fhK6B*^JaJph3fh#@6B*^JaJph3f hhh6B*^JaJph3fh6B*^JaJph3fh&ha5^J hE45^Jh&h5^J hUs5^J '(M"LVwŷ||kZZZZLZLh%6B*^JaJph3f h]+.h6B*^JaJph3f h) 0h) 06B*^JaJph3fh(6B*^JaJph3f h) 0h6B*^JaJph3fh q6B*^JaJph3fhj-6B*^JaJph3fh6B*^JaJph3f hhh6B*^JaJph3fh-6B*^JaJph3fh{6B*^JaJph3fhSx26B*^JaJph3f(Me&6q(D()gd!^gdgd9NLgd@gde & FgdS & Fgd]+. & Fgd) 0gd q KLMYZ}~ޱВВvhZLh6B*^JaJph3fh) 06B*^JaJph3fhS6B*^JaJph3fh6B*^JaJph3fhVp6B*^JaJph3f h) 0h6B*^JaJph3fh]+.6B*^JaJph3f h%h6B*^JaJph3fh%6B*^JaJph3fh6B*^JaJph3f h]+.h6B*^JaJph3f h]+.h%6B*^JaJph3f)-46NWûӴ}q}e}YMAh6B*^Jph3fh6B*^Jph3fh!6B*^Jph3fhZ6B*^Jph3fh26B*^Jph3fh#@6B*^Jph3fh9NLh6B*^Jph3fh&hM<5^Jh&h5^JhQhE45 hE45^JhQh5hQh<5hQh 5 h 5^J h5^Jhj-6B*^JaJph3f hSh!6B*^JaJph3f defg!&*+@`kֻxtpllh>h h| hxsh h9NLhM<hheJb h9NLh>hM<hVphQh+BhG5 h9NLh h9NLhFhh9NLh@6B*^Jph3fhSn6B*^Jph3fh6B*^Jph3fh9NLh6B*^Jph3fhxsh6B*^Jph3f) 5EF"#$%&'456Zfpqxhy2h5^JmHsHhy2ha5^JmHsHhxsh5^J h9NLhARh h!h.sh-h>hVphPhehxq hv8hv6B*^JaJph3fhKhRu h9NLh h9NLhM< h9NLhFhhAk+'(BYZaku;BCDb;paRF:h6B*^Jph3fhH:G6B*^Jph3fhH:Gh6B*^Jph3fh9NLhM6B*^Jph3fh9NLh~6B*^Jph3fh9NLh6B*^Jph3fh.6B*^Jph3fhVp6B*^Jph3fh=M6B*^Jph3fh CI6B*^Jph3fh9NLh6B*^Jph3fh} hR,o5^JmHsHhE45^JmHsHhy2h5^JmHsHhUs5^JmHsHbc~!-HRYefop%'ʻٻ|paUIhPv6B*^Jph3fh"6B*^Jph3fhoJh6B*^Jph3fhKM6B*^Jph3fhyZ6B*^Jph3fh6B*^Jph3fh6m6B*^Jph3fhVp6B*^Jph3fhoJhoJ6B*^Jph3fhoJhKM6B*^Jph3fhoJh6B*^Jph3fhOl6B*^Jph3fh6B*^Jph3fhBh6B*^Jph3f'()GHstuvz =Mk˿˰}sfsfWJht.hqV6B*ph3fh:5Qh7A:6B*^Jph3fh:5Qh7A:6B*ph3fhyZ6B*ph3fh:5Qh=6B*ph3fh:5Qh=6B*^Jph3fhK6B*ph3fh:5Qh6B*ph3fh:5Qh6B*^Jph3fh4OY6B*^Jph3fh6B*^Jph3f h~5^Jhxsh5^JhuW6B*^Jph3fhB6B*^Jph3f)Htw/QVSg & Fgdl & Fgdv & Fgdw\ & FgdyH9gd: & Fgd & F"gd & F"gdN & F"gdQgd:5Qgde %'WXYinoyzv񦗇znzbbSShh6B*^Jph3fhLX36B*^Jph3fhPw:6B*^Jph3fh6B*^Jo(ph3fhh6B*^Jo(ph3fhNhN6B*^Jph3fh6B*^Jph3fh6B*^Jph3fh6B*^Jph3fh6B*^Jph3fhO8hyZ6B*^Jph3fhyZ6B*^Jph3fhO8h6B*^Jph3f vw EHou-./<L_ (9fntxǻ⟓{o{oc{{hh6B*^Jph3fhL.6B*^Jph3fhuf6B*^Jph3fh6B*^Jph3fhQ6B*^Jph3f *hO8h6B*^Jph3fh6B*^Jph3fh b6B*^Jph3fhO8h b6B*^Jph3fhyZ6B*^Jph3fhO8h6B*^Jph3fhO8h6B*^Jph3f xy #P !#,9IPٵ٩xk^kQkDh:5Qh6B*ph3fh:5Qhdz6B*ph3fh:5Qh1$6B*ph3fh:5Qh~6B*ph3fh:5Qh4d6B*ph3fh:5Qh?6B*ph3f h:5Qh~h:5Qh~>*h:5Qh>*h[e6B*^Jph3fhwI#6B*^Jph3fh6B*^Jph3fhL.6B*^Jph3fhh6B*^Jph3fhuf6B*^Jph3fhufhuf6B*^Jph3fPQRYi)*2?TUVWɺuiZKh:5Qhi76B*^Jph3fh:5Qh6B*^Jph3fh1A6B*^Jph3fh:5Qhdz6B*^Jph3fh:5Qh1{ 6B*^Jph3fh1{ 6B*^Jph3fh@"6B*^Jph3fh:5Qh.I6B*^Jph3fh:5Qh(6B*^Jph3fhK6B*^Jph3fh:5Qh>W6B*^Jph3fh:5Qh6B*^Jph3fh:5Qh[6B*ph3fW\]mnr{l_RC_Rh:5Qh6B*^Jph3fh:5Qh36B*ph3fh:5QhL6B*ph3fh:5Qh?6B*^Jph3fh:5Qhdz6B*^Jph3fh:5Qhdz6B*ph3fh:5Qh2q"6B*^Jph3fh:5Qh?6B*ph3fh:5QhPC~6B*ph3fh:5Qh>W6B*ph3fh:5Qh1$6B*ph3fhK6B*ph3fh:5Qhy6B*ph3fh:5QhvCn6B*^Jph3f$%*2BCQRSYZjk¸žuh[[OB8h^6B*ph3fh:5Qh8^6B*ph3fh^6B*^Jph3fh:5QhT6B*ph3fh:5Qh U6B*ph3fh:5Qh6B*ph3fh:5Qh6B*^Jph3fh:5Qhus6B*ph3fh:5Qhm`6B*ph3fh:5Qhv6B*ph3fhK6B*ph3fh:5Qh>W6B*ph3fh:5Qh36B*ph3fh:5Qhdz6B*ph3fh:5QhPC~6B*ph3fhhc6B*ph3f2<KVW ̞̿~rcUDc h:5Qh6B*^JaJph3fhK6B*^JaJph3fh:5Qh6B*^Jph3fh:6B*^Jph3fh6B*^Jph3fh:5QhlQ5^Jh:5Qh5^Jh:5Qhb6B*ph3fh^6B*ph3fh;U6B*ph3fh:5Qh36B*ph3fh:5Qhm`6B*ph3fh:5Qhb6B*ph3fh:5Qhdz6B*ph3fh:5QhT6B*ph3f #5z0156>KXY efgʾʲʾʲʲʦʲʙʌʌukakWhe6B*ph3fhf6B*ph3fh6B*ph3fhw\h.6B*ph3fhK6B*ph3fh:5Qh6B*ph3fhchw\6B*ph3fh;U6B*^Jph3fht.6B*^Jph3fhur6B*^Jph3fh:5Qh6B*^Jph3fh+U6B*^Jph3fh:5Qhb`6B*^Jph3fhb`6B*^Jph3f"9:OWXkv ,7;JVWŻܻviihvhgm6B*ph3fhvhu6B*ph3fhvh Z 6B*ph3fh`6B*ph3fh(M6B*ph3fhv6B*ph3fhuhiP6B*ph3fh#@6B*ph3fhq?6B*ph3fh:5Qh6B*ph3fh:5Qh Z 6B*ph3fh:5QhoR6B*ph3fh6B*ph3f&  #5789]f{LM`adefiŸŸŸŸukukukuah6B*ph3fhf6B*ph3fhSFh6B*ph3fhSFhow67B*ph3fh+U6B*ph3fh;U6B*ph3fh\ 6B*ph3fh^6B*ph3fh:5Qh?6B*ph3fhXTh?6B*ph3fhlh6B*ph3fhvh6B*ph3fh6B*ph3fh-Q6B*ph3f#8Mme4PIGvgdyK6 ngdegds3 & FgdI & Fgd3gd0 A & Fgd* & FgdXgdXgdegd Z ^`gdSF & F^`gdl & Fgdl6Gor*tlmy鱩teYRNhur hMzDhurh6B*^Jph3fh:5Qh6B*^Jph3fhurh6B*^Jph3fh6B*ph3fh:5Qh6B*ph3f h:5QhlQh:5QhlQ>*h:5Qh>*hSFhow6B*ph3fh26B*ph3fhSFh+56B*ph3fhZ6B*ph3fhB@6B*ph3fhSFh6B*ph3fh6B*ph3f5:ETUWbdeloy̨̜̋zl]QD:DhE 6B*ph3fh:5Qh6B*ph3fhX6B*^Jph3fh:5Qh1eq6B*^Jph3fhG}6B*^JaJph3f h9NLhG}6B*^JaJph3f h:5Qh6B*^JaJph3fhB@6B*^Jph3fhE 6B*^Jph3fhes6B*^Jph3fh.6B*^Jph3fh:5Qh6B*^Jph3fh:5Qh6>*B*^Jph3fhy2h5^Jh:5Qh5^Jyz234Z_~ Aab%-TZ^_`遛ttjjh6B*ph3fhPw:h6B*ph3fhPw:hPw:6B*ph3fhPw:hy26B*ph3fh:5Qh6B*^Jph3fhB@6B*ph3fh 6B*ph3fh.(J6B*ph3fh:5QhX6B*ph3fhL6B*ph3fhE 6B*ph3fh:5Qh6B*ph3fhW 6B*ph3f)`!HW~)<EL^az~OPS^䘋}n_Ph3h6B*^Jph3fh&h6B*^Jph3fheh6B*^Jph3fh3hS67B*ph3fh${h6B*ph3fhlZh6B*^Jph3fh6B*^Jph3fh:5Qh6B*ph3f h:5Qh6B*mHph3fsH$h:5Qh6B*^JmHph3fsHh:5Qh6B*^Jph3fhPw:h6B*ph3f9:HI "'1Y̽}paUaFA9A9hy2h>* h>*hIh0 A6B*^Jph3fhB@6B*^Jph3fhIh6B*^Jph3fhIhI6B*ph3fhI6B*ph3fhIh6B*ph3fh3h?6B*^Jph3fhh6B*ph3fhlh6B*ph3fh3h6B*^Jph3fhW h26B*ph3fhW h6B*ph3fh&h6B*ph3fh3h6B*ph3fEFGNSYbfwuvüreXQJQJ hh` hhhyKhp,5B*ph3fhyKh$96B*ph3fhyKhr*6B*ph3fhyKhdo6B*ph3fhyKh6B*ph3f h&hg | h&h& h&hzx h&h0.) h&h~ h&hhs3h^0 6B*^Jph3fhK]6B*^Jph3fh!G6B*^Jph3fh(Gh6B*^Jph3f hy2hv1 q  . d    _  _},h~ & Fgdgde6 ngdegd{gde7@& gdfJgd`/012}$,ɵ}oa}a}a}aRCh5h{6B*^Jph3fh{h{6B*^Jph3fh{6B*^JaJph3fhZT6B*^JaJph3f hfJh6B*^JaJph3fhy2h &^JhfJh^JhfJhqn^J h{^J h^J'hfJhK]5B*KH\^JaJph3f!h(5B*KH\^JaJph3f!h$95B*KH\^JaJph3f'hfJh5B*KH\^JaJph3f      ! " ' A L p q         - . C F 影墓zsl_RhfJh NCJOJQJhfJhCJOJQJ h&hg | h&hEI h&h%z#hh h&hNG h&hhfJh{6B*^Jph3fhfJhM6B*^Jph3fhfJ6B*^Jph3fhfJh6B*^Jph3fh{ hy2hM hy2h!' hxshMh6B*^Jph3fhfJheS6B*^Jph3fF J l      c d         m              ] ŽssssiaRhfJhrf6B*^Jph3fhy2h>*hxshrf5^JhT6B*^Jph3fh}6B*^Jph3fhC6B*^Jph3fhfJh6B*^Jph3fhy2h5^Jhxshrf5 hh5hxsh5hfJhCJOJQJhdoCJOJQJhCCJOJQJhfJhCJOJQJhfJh+CJOJQJ ] ^ _   ^_|} +,fghi|}~ɺɛɛzpczVE hfJhCJOJQJmHsHhfJhp3CJOJQJhfJhrfCJOJQJhCJOJQJhp3CJOJQJhCJOJQJhfJhCJOJQJhfJhrf6B*^Jph3fhxshrf>*hxsh>*hfJh"J6B*^Jph3fhfJh6B*^Jph3fhy2hrf>*hy2h>*hxshrf5>*^JhU:w6B*^Jph3fxUVef34Ǹ{ndZd{nǸSKhy2h>* hxshrfhKCJOJQJhU:wCJOJQJhfJhICJOJQJhICJOJQJhfJhrf6>*B*^Jph3fhxsh>*hfJhrf6B*^Jph3fhh6B*^Jph3fhfJh6B*^Jph3fhfJhrfCJOJQJhfJhCJOJQJ hfJhCJOJQJmHsHh_H CJOJQJmHsHVf4 (>3Xj/fj$^`gdyKgd-d$a$gde Gdgdegd<gdegde  DP %'(=>XYZؽإؙؙ~vnbSGGh~e6B*^Jph3fhfJhvCn6B*^Jph3fh6B*^Jph3fhxshrf>*hxsh>*hfJhrf6B*^Jph3fh<6B*^Jph3fh^6B*^Jph3fh2|66B*^Jph3fhrU6B*^Jph3fhyK6B*^Jph3fhfJhqn6B*^Jph3fhfJh6B*^Jph3fh>>hrf>*h>>h>*h} hqn>*Zv123JnVWXƾ|mcWKD hxshrfh}6B*^Jph3fh6B*^Jph3fhxsh5^JhfJh6B*^Jph3fhI9/6B*^Jph3fhfJh6B*^Jph3fhfJh6B*^Jph3fh>>hM5h>>h5h>>hZsa5h} h5hy2hz5hy2h5hyKhrf6B*^Jph3fh6B*^Jph3fhfJh6B*^Jph3fXij./0efij#$]^Ҩsf\R\R\RhkDCJOJQJhCJOJQJh /uhCJOJQJh9qhCJOJQJ h&h{ h&hhfJhHCJOJQJhfJhCJOJQJ hxshrfh6B*^Jph3fhxshH>*hfJhH6B*^Jph3fhfJh6B*^Jph3f+hfJhH6>*B*PJ^JnH ph3ftH hxsh>* KU^_`l34:;<OPVWXYy{qmf h&hYhQ]hO4CJOJQJh&h-d6]nH tH hSV h&h-d h&hh&h-dnH tH h&hnH tH hfJh-dCJOJQJh)CJOJQJhfJhCJOJQJhyKCJOJQJhO4hO4CJOJQJhsCJOJQJhCJOJQJ!{{ G$Ifgd%Dikdy$$Ifl41% t0644 layt%D F$Ifgd%DE & Fgd-d4;{{ G$Ifgd%D{kdz$$Ifl0 1%BF  t0644 layt%D;<PW{{ G$Ifgd%D{kdz$$Ifl0 1%BF  t0644 layt%DWXY(e ,!wrmdmmmm6 ngdegdegduk0$a$gdegde{kd{$$Ifl0 1%BF  t0644 layt%D &BCGUX'(IYpibQQ hfJh:(6B*^JaJph3f h&hY h&h hfJhrXn6B*^JaJph3fh6B*^JaJph3fhuk06B*^JaJph3f hfJh/6B*^JaJph3f hfJh~u6B*^JaJph3fhA6B*^JaJph3f hfJh6B*^JaJph3f hfJhU6B*^JaJph3f hfJh6B*^JaJph3fBQ^ de" + - Ϳͮ͌{m_N= hfJh:(6B*^JaJph3f hfJh~6B*^JaJph3fhv6B*^JaJph3fhK6B*^JaJph3f hfJhx6B*^JaJph3f hfJh&V6B*^JaJph3f hfJhS6B*^JaJph3f hfJhDN6B*^JaJph3fhs6B*^JaJph3f hfJh6B*^JaJph3f hfJh7+6B*^JaJph3f hfJhrO6B*^JaJph3f- . 0     ! !+!,!^!c!d!s!u!v!~!!!+"9"п|k]kL>h4@6B*^JaJph3f hfJhr6B*^JaJph3fh66B*^JaJph3f hfJh6B*^JaJph3fh&$hr5h&$h&$5 h4@5h&h&$5h&hc5h&h5 h&hrhhK h&h hfJh6B*^JaJph3fh>26B*^JaJph3f hfJh7+6B*^JaJph3f hfJhR6B*^JaJph3f,!v!:"r"""$C$3%q%%&&(n(0)0*,,,9-k$da$gdC0 kdgdegdm| & Fgde & Fgd6 ngdegd{gde & Fgdg39":"q"r""""""""""""L#P#Q#n####±zraPa?? hfJhz6B*^JaJph3f hfJhu6B*^JaJph3f hfJhR6B*^JaJph3fh&$h&$5h&$hg35 h4@5h&h5 hfJhH6B*^JaJph3f hfJh6B*^JaJph3f hfJhr6B*^JaJph3f hfJh6B*^JaJph3f hfJh4@6B*^JaJph3fh6B*^JaJph3fhH6B*^JaJph3f###$$6$8$A$B$C$P$Q$o$w$$$$$$$%% %+%пp__N_N_= hfJh96B*^JaJph3f hfJhip6B*^JaJph3f hfJhU6B*^JaJph3f hfJh$T6B*^JaJph3f hfJh&V6B*^JaJph3f hfJh6B*^JaJph3f h&h&V h&hF h&hBU h&h hfJh6B*^JaJph3fh4@6B*^JaJph3f h4@h4@6B*^JaJph3f hfJh76B*^JaJph3f+%1%2%3%4%F%Q%T%\%k%o%p%q%r%x%%%%%%&&&Ϳ{Ϳ{m\K: hfJh6B*^JaJph3f hS hS 6B*^JaJph3f hS hsK6B*^JaJph3fhS 6B*^JaJph3f hfJh56B*^JaJph3f hfJhV\6B*^JaJph3f hfJh 16B*^JaJph3f hfJh&V6B*^JaJph3fh6B*^JaJph3f hfJh V6B*^JaJph3f hfJh96B*^JaJph3f hfJhch86B*^JaJph3f&&&&&&','a'k'p'''''((m(n(/)0)){j\N== hfJh[#6B*^JaJph3fh06B*^JaJph3fh6B*^JaJph3f hfJhch86B*^JaJph3f hfJh~u6B*^JaJph3f hfJh96B*^JaJph3f hfJhA@6B*^JaJph3f hfJhBbh6B*^JaJph3f hDh6B*^JaJph3f hfJhD 6B*^JaJph3f hfJh6B*^JaJph3fhf6B*^JaJph3f)/*0*8*?*c*z*{*******++K,,,,ƮƮƮ{ƮdI9h&h5CJOJQJaJ4hfJh%6B*CJOJQJ^JaJmH ph3fsH ,hfJh6B*CJOJQJ^JaJph3f.hf6B*CJOJQJ^JaJmH ph3fsH 4hfJh#s`6B*CJOJQJ^JaJmH ph3fsH .h#s`6B*CJOJQJ^JaJmH ph3fsH 4hfJh6B*CJOJQJ^JaJmH ph3fsH  hfJhm|6B*^JaJph3fh6B*^JaJph3f,,,,,,,,,,,,-8-9-׾lQl9.hx6B*CJOJQJ^JaJmH ph3fsH 4hxh6B*CJOJQJ^JaJmH ph3fsH .h6B*CJOJQJ^JaJmH ph3fsH hxsh%>*CJOJQJaJhD`>*CJOJQJaJhx>*CJOJQJaJhxsh>*CJOJQJaJ0h$7h%6B*CJOJPJQJ^JaJph3fh_Zhl5CJOJQJhl5CJOJQJaJh5CJOJQJaJ9------- .".#.H.I....ʺkT=&,h$7hD6B*CJOJQJ^JaJph3f,h$7hC06B*CJOJQJ^JaJph3f,h$7hj6B*CJOJQJ^JaJph3f&hx6B*CJOJQJ^JaJph3f,h$7h6B*CJOJQJ^JaJph3f&h6B*CJOJQJ^JaJph3fhxsh%>*CJOJQJaJhxsh>*CJOJQJaJ4h$7hj6B*CJOJQJ^JaJmH ph3fsH 4h$7h6B*CJOJQJ^JaJmH ph3fsH 9---#.I...C/U///)1i1235j66778Fd$IfgdE & Fgdegde6 ngde kdgdD kdgde......'/B/C/T/U//////&0101˷xhXxhXAxx,hy2h6B*CJOJQJ^JaJph3fhxshj>*CJOJQJaJhxsh>*CJOJQJaJ,h$7hj6B*CJOJQJ^JaJph3f&h^6B*CJOJQJ^JaJph3f&h b6B*CJOJQJ^JaJph3f&hx6B*CJOJQJ^JaJph3f,h$7h6B*CJOJQJ^JaJph3fhxshjCJOJQJaJhxshCJOJQJaJ1&1(1)1-1.1/171@1K1M1\1h1i11132L2M2222222233һtj]SSSFh$7huCJOJQJhCJOJQJh$7hhCJOJQJhxsCJOJQJh$7hA@CJOJQJh#s`CJOJQJh$7hCJOJQJ h&hwop h&h,# h&hp h&h1c h&h,h$7h[#6B*CJOJQJ^JaJph3f,h$7hj6B*CJOJQJ^JaJph3f,h$7hUp6B*CJOJQJ^JaJph3f3D3E3P3Q3\3]3e3f3333333;4?44444455 555&5m555ɺ󩘩{lll_N h$7hy;CJOJPJQJ^Jh$7hy;CJOJQJh$7hCJOJQJ^Jhy2CJOJQJ^J h$7hd CJOJPJQJ^J h$7huCJOJPJQJ^J h$7hCJOJPJQJ^Jh$7huCJOJQJ^Jh$7hCJOJQJ^J h$7h fCJOJPJQJ^JhMCJOJQJh$7hCJOJQJ5555555R6]6i6j6p6u6z6|666S777777ķĪ~sh[QG:h$7hXCJOJQJhCJOJQJh"CJOJQJh$7h@CJOJQJhy2h,#nH tH hy2hwopnH tH hy2hnH tH hy2hQMnH tH hxsh OnH tH hxshnH tH h$7hhCJOJQJh$7hQMCJOJQJh$7hCJOJQJh$7hLCJOJQJ h$7hy;CJOJPJQJ^J h$7hCJOJPJQJ^J777777777888%8&8?8@8F8G8R8S8T8j8k8l8t8嶫ʠ}vreUeNCh&hPJ^J h&hDhDh56B*^Jph3fh56B*^Jph3fhh h&hh&h7VPJ^Jh?ch56B*^Jph3fhhPJ^Jh&hPJ^Jh&hhPJ^J'h$7h56B*CJ^JaJph3fhy2hhPJ^Jh$7h56B*^Jph3fh$7h56B*^Jph3fhy2hPJ^J8&8@8G8S8l8v88F$d$Ifa$gd_ZF$d$Ifa$gdF$d$Ifa$gdCt8u8v8z8888888888889 9 99˻ݰti^K8K$h$7hH|6B*^JnH ph3ftH $h$7hYn6B*^JnH ph3ftH h>>hWJnH tH h} hYnnH tH hy2hH|nH tH hy2hWJnH tH hy2hYnnH tH hy2hnH tH hy2h5nH tH hSVh&h7VPJ^JhW(h56B*^Jph3f#h<h56B*CJ^Jph3fh<h56B*^Jph3fhhPJ^Jh&hH|PJ^J8891% Gd$IfgdWJkdA|$$Ifl4rV %0 t0!44 lap2999 9E9F9L9N9R9S9T9[9\999+:-:9:::L:M:N::::::::: ; ;;;̷̢̍x̍̍x̍x̍̍̍̍̍c(h$7h6B*CJPJ^JaJph3f(h$7hC6B*CJPJ^JaJph3f(h$7hh6B*CJPJ^JaJph3f(h$7hp6B*CJPJ^JaJph3f(h$7hBN6B*CJPJ^JaJph3f(h$7h6B*CJPJ^JaJph3fhSVhy2hh5$h$7h6B*^JnH ph3ftH !9 9S9T9\99::N::::: ; ;;;d$IfgdBjkd}$$IflV% t0!44 lap ;;;;;;(;);+;/;1;2;3;4;5;<;V;Y;^;_;`;g;h;V<W<~iTi?(h$7hC6B*CJPJ^JaJph3f(h$7hp6B*CJPJ^JaJph3f(h$7h0(-6B*CJPJ^JaJph3f(h$7hYL6B*CJPJ^JaJph3f(h$7h6B*CJPJ^JaJph3f(h$7h6B*CJPJ^JaJph3fhSV(h$7hh6B*CJPJ^JaJph3f(h$7hC06B*CJPJ^JaJph3f(h$7hU6B*CJPJ^JaJph3f;;;;1##d$IfgdBkdR~$$Ifl4rV %```0 t0!44 lap2;;);4;d$IfgdUd$IfgdB4;5;_;`;1##d$IfgdBkd$$Ifl4rV %   0 t0!44 lap2`;h;W<<<<<<==d$IfgdUd$IfgdB W<<<<<<<<<<<== = =======#=$=.=/=0=:=F=X=w========묗֓֓|q|fq|]|f|h&hH|PJh&hWJnH tH h&hnH tH h&hH|nH tH h&h5nH tH hSV(h$7hd 6B*CJPJ^JaJph3f(h$7hU6B*CJPJ^JaJph3f(h$7hYL6B*CJPJ^JaJph3f(h$7hh6B*CJPJ^JaJph3f(h$7h6B*CJPJ^JaJph3f$=====3%%%d$IfgdBkd$$Ifl4rV %```0 t0!44 lap2=$=/=d$IfgdUd$IfgdB/=0=!>3' Gd$IfgdWJkdB$$Ifl4rV %   0 t0!44 lap2= > >!>">%>>>B>C>D>L>M>U>V>>>>>>>??@@T@U@g@h@AA AAA͸|jU(h.(he6B*CJPJ^JaJph3f"h;6B*CJPJ^JaJph3f"he6B*CJPJ^JaJph3f(h$7h?~6B*CJPJ^JaJph3f(h$7hO`6B*CJPJ^JaJph3f(h$7h6B*CJPJ^JaJph3fhSV!h&hhB* ^JnH phPtH $h$7hH|6B*^JnH ph3ftH h} hH|nH tH  !>">C>M>V>>>>?@U@h@Ayd$Ifgded$IfgdBjkd$$IflV% t0!44 lap AAA?Ad$Ifgdhd$Ifgd4cAA>A?A@AKAsA}A~AAAAAAAAÿzg\G2(h$7hh6B*CJPJ^JaJph3f(h$7h0(-6B*CJPJ^JaJph3fh&hhnH tH $h$7h6B*^JnH ph3ftH hQ6B*^JnH ph3ftH $h$7h6B*^JnH ph3ftH h} hnH tH h&hnH tH h&h5nH tH hSV(h$7h?~6B*CJPJ^JaJph3f(h$7h6B*CJPJ^JaJph3f$h$7h?~6B*CJ^JaJph3f?A@AA3' Gd$Ifgd[-kd.$$IflrV %0 t0!44 lap2AAAAABBB C CcCykd$Ifgd>>d$Ifgd bd$IfgdBjkdd$$IflV% t0!44 lap AAAABBBBBBBBBBCC CbCcCdCgCsCtC~CCCCCCCCCCCC֬օl(h$7h],6B*CJPJ^JaJph3fhSV(h.(he6B*CJPJ^JaJph3f"h b6B*CJPJ^JaJph3f(h$7h b6B*CJPJ^JaJph3f(h$7hh6B*CJPJ^JaJph3f(h$7h6B*CJPJ^JaJph3f(h$7hC6B*CJPJ^JaJph3f"cCdCeCfC1##d$IfgdBkd$$Ifl4rV %```0 t0!44 lap2fCgCtCCd$Ifgd.+d$IfgdBCCCC1##d$IfgdBkdT$$Ifl4`rV %   0 t0!44 lap2CCCDDE4E\E]EjEuEd$Ifgd.+d$Ifgdd$Ifgd} d$Ifgd1Nd$IfgdBd$IfgdC CCDDDHDDDDDDDDDEE3E4E[E]EiEjEtEuEvEEEEEplW(h$7h0(-6B*CJPJ^JaJph3fhSV(h$7h i6B*CJPJ^JaJph3f"h i6B*CJPJ^JaJph3f(h$7h6B*CJPJ^JaJph3f(h$7hu6B*CJPJ^JaJph3f(h$7h6B*CJPJ^JaJph3f(h$7hh6B*CJPJ^JaJph3f(h$7h1N6B*CJPJ^JaJph3fuEvEE5'd$IfgdBkd$$IflrV %0 t0!44 lap2EEEHFFFGGd$IfgdBd$IfgdCEEEEGFHFFFFFGGGGG;GDGEGNGPGWGXG{GGGGGGGGGGGjHkHlHHH֬֕mmւmmmmmmf_ h&h+ h&h(h$7hd 6B*CJPJ^JaJph3f$h$7hF6B*CJ^JaJph3f$h$7h6B*CJ^JaJph3fhSV(h$7h}6B*CJPJ^JaJph3f(h$7hh6B*CJPJ^JaJph3f(h$7h6B*CJPJ^JaJph3f(h$7hC6B*CJPJ^JaJph3f%GGEG3%d$IfgdBkd$$IflrV %0 t0!44 lap2EGOGPGXGGGGGGkHd$Ifgdd d$IfgdBd$Ifgd=d$IfgdF kHlHHIJ3+&&gde$a$gdbkd.$$IflrV %0 t0!44 lap2HHHHHHHHHIII%IqIIIIIIIIIII JJJJJOJPJQJ澴ٚ搃vi\Rvhib3CJOJQJhg3h$rRCJOJQJhg3hBCJOJQJhg3h#[eCJOJQJhg3heCJOJQJheCJOJQJhg3h4cCJOJQJhg3huCJOJQJh/&CJOJQJhg3h XCJOJQJhg3hBRj5CJOJQJhg3hCJOJQJhg3hBRjCJOJQJhg3hCJOJQJJQJJILLLLM&M1M:MQM$$$Ifa$gdWJ$$$Ifa$gdH| $$IfgdH|gdeE & Fgdegde QJ`JbJJJJJJJJJKKKHLILLLLLϼxiZL>h>>h5PJnH tH h} h5PJnH tH hg3h}t6B*^Jph3fhg3h6B*^Jph3f hg3h,#CJOJPJQJ^J hg3h#[eCJOJPJQJ^J hg3hx>CJOJPJQJ^J hg3hCJOJPJQJ^Jh>>hnH tH h"XnH tH henH tH h%$_nH tH h>>hnH tH h>>hJ"8nH tH h} hnH tH LLLLLLLLLMM%M&M/M0M1M9M:M>MHMIMPMQMȺ랐wfSBf; h_Zh7V h<h6B*CJ^Jph3f$h<h6B*CJPJ^Jph3f h<h6B*PJ^Jph3fh;&q5PJnH tH h&hH|5PJnH tH h&h5PJnH tH h&h;&q5PJnH tH h>>h5PJnH tH h} hH|5PJnH tH h} h5PJnH tH (hg3h>S6B*PJ^JnH ph3ftH (hg3h6B*PJ^JnH ph3ftH QMRMM3* $IfgdWJkdd$$Ifl4rV%el! t0!44 lap2QMRMcMMMMMMMMMMMMNNNN5N6NBNCNQNRNbNcNzN{NNNNNNNNNNNNNmOnOoO1P3P;Pk6 ngdegdib3E & Fgdib3gdib3 TTTTUUUUUV)V3V4VVVVVVVVVWǸӬӬӝuhaZI h>khCJOJQJmHsH h&h57 h&hh%hib3CJOJQJ h%hCJOJQJmHsHheCJOJQJh%hCJOJQJh%hib36B*^Jph3fh&\6B*^Jph3fh%he6B*^Jph3fhe6B*^Jph3fh%h6B*^Jph3fh%hib3nH tH h%hnH tH hYynH tH W WWWmWnW%X&XyXzXXXXXXXXXXXX޿ޮxixWSL h&hGhSV"hg3h`L56B*\^Jph3fh#56B*\^Jph3f"h|8h56B*\^Jph3f h&h`L h&hh&hwnH tH h&hnH tH  h>kh\.CJOJQJmHsHheCJOJQJmHsH h>khspHCJOJQJmHsH h>khCJOJQJmHsH h>kh*UCJOJQJmHsHXXXXYtYYYZ|ZZ-[x[~~qhhhqhhhq F$IfgdUpx *$If^*gdUpx $IfgdBxkd$$Ifl0|1% t0644 la XXXXYYY'Y4Y9Y>hPJnHtHh#hPJnHtHhPJnHtH"hg3h%'56B*\^Jph3fh3KLh56\^Jh3KLh$ 56\^J"hg3h$ 56B*\^Jph3f"hg3h56B*\^Jph3f{Z|ZZZZZZZZZZZZZ[[*[+[,[-[.[4[<[=[V[^[u[v[w[x[y[[[[[ŸŸҸŦҸҙŦyrr`#hg3h6B*PJ\^Jph3f h} h`L h>>h5 h>>h h>>h V h} hhh3KLh$ 56\^J"hg3hex56B*\^Jph3fh3KLh3KL56\^Jh3KLh56\^Jh3KLhG56\^Jh56B*\^Jph3f"hg3h`L56B*\^Jph3f"x[[[[l\m\\\zmd $Ifgd $If]gd xkd$$Ifl0|1% t0644 la $If^gdUpx[[[[[[[[[[[[[[f\g\j\k\l\m\}\~\\\\\\\ۺ}kd`YRYKYK`Y h&h h&hG h&hhSV h&h`L#hg3hG6B*PJ\^Jph3f#hg3h.6B*PJ\^Jph3f h} h`L h>>h h} hGh#hg3h`L6B*PJ\^Jph3f#hg3hq#6B*PJ\^Jph3fh%6B*PJ\^Jph3f#hg3h6B*PJ\^Jph3f#hg3h 6B*PJ\^Jph3f\\\o]p^___```aa~yyyyyqyyllgdjodhgdegde6 ngd#,xkde$$Ifl0|1% t0644 la \\\\\\\\\\\\\\]]]]e]m]n]o]o^va֯L7(hg3hW 6B*PJ^JnHph3ftH(hg3h\`6B*PJ^JnHph3ftH(hg3hv6B*PJ^JnHph3ftHhg3hv6B*^Jph3f(hg3hc6B*PJ^JnHph3ftH(hg3h`L6B*PJ^JnHph3ftH"h#6B*PJ^JnHph3ftH(hg3hz6B*PJ^JnHph3ftH(hg3h6B*PJ^JnHph3ftH h&h h&h h&hBUo^p^^^_ _F_P_X_________m`w````貝ygRKGK@ h} hJ5h% h} h(hg3h 6B*PJ^JnHph3ftH"hUp6B*PJ^JnHph3ftH"h6B*PJ^JnHph3ftH"hJ56B*PJ^JnHph3ftH(hg3h6B*PJ^JnHph3ftHh\.h\.6B*^Jph3fh%6B*^Jph3fh%h6B*^Jph3fhe6B*^Jph3fh6B*^Jph3fh\.6B*^Jph3f`````aaaa0b;bbbbbMcWccccιufZfZfZfZfJ;hg3hjo6B*^Jph3fhh6B*\^Jph3fh6B*^Jph3fhg3h6B*^Jph3fhg3hjo56B*^Jph3fhg3h56B*^Jph3f"hjo6B*PJ^JnHph3ftH"h6B*PJ^JnHph3ftH(hg3h?dk6B*PJ^JnHph3ftH(hg3h6B*PJ^JnHph3ftHh} h5(hg3hJ56B*PJ^JnHph3ftHaacdeeggsiikknwpZqqrrrHrrrsIsgdegdg3E & Fgde&$d%d&d'dNOPQgdjoccddiddeeeeeUf\fffgggggg>hhhhhh"i6iqirisiiik÷ҷҷuhYh}h6B*^Jph3fhjo56B*^Jph3fhjo6B*^Jph3fh:o6B*^Jph3fh)6B*^Jph3fhg3hjo6B*^Jph3fhg3h6B*^Jph3fh6B*^Jph3fhh6B*^Jph3fhg3hjo56B*^Jph3fhg3h56B*^Jph3fh56B*^Jph3f"kkkkkknnnvpwpypYqZq\qqqqrrr rrrrrĵxpe]H(h} h6B*PJ^JnHph3ftHha\nH tH h>>hnH tH h>>h>*h} h>*hSFh856B*ph3fhp}hp}6B*^Jph3fh[6B*^Jph3fh6B*^Jph3fhp}h6B*^Jph3fhjo56B*\^Jph3f"hg3h56B*\^Jph3fh}hjo6B*^Jph3fh6B*^Jph3frrr#r,rFrGrHrrrrrrrrssHsIsOsǵwePH@5Hh} ha\nHtHh>>h(>*h>>h>*(hg3ha\6B*PJ^JnHph3ftH"h3S\6B*PJ^JnHph3ftHh>>ha\>*nH tH h} h>*(hg3h%BR6B*PJ^JnHph3ftH(hg3h6B*PJ^JnHph3ftH"ht6B*PJ^JnHph3ftH"hTC6B*PJ^JnHph3ftH"h6B*PJ^JnHph3ftH(h>>h6B*PJ^JnHph3ftHOsQsRsYsZsssqtrtst~tttttttttttt͸~qaQAh>>hw>*PJ^JnH tH h>>h>*PJ^JnH tH h} hB8>*PJ^JnH tH h%BR>*PJ^JnH tH h2r>*PJ^JnH tH h} h>*PJ^JnH tH hg3h%BR5h} h5hg3h5 h5(hg3ha\6B*PJ^JnHph3ftH(hg3h6B*PJ^JnHph3ftHh>>ha\>*h>>h>*h} h%BR>* h%BR>*Issrttt0u[uuvwDxYyhyyy F$$Ifa$gd( F$Ifgd( F$$Ifa$gd|86 7gdedhgdegdg3gdett.u/u0u2u3uuQuYuZu[uuuuuuuuv`vvvvϬpYE&h2r6B*PJ^JaJnHph3ftH,hg3h[W6B*PJ^JaJnHph3ftH,hg3h(6B*PJ^JaJnHph3ftH,hg3h6B*PJ^JaJnHph3ftH h&h h&h " h&h[W h&hu h&hTI h&hnz h&hBU h&hhg3h16B*^Jph3fh%BR6B*^Jph3fhg3h6B*^Jph3fvvvvwwwwwwwwwx&x2x9xCxDxxİęĂkTkTkTk@4h6B*^Jph3f&h)#6B*PJ^JaJnHph3ftH,hg3hT96B*PJ^JaJnHph3ftH,hg3h6B*PJ^JaJnHph3ftH,hg3hS\6B*PJ^JaJnHph3ftH,hD`hD`6B*PJ^JaJnHph3ftH&h2r6B*PJ^JaJnHph3ftH&hD`6B*PJ^JaJnHph3ftH&h6B*PJ^JaJnHph3ftH&hv16B*PJ^JaJnHph3ftHxxyy"yWyXyYygyhyyyyyyyyyyy.z3z4z;vi\J;JhD`56B*\^Jph3f"hg3h56B*\^Jph3fh>>hPJnHtHh>>hPJnHtH$hg3h}FY6B*^JnH ph3ftH  h} hhSV *h>>h}FY\h>>hr\h>>h\h} h}FY\h} h\h\.h\.6B*^Jph3fh6B*^Jph3fh2r6B*^Jph3fh%h6B*^Jph3fhe6B*^Jph3fyyyy5zPzzzzz{ri`W`````` F$IfgdbF $IfgdbF G$Ifgd|8kd$$Ifl4F3/%{ t06    44 la 4z5zFzNzOzPzgzhzzzzzzzzzz{{{{({){@{A{`{a{{{{{{{vd]VRhK h>>h h} h"hg3h:a56B*\^Jph3fh 56B*\^Jph3f"hg3h56B*\^Jph3fh\.h\hDh6^Jh} h\hDhD6B*\^Jph3fh} h\ hDhhDh}FY6^JhDh96^JhDh6^J"hg3h(56B*\^Jph3f {{){A{a{{{"|M|c||| F$IfgdbF$If $IfgdbF {{{{ || |!|"|-|J|L|M|^|b|c|i|u|~||||||||||.}ƿ䱪Ə|ungZPhCJOJQJhg3hCJOJQJ h&h+ h&h  h&hhSVhg3h}FY6B*^Jph3fhDh96^J hG6^Jh=s%h6^J hkK6^J h6^J h>>h9 h} hhDh}FY6^JhDhK6^JhDhD`6^JhDh6^J h>>h:a h>>hhf|||~~tlgb][QLgdu dhgdugdHTgdPjgd4$a$gdbkd$$IflF3/%{ t06    44 la.}/}}}}}}}}}~~~~~~~~~~~~+]^j췪쓀si_RNhhPjh,CJOJQJh<CJOJQJhPjCJOJQJh,hCJOJQJ%h&h.B* CJ PJnH ph3tH h_Zh.CJOJQJh,CJOJQJhg3hCJOJQJh4CJOJQJh+rCJOJQJhcCJOJQJh`[CJOJQJh4hCJOJQJhCJOJQJhCJOJQJ !4<=BEno۸wh\hMFBFBF; h} h(h\K h} hhg3hu6B*^Jph3fh3S\6B*^Jph3fhg3hys6B*^Jph3f#jh0J&6B*U^Jph3f(hg3h6B*PJ^JnHph3ftHhg3h6B*^Jph3fh&huCJaJ%h&huB* CJ PJnH ph3tH hV8B* CJ PJnH ph3tH %h&hB* CJ PJnH ph3tH "h,6B*PJ^JnH ph3ftH oAsmكڃ#UR 5~"PȉXRgde & F gd$a$gdugd!zgdu )N.@ABEkpqrstyAdĸyoybyUh!UhuPJnHtHh>>h UGPJnHtHh\KPJnHtHh>>hPJnHtHh(PJnHtHh} hEPJnHtHhQ6B*^Jph3fhg3hE6B*^Jph3fh6B*^Jph3fh( h!Uhuh>>huPJnHtHh h>>hu h>>hh\K h} h( h} hdhijlmЃ؃كڃ78Mh|̄ "#$'üz╆rfWhg3hQ6B*^Jph3fh6B*^Jph3fhs) hu5h(6B*^Jph3fh(h(6B*^Jph3fh( h} hhh&hu5CJaJh&h5CJaJ h&h!z h,huh\K h,hh,huPJnHtH h>>hhPJnHtHh,hPJnHtH'.MRSTUVdÅ!$)*9yleXeXQI *hs) h h_Zhh,huPJnHtH h,huh!UhuPJnHtHh>>h\KPJnHtHh>>huPJnHtH h,hDBhq<h\K h>>huh>>hPJnHtHhCPJnHtHh} hEPJnHtHhg3hE6B*^Jph3fh6B*^Jph3fh46B*^Jph3fhQ6B*^Jph3f9:OPQRbijnȆʆ $%h~̇чއŹѹŲzm`m\UmU h>>hh\Kh>>h CPJnHtHh>>hPJnHtH h} hh&hu5CJaJh&h-5CJaJh&h5CJaJh`[h6VPJnHtH hhhX.6B*^Jph3fhb6B*^Jph3fh6B*^Jph3f h_Zh h=s%hh *hs) h *hs) h\Kއ߇45uv|}~͈Έш !"#23OPSljȉ WX|ٶ٩~wwwpwwpwpwlwewp hmhuh%Q hmhu hmhhmh)PJnHtH hmh)hjPJnHtHhmhPJnHtHh,huPJnHtHh,h PJnHtH hbhhuh\K h,hh,hPJnHtHh!Uh)PJnHtHh!UhPJnHtH'|!Inڋ  14ǻǬwplepwpw[wNh,hGPJnHtHhDBPJnHtH h,hehe h,hh,hPJnHtH h!Uhu h>>h C h>>hh !h6h\K h} hhg3hG6B*^Jph3fh !6B*^Jph3fhg3h6B*^Jph3fhg3h6B*^Jph3f hmhGh  hmhhmh645pqrPQRqu'9:ļѵyrngc\U\NDh\KPJnHtH h&hu h&h h&hh h>>hGh\K h} hhg3hu6B*^Jph3fhg3h6B*^Jph3fhg3hMi6B*^Jph3fhg3h6B*^Jph3f h>>huh>>h6h>>hPJnHtH h>>hh} hPJnHtHhg3hG6B*^Jph3fh\K6B*^Jph3fRTUps{oo d$Ifgdefkd$$Ifl4$ t0644 lal$d$Ifgde, & Fgd6zagde:;J ]'37Ts 6շqg]h>>h 5PJh} h5PJhg3h5PJnHtHh,huPJnHtH hDhDhDh%Qh=| h!Uhh>>hPJnHtHh\K h>>hh} h $PJnHtHhPJnHtHh} hPJnHtHhbPJnHtHh $PJnHtHht ~PJnHtH67ESTUoprstɑʑܑߑǒȒȿȿȿȖo`QhZGhZG6B*^Jph3fhZGh6B*^Jph3fhfh6>*B*^Jph3fh6B*^Jph3fhCj h&h$hhg3hu6B*PJph3fhmhPJnH tH hmhuPJhmhPJhSVh} hu5PJhg3h6B*PJph3fh6B*PJph3fhg3h 5PJnHtHst{{ d$Ifgdexkd6$$Ifl0 $  t0644 lal{{ d$Ifgdexkd$$Ifl0 $  t0644 lalʑȒ49Tzzzri $Ifgd ! & FgdkJgdZG, & Fgd6zaxkd$$Ifl0 $  t0644 lalȒ34"789HRSTvw}~Ɣǔ˼zrmhrhZVOKhu hmhhSVhg3hjYT56B*ph3f hLF5 h !5h} h5hkJh1c6B*^Jph3fhe6B*^Jph3fhy hy 6B*^Jph3fhQ 66B*^Jph3fhLF6B*^Jph3fhg3hVj6B*^Jph3fhy h6B*^Jph3fhkJ6B*^Jph3fh6B*^Jph3f hG7hZG hG7hǔc{ri $IfgdJ $IfgdLF $IfgdWizkdd$$Ifl4S$9!  t 09!644 laf4p ytDǔ>WXtAbcd-?@AEFRS[\δ⛔{{tgZhmh^oPJnHtHhmhPJnHtH hmh^ohmh5hs) hQ 66B*ph3fh hQ 6hhu6B*ph3fhu hmhhSVhQ 6hu6B*ph3fhQ 6hQ 66B*ph3fhQ 66B*ph3fhx96B*ph3fhg3h6B*ph3f hmhLFh6B*ph3f"cd@i`WNN $IfgdQ 6 $IfgdLF $IfgdqVkd$$Ifl0Sf$ &  t09!644 lapytQ 6@A\ȗi`````W $IfgdYy $IfgdF3Ykd$$Ifl0Sf$ &  t09!644 lapytQ 6Ǘȗ./_j˜ØĘݘޘIuh[TPLThrah1m h} hhg3hr6B*ph3fhg3hNW6B*ph3fhg3h$6B*ph3f h>>h^o h>>h h} h^ohUp6B*ph3fhg3h6B*ph3f hmh^o hmhhSVhlhy \h} h\hg3h^o6B*ph3fh6B*ph3fh>>h^o\h>>h\h} h^o6/ØJKi``````` $IfgdF3Ykd}$$Ifl0Sf$ &  t09!644 lapytQ 6IJKL[^_ijmnwxʙ˙̙GƺƮ|wrccUhg3hy 56B*ph3fhlh6B*^Jph3f hl5 hD5 h5 hZG5 h !5h} h5hfhy 6B*^Jph3fh1c6B*^Jph3fhYy6B*^Jph3fhf6B*^Jph3fhkJ6B*^Jph3fhYyh6B*^Jph3fh6B*^Jph3fhSVh>>h^o6 h} h^o KL̙iaXO $Ifgdl $Ifgd ! & Fgdkd:$$Ifl0Sf$ &  t09!644 lapytQ 65]|}}}}}t $IfgdYy $Ifgdc7ykd$$Ifl4S$9!  t 09!644 lap ytQ 6њԚޚߚ345\]{|}՛%&89anµ֫{tmfmf\hs) 6B*ph3f h>>hy h>>h h} hy hmhy hSVhEq9hy 6B*ph3fh>>hy \h>>h\h} hEq96h@6B*ph3fhmhy PJnHtHhmhPJnHtH hmh@h6B*ph3fhg3h6B*ph3fhy hmh5 hmh$|}&9i````W`` $Ifgds) $Ifgdc7kd$$Ifl0Sf$ &  t09!644 lapytQ 6nz!"%&)deftҝyri\Ohg3hCJOJQJh>>huPJnHtHh>>hNWPJ h>>hNW h>>hh>>hPJnHtH h&hNW h&hu h&hhhSVh>>hy 6 h} hy hLFh1m h} hhg3hy 6B*ph3fhg3h6B*ph3fhZG6B*ph3fhs) 6B*ph3fhU 6B*ph3f"e"ߞiaYQLGBgdegdegdhu$a$gdu- & Fgd6za, & Fgd6zakdP$$Ifl0Sf$ &  t09!644 lapytQ 6ҝӝ!"45:<ޞߞ4GQRSsܿ}t}eX}KXhg3h6B*ph3fhg3h_Ug6B*ph3fhg3hB6B*^Jph3fh} hu^Jhg3h6B*^Jph3fhg3h_Ug6B*^Jph3fh>>h^Jh>>h5^Jh>>h$5^J hD5^Jh} h^Jh_JCJOJQJhCJOJQJhg3huCJOJQJhg3hCJOJQJhOCJOJQJ LMU_`gmƿ~wpcYOBhg3hjYT6B*ph3fhra6B*ph3fhS-r6B*ph3fhg3h16B*ph3f h&hu h&hh&hPJnHtHhLFPJnHtHhPJnHtH h>>hu h>>hjYThk h>>h h>>h$ h} hhg3hu6B*^Jph3fhg3h6B*ph3fhg3h6B*^Jph3fhg3h_Ug6B*^Jph3fMDyvѤHF$d$Ifa$gd>>F$d$Ifa$gd} gd;5gde>gdegde$a$gd[3- & Fgd6zagdemn}àΠР "#BCDEPcƼrir\\iUHUh>>hPJnHtH h>>hhg3h_Ug6B*ph3fh} hu^Jhg3h6B*^Jph3fhg3h_Ug6B*^Jph3fhg3hjYT6B*^Jph3fh>>h^Jh>>h5^Jh>>h$5^Jh>>hjYT5^Jh} h^Jhg3hu6B*ph3fhg3h6B*ph3fhg3hjYT6B*ph3fhO6B*ph3fcuvwxyz~!PQVWbqr͢΢Ϣ0zmREh.vh.vCJOJQJ4h.vh.v6B*CJOJPJQJ^JnHphtHhg3h_JCJOJQJh.vCJOJQJh_JCJOJQJhg3hkCJOJQJhZTCJOJQJhg3hCJOJQJ h&h  h&h\ h&hQn{ h&h h>>hu h>>hh>>hjYTPJnHtHh>>hPJnHtHhkPJnHtH08stuvۣݣäȽȽܐ܃ȶvlvl_Rhg3h(7CJOJQJhg3h_JCJOJQJh_JCJOJQJhg3hxBCJOJQJhg3h&UFCJOJQJh=|CJOJQJhg3hiCJOJQJjhg3hOJQJU h&h\jhg3hU h&hhg3h\CJOJQJhg3hCJOJQJh.vh.vCJOJQJh.vCJOJQJäǤΤϤФѤ-7FGHMP泬nVn/hg3h56B*PJ^JaJnHph3ftH,hg3h6B*PJ^JaJnHph3ftH h&h\ h&hw h&hz1h t h&h(7 h&hE h&hhg3h3 CJOJQJhg3hpCJOJQJhg3h CJOJQJjh0J&CJUhg3hCJOJQJhg3hyCJOJQJĥҥӥ12KLYZde˼yyrfZR<+hg3hQ^56B*CJPJ^JaJph3fhg3h5hg3h{5PJ^Jhg3h5PJ^J h&hm*h&hm*PJ^J!h156B*CJ^JaJph3f'hg3h56B*CJ^JaJph3fhQ^PJ^Jh&hPJ^J h&hC0h1Xh t h&h,hg3hy;6B*PJ^JaJnHph3ftH,hg3hC06B*PJ^JaJnHph3ftH2LZe$d$Ifa$gdR7$d$Ifa$gdg3F$d$Ifa$gd,e֦ަ$%JKXYZ베땑mXCXC.(hg3h6B*CJPJ^JaJph3f(hg3hm*6B*CJPJ^JaJph3f(hg3h6B*CJPJ^JaJph3f"h6B*CJPJ^JaJph3f"h6B*CJPJ^JaJph3fhSVh&hm*PJ^J"h G6B*CJPJ^JaJph3f"hR76B*CJPJ^JaJph3f"h16B*CJPJ^JaJph3f(h0khQ^6B*CJPJ^JaJph3f(h0kh6B*CJPJ^JaJph3f%KYZeI;;;;;d$Ifgdm*kd $$Ifl4\V#- t044 lap(ZdejLM`aĨŨ  믚kUB%hR76>*B*CJPJ^JaJph3f+hg3h6>*B*CJPJ^JaJph3f3hg3hm*6>*B*CJPJ^JaJnHph3ftH(h>>hQ^6B*CJPJ^JaJph3f(h} h6B*CJPJ^JaJph3f(hg3hm*6B*CJPJ^JaJph3f"h6B*CJPJ^JaJph3f(hg3h6B*CJPJ^JaJph3f(hg3h6B*CJPJ^JaJph3feMaŨ <id$IfgdR7d$Ifgdm* ;<BNghijqmf_TL8'hg3h56B*CJ^JaJph3fhQ^PJ^Jh&hPJ^J h&hC0 h&hhSV+hg3hm*6>*B*CJPJ^JaJph3f%h6>*B*CJPJ^JaJph3f"hR76B*CJPJ^JaJph3f(hg3hQ^6B*CJPJ^JaJph3f(hg3h6B*CJPJ^JaJph3f%hQ^6>*B*CJPJ^JaJph3f+hg3hQ^6>*B*CJPJ^JaJph3fijKC2F$d$Ifa$gd} $a$gdrIkd4$$Ifl\V#- t044 lap(ǩȩɩީߩ '(./?EΪϪЪϹϮvdvOD@hSVh&hQ^PJ^J(h>>hQ^6B*CJPJ^JaJph3f"hR76B*CJPJ^JaJph3f(h} h6B*CJPJ^JaJph3fhm*PJ^JhR7PJ^Jh1PJ^Jh&hm*PJ^Jh&hPJ^Jh&hwPJ^Jh&hPJ^Jh&hm*PJ^J'hg3h56B*CJ^JaJph3f!h156B*CJ^JaJph3fɩߩ /ϪF$d$Ifa$gd} $d$Ifa$gdg3F$d$Ifa$gdmF$d$Ifa$gd,F$d$Ifa$gd>> ϪЪ֪I;;;;;d$Ifgdkd($$Ifl4\V#v/ t044 lap(Ъժ֪(*xzDzǝDzǝr`J+hg3h6>*B*CJPJ^JaJph3f"h{6B*CJPJ^JaJph3f0hg3h6B*CJPJ^JaJnHph3ftH"hQ^6B*CJPJ^JaJph3f(hg3hm*6B*CJPJ^JaJph3f(hg3h6B*CJPJ^JaJph3f(hg3h6B*CJPJ^JaJph3f"h6B*CJPJ^JaJph3f"h6B*CJPJ^JaJph3f*zʬd$IfgdR7d$Ifgd>>d$Ifgd} d$IfgdȬʬ̬جڬ ">TptZvʮ̾̾ųŬpaRRhg3hsB6B*^Jph3fhg3h< E6B*^Jph3fhg3hi9H6B*^Jph3fhg3hu6B*^Jph3fhg3hx#'6B*^Jph3fhg3h6B*^Jph3f h&h\h[ h&hU h&hsB h&hE h&hhSV(hg3hm*6B*CJPJ^JaJph3f%hR76>*B*CJPJ^JaJph3fʬ̬9KXKFAAA8^gdgde5gd=HkdO$$Ifl\V#v/ t044 lap(789JKWX^`k~DEbjötcRAc hg3h$T6B*^JaJph3f hg3hv6B*^JaJph3f hg3h6B*^JaJph3fh&hEPJnH tH h&hmSPJnH tH h&hPJnH tH h&h5PJnH tH hg3huCJOJQJhg3hCJOJQJhh\5hh5hg3hg6B*^Jph3fhg3h6e6B*^Jph3fhg3hVG6B*^Jph3fXkòp5RN>R!Z5gde 7d^7gdB & Fd^gd$d^a$gd d^gd^gd dgdejkz˱ͱN²òɲ˲حxk^kxTFk9kh&hi9HPJnH tH h&h5PJnH tH huhPJnH tH h&hvPJnH tH h&hPJnH tH hPJnH tH ,hg3h Y6B*PJ^JaJnH ph3ftH &h}R6B*PJ^JaJnH ph3ftH &h6B*PJ^JaJnH ph3ftH ,hg3hu6B*PJ^JaJnH ph3ftH ,hg3h6B*PJ^JaJnH ph3ftH  hg3hmS6B*^JaJph3f)opڳ۳bƵȵɵ«}}f\\RD7h&hPJnH tH h&h5PJnH tH h{PJnH tH hPJnH tH ,hg3hE6B*PJ^JaJnH ph3ftH ,hg3hi9H6B*PJ^JaJnH ph3ftH ,hg3h$T6B*PJ^JaJnH ph3ftH ,hg3hv6B*PJ^JaJnH ph3ftH ,hg3h6B*PJ^JaJnH ph3ftH h&hEPJnH tH h&hPJnH tH h&hi9HPJnH tH ɵڵ 45QRV\enҶնض7;̵pYpBY+,hg3h6e6B*PJ^JaJnH ph3ftH ,hg3hb6B*PJ^JaJnH ph3ftH ,hg3hE6B*PJ^JaJnH ph3ftH ,hg3h6B*PJ^JaJnH ph3ftH ,hg3hi9H6B*PJ^JaJnH ph3ftH ,hg3hn6B*PJ^JaJnH ph3ftH ,hg3h6B*PJ^JaJnH ph3ftH h&hEPJnH tH h&h6ePJnH tH h&hPJnH tH h&hPJnH tH ;ELMN\ik|=>վ|h||ՐQ:,hg3h3Z6B*PJ^JaJnH ph3ftH ,hg3hb6B*PJ^JaJnH ph3ftH &h4GR6B*PJ^JaJnH ph3ftH &h{6B*PJ^JaJnH ph3ftH ,hg3h6B*PJ^JaJnH ph3ftH ,hg3hn6B*PJ^JaJnH ph3ftH ,hg3hE6B*PJ^JaJnH ph3ftH ,hg3h6e6B*PJ^JaJnH ph3ftH &h6B*PJ^JaJnH ph3ftH >QRdø͸и !'(<IJYZklx{˾yky`hR%5PJnH tH hujh '5PJnH tH hujh5PJnH tH  h&h\ h&h_Jh_J h&h|~ h&hh&h4GRPJnH tH hgPJnH tH h&hvPJnH tH h&hPJnH tH h4GRPJnH tH hBPJnH tH h{PJnH tH hPJnH tH !Zl|,λ½n Qs!tm & F gdmgd_Zm & F gdsmgdsmgd`wmgde5gdegde dgduj dgde{|ع'5_{+ґyufUGGh=|6B*^JaJph3f hg3h1B6B*^JaJph3fh&h|~0JVCJ^JaJhSa h&h hg3h\6B*^JaJph3f hg3h6e6B*^JaJph3f h`/h_J6B*^JaJph3fh_J6B*^JaJph3f h`/h`/6B*^JaJph3fh`/6B*^JaJph3f hg3h6B*^JaJph3fhujhuj5PJnH tH +,23grͻλB^io߼źŞp\H4&h_J6B*PJ^JaJnH ph3ftH &hpO6B*PJ^JaJnH ph3ftH &h=|6B*PJ^JaJnH ph3ftH ,h h_6B*PJ^JaJnH ph3ftH ,h h6B*PJ^JaJnH ph3ftH h&h C5PJnH tH h&he5PJnH tH h`/5PJnH tH h&h5PJnH tH  h&h\ h&hb* h&hW; h&h hg3h|~6B*^JaJph3f½۽ܽ;@]egpһҮrrrr^J&h$6B*PJ^JaJnH ph3ftH &h6B*PJ^JaJnH ph3ftH &h_J6B*PJ^JaJnH ph3ftH &h6B*PJ^JaJnH ph3ftH &h6B*PJ^JaJnH ph3ftH h4h3Z6B*ph3f,h h$T6B*PJ^JaJnH ph3ftH ,h h6B*PJ^JaJnH ph3ftH ,h hh>6B*PJ^JaJnH ph3ftH   +-n  t]Nt7t,hshs6B*CJOJQJ^JaJph3fhsh`wCJOJQJaJ,hshs6B*CJOJQJ^JaJph3fhshsCJOJQJaJhsCJOJQJaJh]vCJOJQJaJh`wh`wCJOJQJaJ,h]vhs6B*CJOJQJ^JaJph3f&h]v6B*CJOJQJ^JaJph3f&h`w6B*CJOJQJ^JaJph3f,h?h?6B*PJ^JaJnH ph3ftH  !stSTvwxtxEIz}\]-.bìì҆҆҆zzhCJOJQJaJh&huCJOJQJaJ,h hn06B*PJ^JaJnH ph3ftH ,h h6B*PJ^JaJnH ph3ftH h&hn0CJOJQJaJh&hCJOJQJaJh&h5CJOJQJaJh_Zh`w5CJOJQJ,Tx].LRjF;m & F gd dgdem & F gdbrsKLQRijEF:;ʺʣʺـʺhUCJOJQJaJ,h hn06B*PJ^JaJnH ph3ftH ,h h6B*PJ^JaJnH ph3ftH h&h5CJOJQJaJh&hn0CJOJQJaJh&hCJOJQJaJhvCJOJQJaJhKCJOJQJaJ2;|8jdF7O dgdemgdem & F gdm & F gd {|+78ijʻqeN,h h\6B*PJ^JaJnH ph3ftH hcCJOJQJaJ,h hn06B*PJ^JaJnH ph3ftH ,h h6B*PJ^JaJnH ph3ftH h&h5CJOJQJaJhQCJOJQJaJh&hCJOJQJaJh&h%SCJOJQJaJh%SCJOJQJaJhCJOJQJaJh&hn0CJOJQJaJcd%)EF ./6վyyyyyjyyy^R^R^R^hKCJOJQJaJhQCJOJQJaJh&huCJOJQJaJh&hn0CJOJQJaJh&hCJOJQJaJh&h5CJOJQJaJ,h hn06B*PJ^JaJnH ph3ftH ,h h6B*PJ^JaJnH ph3ftH ,h h\6B*PJ^JaJnH ph3ftH &h6B*PJ^JaJnH ph3ftH  67NO\]^_TZ[\]  ⶪⶏxa,h hn06B*PJ^JaJnH ph3ftH ,h h6B*PJ^JaJnH ph3ftH hACJOJQJaJh&hu]/CJOJQJaJhu]/CJOJQJaJhCJOJQJaJhosvhosv5CJOJQJaJhosvh5CJOJQJaJh&hCJOJQJaJh&hn0CJOJQJaJ"O^\ MGO]gno$d$Ifa$gdP $Ifgd \gde5gdem & F gd dgdem & F gdosvm & F gdosv#LM"UFGNO\]f|ud\T\TLh,h5h>>hP5h>>h5 h h15P6B*^JaJph3f h&h15Ph h15PCJh h>CJ h h*\6B*^JaJph3f h h6B*^JaJph3f h h6B*^JaJph3f h&h\ h&h|~ h&hh&hn0CJOJQJaJh&hCJOJQJaJhCJOJQJaJfgmnopz|3:;RSTjkluvĽ˩ҍ~jjjҍ~j'h hdHD6B*\^JnH ph3ftH h!UhP>* h!Uhh>>h>*'h h6B*\^JnH ph3ftH 'h h6B*\^JnH ph3ftH  hAh} h,h h>>hP h>>hh} hmhhSV hmhPh,h5h,hP5(op{|SbYYYYYYYP G$Ifgd G$Ifgd \kdC$$IflFk$  t0$    44 lapyt9 Slv+q8 G & F$Ifgd G & F$Ifgd G$Ifgd} G & F $Ifgd G$Ifgd G$Ifgd \ *+3pqrɵڵڵ|t`L`=hvth6B*^Jph3f'hvth} 6B*\^JnH ph3ftH 'hvth6B*\^JnH ph3ftH hvth} >*hvth>* hvth hh} hh>* hh'h h6B*\^JnH ph3ftH 'h hdHD6B*\^JnH ph3ftH !h6B*\^JnH ph3ftH 'h h6B*\^JnH ph3ftH !hc76B*\^JnH ph3ftH /789:;<UV|}~˷}yrjy_jrjT}yMyMyMy hh_ZhRgh_ZmHsHjh_ZUjh_ZU h \fh_Zh_Zjh_Z0J&U h&hPhSV'h hP)6B*\^JnH ph3ftH !h6B*\^JnH ph3ftH 'h h6B*\^JnH ph3ftH h>>hP>*h h>*'hvth} 6B*\^JnH ph3ftH hvth6B*\^Jph3f89:"b]XSNNI(gd%(gd[(gd(gdjgdekd$$IflFk$  t0$    44 lapyt9klm !"#AQS̅zmb[[ h%h_Zhch_ZmHsHh-dh_Z0JtmHsHj.h_ZUh-dh_ZmHsHjh_Z0JtUmHsHhh_Z0JtmHsHjh_ZUh-jph_ZmHsHhh_ZmHsHjh_Z0J&Uhnh_ZmHsH hd h_ZjDh_ZUh_Zjh_ZU!,.789QRSTUYZЯФޙԎЃwlЯh0h_ZmHsHjh_ZUmHsHjzh_ZUh}Mh_ZmHsHhZh_ZmHsHj׫h_ZUh_ZmHsH h.fh_Z h 5h_Zjxh_ZUh_Zjh_Z0J&U h%h_Z hd h_Zjh_ZUjթh_ZU*S8j(gdu(gdo(gd|((gd%(gdC16789:;cdeɾ찞쌴vk^SHhh_ZmHsHhch_ZmHsHhxh_Z0JtmHsHjch_ZUh-jph_ZmHsHhxh_ZmHsHh gfh_ZmHsH hd h_Zjh_ZU h*h_Zh_Zjh_Z0J&Uhgh_ZmHsHh_ZmHsHjh_Z0JtUmHsHh4Fh_Z0JtmHsHjh_ZUjh_ZUhijklm ?ADThƻƃxƃtkekXkekhoh_ZCJnHtH h_ZCJhoh_ZCJh_Zjh_ZUhch_ZmHsHh-dh_Z0JtmHsHjQh_ZUh-dh_ZmHsHjh_Z0J&Uhh_ZmHsHjh_Z0JtUmHsHhh_Z0JtmHsHj h_ZUh-jph_ZmHsHjh_ZU"hp|>@*+,ɯɤzzzzsf]h 9h_ZaJjh 9h_ZUaJ hKh_ZjhSVUhSVh h_ZmHsHjh_Z0JtUh_Eh_Z0Jtjh_ZUjh_ZUjh_Z0J&Uh_ZnHtHh_ZhRgh_ZCJnHtHh_ZCJnHtHhoh_ZCJnHtHhoh_ZCJ h_ZCJ$_ ` a QH $$Ifa$_kdd$$If04$  t62 44 lapGkd$$If$ t62 44 lap $IfGuidance on the format of the risk management plan (RMP) in the EU in integrated format <> "Error*" STYLEREF "Doc title (Agency)" \* MERGEFORMAT Guidance on the format of the risk management plan (RMP) in the EU in integrated format \* MERGEFORMAT Guidance on the format of the risk management plan (RMP) in the EU in integrated format  IF  DOCPROPERTY "DM_emea_doc_ref_id" \* MERGEFORMAT EMA/164014/2018 <> "Error*" DOCPROPERTY "DM_emea_doc_ref_id" \* MERGEFORMAT EMA/164014/2018 \* MERGEFORMAT EMA/164014/2018 Rev.2.0.1 accompanying GVP Module V Rev.2 Page  PAGE 51/ NUMPAGES 51  30 Churchill Place % Canary Wharf % London E14 5EU % United KingdomAn agency of the European Union  Telephone +44 (0)20 3660 6000 Fac Y Z f g       \ ] ^ ` a b f g           468BJսĢĜսwwjhU h_Z0JwUhU h_Z0Jw h naJh>h_ZaJ h_ZaJh_ZmHnHuh*`h_Z5\mH sH hSV hKh_Zjh 9h_ZUaJh_Zh 9h_ZaJjh_ZUmHnHuh}mHnHuUjh_ZU, &(@FHJj;Vڼֵֵڼڼڵֵֵֵڃ| h@Xh_Zh@Xh_Z0JU$j:h"dh5UmHnHtHuh 9h_ZCJ aJ hCgih_Z0J h:h_Z hKh_Z$j(h"dh5UmHnHtHuh_ZhSVhU h_Z0JwjhU h_Z0JwUh}0JwmHnHu0$If*$a$gd6gd>=_kdƳ$$If04$  t62 44 lapj@8$IfK$hkd$IfK$L$T440 s ` ` t244 lapT $$Ifa$K$$IfEkd$$If$$ t2 44 lap (akd{$$If4:0>$>` t2 44 lap $$1$H$Ifa$bkd $IfK$L$T40 s   t44 lapT$IfK$Vvrkd$IfK$L$:\H ]Hp t4a$If$IfK$$IfK$simile+44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact  European Medicines Agency,  DATE \@ "yyyy" \* MERGEFORMAT 2018. Reproduction is authorised provided the source is acknowledged. VWXYZ[^akd$$If40>$>  t2 44 lap$If9kd]$IfK$L$:]] t4aVWXYZ[\yz h&hPh}mHnHuh_Zjh_ZU hxh_Z hKh_Z h:h_ZhSV[\jecc^gdegd>Ekdb$$If$$ t2 44 lap $$Ifa$Ekd$$If$$ t2 44 lap 9 0&P 1F:pz<. A!"#$% }DyK _Toc528579154}DyK _Toc528579154}DyK _Toc528579155}DyK _Toc528579155}DyK _Toc528579156}DyK _Toc528579156}DyK _Toc528579157}DyK _Toc528579157}DyK _Toc528579158}DyK _Toc528579158}DyK _Toc528579159}DyK _Toc528579159}DyK _Toc528579160}DyK _Toc528579160}DyK _Toc528579161}DyK _Toc528579161}DyK _Toc528579162}DyK _Toc528579162}DyK _Toc528579163}DyK _Toc528579163}DyK _Toc528579164}DyK _Toc528579164}DyK _Toc528579165}DyK _Toc528579165}DyK _Toc528579166}DyK _Toc528579166}DyK _Toc528579167}DyK _Toc528579167}DyK _Toc528579168}DyK _Toc528579168}DyK _Toc528579169}DyK _Toc528579169}DyK _Toc528579170}DyK _Toc528579170}DyK _Toc528579171}DyK _Toc528579171}DyK _Toc528579172}DyK _Toc528579172}DyK _Toc528579173}DyK _Toc528579173}DyK _Toc528579174}DyK _Toc528579174}DyK _Toc528579175}DyK _Toc528579175}DyK _Toc528579176}DyK _Toc528579176}DyK _Toc528579177}DyK _Toc528579177}DyK _Toc528579178}DyK _Toc528579178}DyK _Toc528579179}DyK _Toc528579179}DyK _Toc528579180}DyK _Toc528579180}DyK _Toc528579181}DyK _Toc528579181}DyK _Toc528579182}DyK _Toc528579182}DyK _Toc528579183}DyK _Toc528579183}DyK _Toc528579184}DyK _Toc528579184}DyK _Toc528579185}DyK _Toc528579185}DyK _Toc528579186}DyK _Toc528579186}DyK _Toc528579187}DyK _Toc528579187}DyK _Toc528579188}DyK _Toc528579188}DyK _Toc528579189}DyK _Toc528579189}DyK _Toc528579190}DyK _Toc528579190}DyK _Toc528579191}DyK _Toc528579191}DyK _Toc528579192}DyK _Toc528579192}DyK _Toc528579193}DyK _Toc528579193}DyK _Toc528579194}DyK _Toc528579194$$If!vh#v #v::V l t0G%65 5:/ $$If!vh#v #v::V l t0G%65 5:/ $$If!vh#v #v::V l t0G%65 5:/ $$If!vh#v #v::V l t0G%65 5:/ $$If!vh#v #v::V l t0G%65 5:/ $$If!vh#v #v::V l t0G%65 5:/ $$If!vh#v #v::V l4 t0G%6+5 5:/ / / / $$If!vh#v #v::V l4 t0G%6+5 5:/ / / $$If!vh#v #v::V l4 t0G%6+5 5:/ / / / $$If!vh#v #v::V l t0G%65 5:/ $$If!vh#v #v::V l4 t0G%6+5 5:/ $$If!vh#v #v::V l4 t0G%6+,5 5:/ $$If!vh#v #v::V l4 t0G%6+5 5:/ $$If!vh#v #v::V l4C t0G%6+,5 5:/ $$If!vh#v #v::V l49 t0G%6+5 5:/ $$If!vh#v #v::V l4. t0G%6+,5 5:/ $$If!vh#v #v::V l t0G%65 5:/ $$Ifl!vh#v$:V l4 t065/ /  /  alf4yt8$$Ifl!vh#vu#v #v:V l4 t065f 55I/  / / / /  /  / alf4yt8$$Ifl!vh#vu#v #v:V l4 t065f 55I/  / / / / / /  alf4yt8$$Ifl!vh#vu#v #v:V l4 t065f 55I/  / / / / / /  alf4yt8$$Ifl!vh#vu#v #v:V l4 t065f 55I/  / / / / / /  alf4yt8$$Ifl!vh#vu#v #v:V l4 t065f 55I/  / / / / / /  alf4yt8$$Ifl!vh#vu#v:V l4 t065f 5" /  /  / /  alf4yt8$$Ifl!vh#v$:V l4 t065/  /  / alf4yt8$$Ifl!vh#v$:V l4 t065/ /  /  alf4yt8$$Ifl!vh#vu#v #v:V l4 t065f 55I/  / / / /  /  / alf4yt8$$Ifl!vh#vu#v #v:V l4 t065f 55I/  / / / / / /  alf4yt8$$Ifl!vh#vu#v #v:V l4 t065f 55I/  / / / / / /  alf4yt8$$Ifl!vh#vu#v #v:V l4 t065f 55I/  / / / / / /  alf4yt8$$Ifl!vh#vu#v #v:V l4 t065f 55I/  / / / / / /  alf4yt8$$Ifl!vh#vu#v:V l4 t065f 5" /  /  / /  alf4yt8$$If!vh#vw#v #v :V l4 t065 55/  / / / /  /  / yt8$$If!vh#vw#v#v#v:V l4 t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  /  / / / /  /  yt8$$If!vh#v%:V l t065/  /  / yt8$$If!vh#v%:V l t065/ /  /  yt8$$If!vh#vw#v #v :V l t065 55/  / / / /  /  / yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  / / / / / /  yt8$$If!vh#vw#v#v#v:V l t065 5[5\5Z/  /  / / / /  /  yt8$$If!vh#vv#v #v :V l t065 55/  / / / /  /  / yt8$$If!vh#vv#v #v :V l t065 55/  / / / / / /  yt8$$If!vh#vv#v #v :V l t065 55/  / / / / / /  yt8$$If!vh#vv#v #v :V l t065 55/  /  / / / /  /  yt8$$If!vh#vv#v #v :V l t065 55/ / / / /  / / yt8$$If!vh#vv#v #v :V l t065 55/ /  / / / /  / yt8$$If!vh#vv#v #v :V l t065 55/  / / / /  /  / yt8$$If!vh#vv#v #v :V l t065 55/  / / / / / /  yt8$$If!vh#vv#v #v :V l t065 55/  /  / / / / /  yt8$$If!vh#vv#v #v :V l t065 55/  /  / / / /  /  yt8$$If!vh#vv#v #v :V l t065 55/  / / / /  /  / yt a$$If!vh#vv#v #v :V l t065 55/  / / / / / /  yt a$$If!vh#vv#v #v :V l t065 55/  / / / / / /  yt a$$If!vh#vv#v #v :V l t065 55/  / / / / / /  yt a$$If!vh#vv#v #v :V l t065 55/  /  / / / /  /  yt a$$IfP!vh#vb:V l4 t0&5baPf4pyt a$$IfP!vh#vb:V l4" t0&+5baPf4pyt a$$IfP!vh#vb:V l4 t0&+5baPf4pyt a$$IfP!vh#vb:V l4 t0&5baPf4pyt a$$IfP!vh#vb:V l4 t0&5baPf4pyt a$$IfP!vh#vb:V l4 t0&5baPf4pyt a$$IfP!vh#vb:V l4 t0&5b/ aPf4pyt a$$If!vh#v#v[#v #v#v#v`:V l4F t0+,55C5!5559p<i$$If!vh#v#v#vx#vz#v x#v #v x#v p:V l4 t0)v+,555 H5 `5 H5 D9p֌Hkdf$$Ifl48i Y I;YI "1%$$$H$H$H$H$H$H$H$`$H$H$H$D t0888844 lap֌[$$If!vh#v#v#vx#vz#v x#v #v x#v p:V l  t0,555 H5 `5 H5 D9p֌Ekdk$$Ifl 8i Y I;YI "1%%%%H%H%H%H%H%H%H%`%H%H%H%D t0888844 lap֌[$$If!vh#v#v#vx#vz#v x#v #v x#v p:V lL t0,555 H5 `5 H5 D9p֌EkdBp$$IflL8i Y I;YI "1%%%%H%H%H%H%H%H%H%`%H%H%H%D t0888844 lap֌[$$If!vh#v#v#vx#vz#v x#v #v x#v p:V l t0,555 H5 `5 H5 D9p֌Ekdt$$Ifl8i Y I;YI "1%%%%H%H%H%H%H%H%H%`%H%H%H%D t0888844 lap֌$$If!vh#v%:V l4 t065/ yt%D$$If!vh#v #v:V l t065B5F /  / / / yt%D$$If!vh#v #v:V l t065B5F /  / / / yt%D$$If!vh#v #v:V l t065B5F /  / / /  yt%Du$$If!vh#v#v #vP#v#v:V l4 t0!,555055/ / / / / /  /  / / / ap2$$If!vh#v&:V l t0!5/ /  ap F$$If!vh#vs#v #vP#v#v:V l4 t0!+++555055/ /  / / / / ap2T$$If!vh#vs#v #vP#v#v:V l4 t0!+++555055/ / / / / / / ap2P$$If!vh#vs#v #vP#v#v:V l4 t0!+++555055/ / / / / / / ap2P$$If!vh#vs#v #vP#v#v:V l4 t0!+++555055/ / / / / / / ap2$$If!vh#v&:V l t0!5/ /  ap 4$$If!vh#vs#v #vP#v#v:V l t0!555055/ /  / / / / ap2$$If!vh#v&:V l t0!5/ /  ap T$$If!vh#v#v #vP#v#v:V l4 t0!+++555055/ /  / / / /  / ap2T$$If!vh#v#v #vP#v#v:V l4` t0!+++555055/ / / / /  / / ap2>$$If!vh#v#v #vP#v#v:V l t0!555055/ / / / / / / ap2B$$If!vh#v#v #vP#v#v:V l t0!555055/ /  / /  / / / ap24$$If!vh#v#v #vP#v#v:V l t0!555055/ /  / /  / / ap29$$If!vh#v#v #v6#v:V l4 t0!,5e5l5!5/ /  / /  / / / ap2$$If!vh#v&:V l t0!5/ /  ap &$$If!vh#v#v #v6#v:V l t0!5e5l5!5/ /  / / / / ap2$$If!vh#v&:V l t0!5/ /  ap F$$If!vh#v#v #v6#v:V l4 t0!+++5e5l5!5/ /  / / / /  / ap2F$$If!vh#v#v #v6#v:V l4 t0!+++5e5l5!5/ /  / /  / / / ap2F$$If!vh#v#v #v6#v:V l4 t0!+++5e5l5!5/ /  / /  / / / ap2&$$If!vh#v#v #v6#v:V l t0!5e5l5!5/ /  / /  / / ap2$$If!vh#v#v:V l t0655/  / / / $$If!vh#v#v:V l t0655/  / / / $$If!vh#v#v:V l t0655/  / / / $$If!vh#v#vg#v:V l4 t0655{5/ / /  / $$If!vh#v#vg#v:V l t0655{5/ / / / / $$Ifl!vh#v$:V l4 t065/ al$$Ifl!vh#v #vy:V l t0655 /  / / / al$$Ifl!vh#v #vy:V l t0655 /  / / / al$$Ifl!vh#v #vy:V l t0655 /  / / /  al$$If!vh#v9!:V l4  t 09!659!af4p ytD$$If!vh#v #v&:V l  t09!65 5&apytQ 6$$If!vh#v #v&:V l  t09!65 5&apytQ 6$$If!vh#v #v&:V l  t09!65 5&apytQ 6$$If!vh#v #v&:V l  t09!65 5&apytQ 6$$If!vh#v9!:V l4  t 09!659!ap ytQ 6$$If!vh#v #v&:V l  t09!65 5&apytQ 6$$If!vh#v #v&:V l  t09!65 5&apytQ 6%$$If!vh#v#v#v #v :V l4 t0,555-5/ /  /  / / / ap($$If!vh#v#v#v #v :V l t0555-5/  / / ap(%$$If!vh#v#v#v#v} :V l4 t0,5v5/55/ /  /  / / / ap($$If!vh#v#v#v#v} :V l t05v5/55/  / / ap($$If!vh#v#v #v:V l t0$55 5pyt9$$If!vh#v#v #v:V l t0$55 5pyt9DyK yK 2http://www.ema.europa.euDyK yK 2http://www.ema.europa.euGDyK yK http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124DyK yK 6http://www.hma.eu/464.htmlDyK yK 2http://www.ema.europa.eu_DyK yK http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000429.jsp&mid=WC0b01ac0580029590DyK yK 2http://www.ema.europa.euDyK yK 2http://www.ema.europa.euDyK yK 2http://www.ema.europa.euDyK yK 2http://www.ema.europa.euDyK yK 6http://www.hma.eu/464.htmlGDyK yK http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124DyK yK 6http://www.hma.eu/464.htmlDyK yK 6http://www.hma.eu/464.html_DyK yK http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000683.jsp&mid=WC0b01ac058067a113d$$If!vh#v$:V t65/ / >2 p `$$If!vh#v4#v :V t65 52 p`$$If!vh#v4#v :V t65 52 p6Dd   zA?Logo MSWordPicture 1Logo MSWordb5^Qy7.]Qw5l3n5^Qy7.]QwPNG  IHDRg pHYs&s&slu OiCCPPhotoshop ICC profilexڝSgTS=BKKoR RB&*! J!QEEȠQ, !{kּ> H3Q5 B.@ $pd!s#~<<+"x M0B\t8K@zB@F&S`cbP-`'{[! eDh;VEX0fK9-0IWfH  0Q){`##xFW<+*x<$9E[-qWW.(I+6aa@.y24x6_-"bbϫp@t~,/;m%h^ uf@Wp~<5j>{-]cK'Xto(hw?G%fIq^D$.Tʳ?D*A, `6B$BB dr`)B(Ͱ*`/@4Qhp.U=pa( Aa!ڈbX#!H$ ɈQ"K5H1RT UH=r9\F;2G1Q= C7F dt1r=6Ыhڏ>C03l0.B8, c˱" VcϱwE 6wB aAHXLXNH $4 7 Q'"K&b21XH,#/{C7$C2'ITFnR#,4H#dk9, +ȅ3![ b@qS(RjJ4e2AURݨT5ZBRQ4u9̓IKhhitݕNWGw Ljg(gwLӋT071oUX**| J&*/Tު UUT^S}FU3S ԖUPSSg;goT?~YYLOCQ_ cx,!k u5&|v*=9C3J3WRf?qtN (~))4L1e\kXHQG6EYAJ'\'GgSSݧ M=:.kDwn^Loy}/TmG X $ <5qo</QC]@Caaᄑ.ȽJtq]zۯ6iܟ4)Y3sCQ? 0k߬~OCOg#/c/Wװwa>>r><72Y_7ȷOo_C#dz%gA[z|!?:eAAA!h쐭!ΑiP~aa~ 'W?pX15wCsDDDޛg1O9-J5*>.j<74?.fYXXIlK9.*6nl {/]py.,:@LN8A*%w% yg"/6шC\*NH*Mz쑼5y$3,幄'L Lݛ:v m2=:1qB!Mggfvˬen/kY- BTZ(*geWf͉9+̳ې7ᒶKW-X潬j9(xoʿܔĹdff-[n ڴ VE/(ۻCɾUUMfeI?m]Nmq#׹=TR+Gw- 6 U#pDy  :v{vg/jBFS[b[O>zG499?rCd&ˮ/~јѡ򗓿m|x31^VwwO| (hSЧc3-gAMA|Q cHRMz%u0`:o_F*IDATxuǕϭG fɒl2c 1i/Ɇ9dl8qI6l'cI bf 󃮺?7Ҍ,idɒcW]]}{EUA!B٧u6!B!لB!PgB!BM!B&B!:B!lB!Bu6!B!لB!PgB!B !B&B!:B!BM!Bu6!B!لB!lB!B !B&B!PgB!BM!Bu6!B!لB!PgB!BM!Bu6!B!:B!lB!B !B!لB!PgB!BM!B&B!:B!lB!Bu6!B!لB!PgB!B !B&B!:B!BM!Bu6!B!لB!PgB!B !B&B!:B!BM!Bu6!B!لB!lB!B !B&B!PgB!BM!Bu6!B!:B!lB!B !B!لB!PgB!BM!B&B!:B!lB!B !B!لB!PgB!BM!B&B!:B!lB!Bu6!B!لB!PgB!B !B&B!:B!BM!Bu6!B!لB!lB!B !B&B!PgB!BM!Bu6!B!لB!lB!B !B&B!PgBAP(@*"d7.u#Bu6!B["A8X&{MqDWdIeP~OЮwB!لl܉ֲhrY/߫ˆ⠢(f7E6!PgBȳHcWTB$e]H< Nک8( =("l)&lByֈl},PxjuBU T"B !Y#!B`}0* Zr;6g#'6fԉu;ش;!lB9,k\յbS#Kom,  C% U\ڪPL Skl:uQgO7y'7Q_Bu6!dMn@zX4w_wv{ddaVQF F;t`ILJZ>9ǎ? g6դr|85Nx0# 8!PgB~Rڱ6YhvJ%vKMw-6=xD@W$**,O}α=aiL3~Bscx8HBM!ل߄6T|6kDwwĒ- w<}N-R)QUㅺT] (%E9M=I9f)Gkxqn#sB}0^&oB&%JlЪ?W^wƇl[ 5!@O N>ȾC5^2nJ5r”3c&?SQ:B&%yڮ^{/]S,  mDqF1PcNąjh,g? W'j: 6&=o_xKϛJ~ep pLH!لDj\/}`(zlUSB)B*@8uxieDbꀸ>כG:cJ*\8^xes'C> #BM!cOeᨼgxCO&WxݠqqjU'b\\1H}E>ܡCԉrQ|U0BJ:qJ_8e[89yI B&lU_ܯrK,: \?<~k99DS &Noz]yGi+v(c܄BM!{$}[ժ7ܷ_r-k FaF!Pi_# mTD4VڄBM!):3~`0mO߰k 2iI8Hv9d`a渣ǿ ߜ'$LM!ل"3sPу8$#N2 |&mQZR)̤=uч !PgBl-'@tﱕWߴA5`*(TL (eBo?;&EM!ل[Ԩ8 P6olZJyf`wh(O_ĵG5EE)z%}ǟ`{ !PgBQQqJVl?~"ęG_#6V-<Ok|*s}q%I+B&Pg;j>Y]\{7W\^; |Jhbʋ/6e\]ҔsB!لGo$eQ,ٯ/ᡡ̪FȻNySBu6!"p#}_] M%$khƍ|%s*}ح!:P#kwjBH UFiyF,*zPu ŗT*dB&T|U,Zq_SjjBᔺ$J3\8Wt(w\qW)Lȶ"lBu6r-k;7mAMZ gTI'h,UL-(J־¹?s'XBMyjT8?߲YDwyk"69 !لPqF)[ܺM!@Q ϝϝ3)eBu6! JH/)F޺-kHrAR81Uw3>{ZPfB !٪"Ir$s)(Dc[uF ?|h'<{`<rjV`DͿs/[ցL>H17$4zyā>xBu6!|*[*wPu PC7ݶBMtwK!Q/uӽQLQi !لr Q$kvQIp{z3@O_{N'PgBB|u'-}D@~>6T4w.\CŢ@( :lB95v@=ŷ|ᎁ"!O$'w&.QBM!"~pX}.Y։_0XC;DE:{dB !B@˿/_TrP=-:Dš|?;ZvH!:BWw,]_.EPMv9A1+ T2_?yA$VvlByf+m _#fȉ@E ~߽A`Dը@aC&g:Z__]5z>`6=[GJHB&g.[w+ I0U RwOZ/e37!PgB3Xթ-dvI0߁q* u+Qk% !:BJb}W~0RDXiYWx1Du+:'"k!QSjB !*`]}}E+ @$1F+Y|q@D `$^/(P/J<IzU;M@?9@C-㬚<-Z%-ԏdņ^ę!Bu6!<5.jybuUg!A`DH9unxU-NDUW""F`TUU@Ԋtґ?+ 7@,E>wa U@T]IE#ADE H}5$ZlB%?ӓ[Iāc~ep/N  5puM TИl&q:*TՅb2CXJj0!_Q b85QB`T!tDgBbI kudJlBȡ(WBj 8,G]l5Sy"_{?*0 /, 4l6f]siqٌi1u MEQ(*ER$ ɴvlA@QۺK}m{! DJlE]%÷>"p A]i7|y !0M9؅xJ?WmYӉ ͢7zLj1H嫓T vR]iB׹qȥ\6R5Ps TP[dBP( B Z,DRX( Ba9 vnh_KE+y[( E}y]q|]~m['hiL9QPD6qGbwlgZ)(ߊ3SL%Wܔ<41JbL @RhI(rFT{^̌PpDUuñY뢨dmEjKΡoigy愉JjIĈ@ "@5Yct\s0wfϓۊ-`iutv0TBZqeqQx/| C@{7>y-^7L !:B  o 굯85żn8#jQ/;mz[ Ӛg64fTM1Չ@ "NEk7on}CАXSujksZu6ET*"9.[K.={F)_TĩB1RR , 3&fͨ{gr-}tE[aM9}ޢp{Ps`݊οkZ4'w&PgBx݋ZՍ>XX/;:Hcf`Fcה MْJ&AH>jrGstMm&N>8窿;bh5/ٳfEQHl~IfPt%[L Ng VݳwmM(f0.q;Pō k#&`|a!Il܄BM!dw^gU# uLk) @*%rO8ihhhD!wFL[o^r䉓JŢBC|Qis>qdmn^( jB +C ?Cs ؖ3[! ֩!k{|x+$NDD\8P5ϝiִ>W[:#co9rQ&MΪTts޵ 0JAAJ?#A$. 9 d10T*Nߋ_~u5Q ֛s|'>XGP_)қCkc)rU lB9p$w7ST@T)`ʢium)cU8n,ZQ"R*fϙ3k, "KcLcLARt*fL* Td6oڴjZgbTQv:ظ8UgɗX,Cs̜?|ϜNn02*%^JO*5oXs|MBM! d`0Z$t)#9ϚFjgq T`U0*va{,8rAMMMu ,˪ 'H0fL&N00+W*죆E?ED`` A]o?Ys4!Q3.JBԻE!x@EqlBu6!ph_^6RT4 {Oly'R,SUQu93DT`%lQvΜ9SN-J;Ha-A,0 Kt&dl&Kg3e],֯ x:8%Q)?G\.İ L$Ne1*NST:S!*Xhmcgٰa Pq7b ‰&E&ǢOA;{elBqI‘HCQ#jlޫͫcZ[[kr"laINN0NAQAɑG:G5NK%,hc ܹ 0Bu6!@^mӺ.i CMHo\B*D!A^Wa8yԲcd1]Yh*ںTR;t?/Sa* S(h98;2)?950ƗQqn' 9!PgBȁ©.^ىE`8EeVN:"Ƶ'Dsv |`{{ðZg*Et*]!dK&[it/ D0VO85:vϝb%rD5.t׍!ξOŻd&PgBȁb{ڑ Bc(D̙GiWUCԉ RKcrid]LU vٗFl2A{H\&~Y0Q{r}HWGǶpBM9auBͶ5Dۨjĩ p#iŗq{/Us;g֖s.*oZc!wuhd̶[N]8a:r0uv^a.=cBs&[Sh`oKv:~kmOOOYWH9HUϘ`7z{7Ni3&#P[- !x6!T>90Xzm&e '2{bp1.=V[W>-[,Xl鯼ߡNdٜ]vT+RuxT3YV @e;J1bչ8mԡ!պmiݴqSy°sj]6젶vWt )SQO}Y MqcޔφB,`{첖zgCuv#&(䇬ĕ,QZk{{{{SL{L(&ꏚT oW4ڇEvwBu6!(׏}1d7a+4ٲ~y_x뮻n}}}\K=s:~lcӧO3gҶZat/G"_c"AANT nWtksckEc|48"  !ل_TB;F  |MǘNaDE gsڊ)gr)rʝwC\r۶ml6푼Rp?~|}}}eHE.-_]*EU 5s®\nʕ+m۶0 #gZQICP>˷# 9 ^'PgBM\ RBM!O~a֬Jv,Dъ:E*5mekN翯2eʙgY,׮]iӦM6 |> |1(0  mO8a\_,B!qU?)S646ToyׇXvwuuFĨ:U:u>`)* šPappPUX1B!">%NSԷ>(M/N52M&Vl" 'c jZEٮ=(-I*8VfҤI&MPPBPt.yr͛ƍA6-,ڡ޾޾(8g#(QJ%ö֩: S)nDLv8jɅUf)O =c5Bu6!즮XP?[|^:"NKv={HԮ.)A444t~BKbdh(/J}R ޅΉqDFd:AաLEs~!UYUtO@̠—ۼ@:@"Oe'lBWlں6m }SeN9'A6sLƩFǧ D!Q;~; hHQT.Ett|Z[|EФ1wGL`B !d eŜa@118)!X;r/}6;^[B!ְO}6^- ԉ@-MI !1M@9X%ˈ-_"U%I8\-4@ R|FI,]U΍oًBM!{. 5kT;9b_vޣSUdd"\ğ";͗nkQT$PgB~CDSTT7eƮ506Ȼ?I=v@ADyAy؂ڒH]'ƻB0on2Yޡ!لt‰ sA5ʶ%k:λ=Is(Ԋ**jE‰Z ZT:Z> OTæ6 !لt(yN6/e;shc[) 0()X>߾HVM+Tg00ȥRBM!o2*u=R>wGQ@>+lJ)(QlKg8J*""jTJѨBAΦPgB !d>,1 .8"P5`ɚ5{a!X0*| uVKcUء֏Su"0u\mCB !d"*11aEVD{C*Xk>- It=<(7_ 8R|YFҖ\"O"[35i62!:BCu23Z}~ x7FG QO'CՅI5 C5P *UǸQUﰇfԌ"*VgLnjm̱ !لUߜZ)t.c^ }ݶ!@g$}͑`8T4~ Q^GKGn|s&BM!Yy_K kE*2vQJ-zm>"JȨb79ȭj=Z|$^*N) kB !dHlM ͥkuNNMǦdr뼿8vEU(4NW7XaJP@]"#^I*@U9<QquSelyBu6!W,)sfbsrcڪȄvYgO_qI5J F6מIf<^Oe4ka'RwvbsnZlBu6!Hi:A9ylm{W׬ڝJ/ƨCp[ƊS+&spjHVi6U(J:gJ3 !لr 2n#{y&QuvylJ"bAdR) XU+N`v>z-l7B )69!:B$&;bJڐ1p+mlD.B#a|ADP '*)cӈVK!M]qba]KCͱZ*'lB9P ac֩36i~yr-Q!=-bUCjQkY:\~3#`)G:@ǔ B !d-ڢc̢- %*;i-Yyhm9UE)-XGvlȴ+gޏ&eQdB !2fsPw`Q8&޺;Xbd>͟gaUn79N;/Mbһh>nua(<^ !لr9&V!P#Ԁb..ŵ+QQ5PQ,2 ed{yr(ug N|RX98-ӲL5l|!)^Msc쓧!u+m#lB9p(ܙ'h]n,"XU4y O|z%^gijmѲ6NZRUC#<CCV:xcR)W~,KmI2GjR]v@ٻ !لrUգkY0P1:3ƉBQlWgo@ EXk`V][ܴȵuӒCyO4U5K%8B&FfK:ٜ8S@UȤngǿ_E?; MVl_5-$]VLǤ$r-; G:}zK^3M&xų2PT/c&8*NTa}&ʻzqײCl(xS S;ncomjo=BM!N 71w3`F= V"'.)4}UݪV$aH.gSuPdRA[Oz2ѩV' eސGVABT=7` \M_r4#- لlB9@^ '@U eC_6E#%|AmUE[ quG1:oz}lujDNjֺ9o 5*Nŀ=3?rU: !ل ЊIwSdj*`R7VGw"b E&@Tꉮ}{[^(S'P qz?:zoEԨUϞ]K#NM&gD, rm/= bƘO(8Rٲxk|m=83$O ܳeA"$ς!+6k#"P(.\83f&AB !JEM\# .>mq'Là:D, P7tע*ܺFRڶx,"SJQ]c 7n-6o@-@lȎ?'dUU7XlHf̘\ST;!PgBو Ɔ)_vL,qⴒduE#j? E{]E "0& SmeM@I?*ѷSrl;uIU{onԦ7h2M&_\\e͝` 5cL"UUicKW|u[%.ŮeY&JƂ6crlQ7M?x!8X:'[FO%F$e@eG@<x Sb Lj֪-Ul^gN= Bu6!C` @El .q(rށgs6Y|Mqp.pixG*%PſfqwR_-'؞]7Qu|{/?T "lB9(xKϝgo "NE85;x;NĎn*QlQXQ LPIwn{ŏwË7j@0Ek [b]Ig/O6(ԧf%bg C ajʸ?s9 y2daTDEUa-޳{xϘAV+M֧n?:ɤ w/Z~{pM$Hi8i^P#"$$%9Ł@ 0_4ɧ̈́WGBȡw?bRB!D^ᛮnR׶hɏ&JzBp^zaWkXWBDRBU7ZYW:Y眵/wUuVZuNށ{^~l ,B V Bb  c@ 10@L5j1@J:0 ^ui%ׅB !+}Yw_R U*VYE65y|3%G35b4*bTtNjΪکZ9kْ꜋"NFEyEv֩R䜳ߘU(DK/uu=cȖJ B@bo0`ΆQ#0ZAD5>1Ϳ[&PgBǿ/ԧBW1> ӎ=븉[s ) BGh8Fu6r"0WEZ`m$PcH_@wU}x/JV5@Dpu6&T1@~D vڴ֫L&PgB&+ukd[>rӝwo@Mp^Jz?QUQ 0 M1i=f:bXtbZx U`]Iq(q` 0bV;mڲykג=f 1 40_"{(_QRň0} #j`5;]<, !لrl-NU0祝*b&r JM?yA M?nڙkRlFQQZ6rYUk@S@CCή56oؾv[Xm6 TJE@('AAq}2*@%G;4޺KPmB !`5/l'jTrFa"-Wo*Pt"D@MښmmȎkLOhJ͘T;%\ :'dcsetBL{{׶Bɭ[gpㆭ|Ww_gW I#LICQ%1Fa,Rg"Fa:j I$% @왭5g&PgBA"`J%t͍kNnb~zYP(Ԉԉ@|rm) Ccd0S؀Ga{չ$I JRsb C01 /L%b|C/udXw_T؄lB9t*"T𥳐w+("Nou*"N' _;QϡNCڀǑ;8qK>csV_8mh bQg!$VP..D:UB&C[^9PLJU!* q^P Pbdh #U (v 4L5zr ǨTz^ gN*(24$@ZD^BT$tEF\zoʖl<`uBu6!*fo;4$V[,|ƌ~oWI1Pخ-(*i/pqZ@5j|AFItx&HփbL\hDŽ{! 5sN8bxhym*!PgB!u?wGJHRQ 5$W>`v~Stu2QqH/|Lbޠ TMYPx/Ƴ ĄUuZ[Wϟ嬓f.Jl'lB9460T.-Wݸ )ANApϤ1ѡ"F5UQv*Z b#. -nmko' g|5/8 8c2M&CBc.a: <! >cQQ27F`DTSO'U$UgЎb7(-BŠ-B[I#_ _,]<,{lRK><%6!:B%qcǪ}/ЍmA. F*3(\\x\6yNW4X ۏb7la{ A+: xCxvKH'E(QxȆ?|]&E4Y.thB !و#rCe犥hg fedQwi>Qmy Gw1> _Qpp%CV[+::u4) Ź5)4 C[8za:0P ɮXv0M&Cm7܋\Z|@Džc*=F8|• +&]"5>W/ Qa5pzޑW~i8_#B !مr˃[ۗBbDȍS8TI+TN7.W-qPU5@pǟ[  B !Y„6C7=/ۢ"F*=UWm.6pGj⻈QOThǿ-`h&PgBȳMh$u4l{GoXVԄ"Pũ;Ub2=bWwU2|ƄfE|g|&]}Z !لSـrw~k el:C6P_.6{5rD/'u+!`!r&׽G|'x* q@ĩB&=SߕJm~7om PT' hRa]`5L3=/_&57dgLBu6![e 'qh$IVM-%~݃t jYcH9 )3n\sW,i){}rlsBu6!<-B[KׂA 兑?ߴ5+:\ $J1P1h=3Osr̄rBeH~CM!لmjU@:ݻnz`SdRlxp$w%GE" ;"OE6N~D˯o"vx˥g|©1.$[V>G%i3Bu6!H!+g/Vu>{6^wߦ~COT`6PĎX*y$=Lj;U?8W"Rflzs>aGjY#lByѼc b[W7?7/_WYH#@(DFiQA &H 5>g: &Ml B ! BHl0`Ck涡{o>ޱmh E V !c+`-&6S 2 GM8~~IG; 50EA'!PgBAU "عDN-طluצ6nϗz E+8E˥Lscm&Ds]69iRSf᜖9gNaL*rMyB!ل VH@j#v]r68kH*8P(mVwB&SUucmaq⠺gz4ӝ6%|NEP3˝>V}s}\15Bޢ HU7'+_I[jGϼ=)9i57lkVw(Fz.i]W~z;rկڞU"y+PUcnWTVKN~&Ҫ!T?]Q՞Z= ir]զэe^W(|]vrucú>E7x#un*TKUgи'+9U).j-_nvu/wIop=Dv;U_Zn0m5cŠ-2|IVT{VUjggXPR]W3UQ"@*J҇U GVID".I[|!&LB` ƃ 8B 5ɑ8(Sqz!Ziª TqjToME$Qs2ҙs"r?0hQubN4>FAUH2?T$%bv^F3nm`2wO3hBJa49[{dۧA6d_&ʗ󍺻m(5껙3MC?0oG]"`T>gQˊ@]y' NpFşNY$B$o<*\|'bfDQ="H> )rJTT T TA!_tSnGr@TTʃ9#*~D2|-"ɖ sQ;]]p2L[Aс!|/oQۤØG/mT$duSasy-Ki~Ru"2`&_J DaDm Tn*wx:Q:tJ(^a#VxPTĵ:J* jcʞhFL'ĩ :ujC7<JB`5EFc]$UT$n7x- $c*.2r0ͿD+ !⣡b$ї"'0q$ɍ [#M0ɞ6j[PQtM;R$ 5nYoD)7Lx٣wc#)ZGо5m; =V>C%Ivw݌Jx*k@hE0$w3Iz>$)?NƯ0^D=]&X(_o:'#aoic_^X7x1#z9~">w>φbT3z]KxbUu(7c3Ck-s5}?OCxO[-Dp{\{|2LʘT̟^ iqSEĪGWvubȋWtb$0&3>4!m:X;)=9<17vڑ4F3>UjlI@Qo/F]0[df&>)盧pXҶި7 '83lR=aδ#61yzS ۯ{ZN6էT ŵr /:gf,vʾQ%?|9g;).n=*c咵A@LmnضmhS{PN_ox4ɵp#U$Pۆ6\yṳF W5ݿaŚ(_( \C]8n洆 -3|iMw#'TBt[ಶ|*Y+b'[!'d3'.h?iԺ-5u[} 4֤fLդSpd(mڷlMϿd : m0g[WN3aneww!JmMzԆL&Ղs7vo}Θfso|lEu]]P(-0c7ga!}3lXxXKkC_=[ja}]8Vs ֫6 ]`v҂qk~,_tZsS&AqޡmiH5>!e uBT6t=;{uuIEuQdw$ PLPPWKCRGoiʭl  AZQ/MZ) fF㹮A7m+(WξBNP{ڱgLlȤChipWGWtdLz#|TxjI3ҜL_s#T%K)=ck{"5ۘ9zN1K ^U);f gBTդ` +`cJɄɂ{/^ޖ X[r51uڄ:)D婝BOPГ?ϛ}e_ я^dіez&vqHgG?61AuRvV#20X#g5dRn[G_n]6eU1FТTLsdsSScri9bZ9Lsէ]GaSa07^dsٔ*1% '-tQiw4HF1-߹x֎B_ Ra@($Yct]!RC6eraC]X_I]~^դ -ɦ'gqGMx‰q<ċbL<ɽ-/~s7>ٺGq9h|Jwؗ/ut ]sbmM? VG}H`LhBg(Dz/{@r 5&n/#8E=mE:@d_#.nZ}{G#:~'oyhC% #dbɺU="X 6a.ͥP/dgrRoB7KWwքA`TA 5CHo{qs]CO\틳b3n6$%YlO]ڊE8X褣&D@cȿjp+]u?'wl-@C*@h*Wc֬*F~ jLm66֥ 39ql[G{׷f1NZ{ _w=8T`zKWBJFXEϙ^k}7Q4[W8]՟6""kʎop;*"A*lMYjDS(0PzegkΉ (dxvl#SuNWo=׬Y <|µ߾d#b NZ+/) 259s)3LΞќc%Ktl6"!RAM&|K[NhiE0[U^#߼E̜i/:wօN=aFXǶM7k ]RRAc}.x𢡊1vGNUZO>0V/9wy'MTM*'t])2gM;O;jvk:UCͷݵ x4MOlUwUm`Q_ qSo揫oKuoџ7.yk^򦿣!ښW.<) P.N'!e~W~7pc$Anqk6zO|;/yՇo*߿sΚs:E|Qf͌'wdE7&~_qxYSu҇u~(RA dƄڣohHYFjd ҵCE7P<"e %t=]:ӦM_!/~o%0d/+?rz}mp8L/zXh|Y7w_WG`Z&͜Xq=尉SMՍ[7v 1"k1f_K\"+y>q-X/R!wx^btѹs~s'idlx3#\s=ߺtތF#b mʿ7uzC)ҐٱzQ_:鎟>oԆ~gj#_vֹ՛M]y8y%V*aڮKyu=Sf4.s!tLLJ}G_"2f҄ړpIά7y{zKk-<־vcA䣸ٝAɞwάk}I&xqlR> AԤq5p`)HW\0'}|uK>peR[ԛNHFeR^ՉsK7nX׃L{ÿūSYô/_>hvGOO;n?Ȗ͹͹j",_;߾xYΡ j_6wm]0 W\~w?|+'-kd}Nj|dzWϼbq{Hjӗ^t߿u 'x7>H<K/Z0 $H/9[q= ˽b);oyGmAbQ v˜DWo]SBC՝;k&*qF8Eƈ  u&L7n\7-?W9הCtw_cya(B чk͎%䪎'VE(>S{p7|dzIhNc}UlDP.;ss|k$S䂗7>c_2IXCohQ'L_Ï1 3SjP+-﷩6ˏtT{W~2K D6ӷ}K=3K^x|;îΥYdS7#7/īUVÝӓZj 2vyBs/\]rQH&zEǛ>}-ޟR [jUYd1Z^{ Ν](0bFW\9Ԥ~뚥MSl}gʦm?uҵC;,j>"ԇk^ 4]m}hYHg̓ H) -i > hgwIRZU\b}F]6=gFF?Tnll@ub@Uk3.=c/>}{_}\~0,U9o܁S)31wܘjYQ-S˹lJN8bk/O}ϞW.4A_Q5[z_^*\"bY_1)qZr#i6[??w !|NwsڑsGRp x|wL:ɌЩM7եᬨL:v7śRu=%$TM}3kҢ ..rT96s̼?Eg>gj*6֦G]~{I5yEY/:g-?[ڴO?=qJ[:^[??w v4|'_K>5FүTl;O}5d\.1c񺅈P ?zI`)y}ёoK?цtHc>l,[,@KC64ZD5yNύ7jkrL& }|Zk thJS:7kRh X)+'Tg4pZgk~86 "R!ATxn?Vuxv|WfT@]KCo>w_`/! Яw|_X3 ^V閙T%s97,VW9~O:a*"(wǏ IQ1AjAFn^2м٥Kd>]l"C*sÛUcoA6\t?r]^I =:` 4.㟋ΚZlhηw ~q͊-O{r` %ÿ,.jh"wX9;i)I LrF8kiGԐAeQCɭ&3mB=i\n 0!)TyE~KO?eKP'nZV%A-q>rBlg\Kc13?~K?|t}s=I5q/퓌I"@9~ >r u~ `ݽuw~΢ݡ {NSaӛ՟]^S&f2!ԕkaXŐ{틎8q#'N/>) q{+}=1*yYU\o׭I6w}rZ2p7_ǨnRkK>{nc}%{شF3RɅȦ}*"V0:%ҔT]t{gm7.W= Ce gsx|eiٲvԦ?vҟz^~TM6F - % E:kS9>Fn.'2q#,o=RC L8dߧy3˷H4"u3']kjSpԥG7mJb#ƳqwEZ&N/e٨Wy|.;w67^4|`nSOʏw{|u .Q3/1zS!E`FmT?8툉g7z|Moh%>yTz:n&ϷWaBWߖWx ?ٗ6=Iw_ɳ.d{_},JBAExF EAܛ&N_kG f%vn{xK,hXݍ L\P:g乍<aNS O;z|>ɤ$գ|e8Ґ;O<9SY}!Қu~ɏHOI y*YHd[Ї'*}פA\s:ـ8ئFy0K}m'Sf|$جJMG&;]a {tn20Rrw'{q9^\C[jR//_W8ٳ6q |_=. _nreskVJ꼍ظuh]Uib(""g'W:9a f5cgΝw-RǪ+ODx=S(;7*o/@FNH6-|{oypSC$2LAv)>ͻy R)o<όx~kę-qh`;,՜ S9/W1{piEV"S?cGož΍Z?JkCzW]b⡨hiM{Ou/m2n޴& .7jxzѓO{Z~7\T`1R|qev)}[\L1<& 8_^UzKϚ^7P%b&ښ/'%1%ϟ71(N*鰿pŧn~hYg|A'5vJoWpU=|>/\8oZcƧ|E;IN\0d wj' w揿D8Zdǖ/OT6,qÎ։OlCo89NpCDb/]DoNj8Ǿ\HP; FOA)1oof(r0 x닏memM'PKΙ^tQT׾& ile ȗ`!>v}Ku>VPmyATU¸$1i_oL P sħr`{gm<M>o:1-#VɶΚyQ9 e~eZ6>s9ën\5dʾ1Q5c޾ǩ<>ض}$ 2%Wk mZR޹Vg0תD%Z_ZKϚ\N_x/q08_r*nS.bW%MR.j&Gxg{ZFUm[+woi([}'7tX1[oWD5/]\Ih͍&5wΦC3N:6.nAVqܜpa:nBrx|@`D'3.9}rs]>U}/wOCևGVmOZSFO;#,o}7`ʶ3|"3>Pg@b\{Mk &J*tKzIPzg[G|X5ki)GM֦U"D߿ʻ2Ib/tTA-1ʜ! Nmݹ;N$"PY|3H& ʷ/D0"7B&I-Z˿x$Y3UUd5QP)T]KJ}dwŽ0~\o8n\S&8$ 3ZJ]W"IS'ԍolYnG|(sܔ7 aE90F_|J!J&8jNKC]8oFSU<K'罧441c߿(Kjo̎OВK&! s3QTטs_V ;(u9󽏝K硧$A&UO|X FtThwL*.^,OS<[W [d2FU /_VD̞oukO4d0ܽS*l[ETT &W\*[#=A [~P~|?N:I"4d㓋awI*UKp*o_w]k a#ƝsҔds+P IKvGoqaͿ6B uC߾ϷAb@9I} )˝jJkh'R&#EQsCo>ՊXz5j}7oiP,2crsOԤT -nZ7yڛ R}hkW-l;S}ޙhLnf:k㮚z'[Eszxh'()¨;NmGʮpeG|' SyW~ $e]0)e ѕ_ߞGt]uvly:{$w%*ÕL\2yk& ണ'kѡ7ܹ?M~'CgiwCysdMBXTmg~֜``( H0s& >$lj?#S@x|AhZ9G3E Mmأ4a f6!JF}$~*:~%gjLTfa(8DkW&hL#W~茳ΘEQAD/}Oȧ ޲xCSf~/D*\tʴL@> oX|]\GϮZq]oMC}sM(FSVKU^p_sriq0)Ρ]\HּɖN쀯礋3u_jJGlGmjd*`;rj)gԪ6k({m=`ĺl&4osn^[QӢFa(EßMkn߸q@Epi[[s2ew.RuAi21Ճ`GoG^lW,ZUPGM3~\Q>c`}lx/[z@N&d6רDL~ý1n;cF0 ̹g쨮9wfu$l @uJ[_iiiKw(n+Yw{̾lv7+%}2sYCpK'Θa)LThL7 z8G؈Q)þ}a~vB kc0mfUG^F K Z_5OEq$\PeеqF8Ӂqɴ|YN|溊ND<\dN;Ҷ~GA73U$ޙyOG!qY V0޽>NG3gN,Ј@ Uؒqp*b@VcSn]2^3׶G>HyYG靵 cSCUTӮ,ގ۔Fx fe$OpNs')!XSmͬ>Lˆc3&d&m@: M F^>Q3sZ]gSfD{cmM(b49pb `ݮƲfTt,/N>Q,z$4z'0 KϽeXiDH!VwݝQ\$c92`?]9_GYGK=zaq;8z{1{ZdwTt\7ZZ(B*׬7;DGJx ?n\oI 4GH~wՒ"Dȟ4Shfpvs&eDJ۷ %:Q3QmO(75&P_/&eOmXN>ll&8(~#`" k8/?[82Gb%􃿮yx?Id_rX%y[1cu$e",jFsƦ'ҼAUw"RA")2p.yJ"1 G@^%2YЭhO":@4~rφ@{f$ v$$s'M2@vYtB[n9ve\&~zٙƐ7Xfu*1P鬓`!1ok ޟ@{T4uN/PETbﭪC1k.¹n5 u-VB@hSNcd] 1`Y/ Y5+qނJ<1]]Xc uZE |4 ?'Ƥac*Մ!pf?㤂x wަJ?0 @&J8Vt-D1;_<$Q!ޮ󵻚@@I2IszS&7iF{Lͅ66;`>SEÒAňro4 ɢOSvqvM"(EA ܿ͵LJiǞ 8xa&e@'UnƻC,zM?k^>bxT]n 9Am#1}zIUl,@F;Lp2pO#Bj0"ƫ*E*Gt;o-oC Fh̺"8Ո';+'̀t"\[w_^QT ߏXK_]uvqW!Q?0 ,F5\#NB&Cݡ3 |O)tM2#O?b2P{߾{&ZnX5 nA9p`(2 66 0VL m@g%IҟuRja;Ht/}Zw~saFjnv‹ўkLhQh6*/ GjH.sQC0&/Iϒ0< 4]b˥՝U"] #W;&/ -1dL?AY=$O(Pv|hv@v|o-wvD;WWdn% &K7_4:+e ;[}Au@T]W ?aeS14j7>p2tHƬ@gߨƂ8ԷnEIl^vE&> Pf~<c*WO 3cgҟ}p@bt@;~_8rꌼ[/MTA^+L4},=/AkGݵ5@<-~HRTc =^/3#`HN_0jt-?$C ]S4=d$$w:uJ"LE~ٽ>L qυy$ *npOihS`d e`"}rsŠ# ѭM{@`f7 ^scҍyXB„HqK+ohc掎0鐑;$kPTt';S0dql"H1mpl&U vycOt~cMAurDyS ntTT:ӏ6wiLTN-6Y!M@߮\:P̐1 "Nܞ֬O]S8-3 io-N I۟~9!KxscIY:\촼Lh@fp{ 2@RV@ȎCUv0O2et; ֎خ-1pOW'B6c'llEpEe!۾oWwohioP<"OZ啽Qp7f|R>DL.R߻kͷ66y$ȉfZsX[k)p;l]ל34 #5nH`kw֫)- ]Lရ&! "lƉ!cNHs{#j׬`مY'!#8?ݿoOB@@nMSwa쮴d.w5{ƈJȒ]6+D..㼔v3H%X~ I_dd0 ?;emZyWZ+,k}ݱ@UgF!\`raS 5ԛaO16 MaLbA'$? x'acc(W{O)1ā"=O턘_>qT֋ϯk;.k}5ݥ<￷tj9LĀ @\@e'R\lxM384҇jVvt2 F7{c,4tM+~|9bwZש MAѦ^wnЌgw*CB`dp5nv0avi]~. b0 `4F( Z% lj YmGyOܻe|}XyrVVtA_7J)sMPR _߾" :q̢j0jg,h[ c(:i^/8K~ᣯ$uTW'޳he!Hda[̎^Q @,IO%{}q dÍuϿ/ZmtÅcK%%<B@<`BcȚ!mȬz w8d("fЙ#j߲U6뗎HsGd @BιA-hHuR4$b?j}d ˗5m~Y7]8!Ğ/DX0쵁LQO'fay]X8o΅+#pѢ/U w7L.I5dX? )>}餆 3TΥ?Ν42>0%*Jq ǎ2ל3lWx`E}xVP)gTeg0/R\U7rҝqq $2H1GO;nP8?y&B:_o.(0Hs9:gU&j:׮ )-{:ɻNKv{%L p@-meb jLE &[3xSJܛڇPHwW{~Y e`OF}W]NmL0c!3Fߛ(j),H2&= Tֵ΁!Jwr@1Hd(ӮCu!F-jRpQ1:kCH,O!ɤ0?dJGeP4UΩ-h2Lqe?59}VUK<Him9g^]-Ѷԙ9.p'^D yEE^O+)x]'uP $ɞbK(d6(63&ba4~k[ KR2"6I,2]118&(ᙞZDH27ZWhy1"HOv~x'fpT〔l~;8GBY޷~dgI]vYups(HtpmNsf$;kX{@i O"Z/*1 `uF7m~M$N3Qu 2c}szqG\Rⲉl6:4H 7kBxՃ#'h5(^{դ^53 c"T7?R8$~lbK`E ̚__ֿ~) PG1x>z| y\pQ|;kn&pDfjtiIwib6;F[_d9d2ˍ:.!"11 Dh?!bAx݊_;(9MBYxr=#Q^#@]ѰF&XcʆsfC{gT0շV|u_վf6S~^>ђG}wx % ?3ϛ_$"Mc.d~F9Ęʫy^>034mL.6Nߞ+ѠK 2g`SY.X8,)=:غSY~זe:'JMI,H6h۶_PΚ9.:L#H `@kGUVlj Ɉ9΋ iɎ^S&_ag <Z}TtMk{'~{Z'g->`0.eIhgvdز]8.٭h1p fo0CvdzTiJf#qs OyO>H `hQ @Hsw-?o@3r΁ᾃ-(۶. N3ox܄Q9.NN#C8pJ*c%V0aTW 6>"pěn||DHE \J{vO L-#ct\ΌI@<hFc7]4w]k/n*,d'޶fO5n߾C>}nl ̐(F 3pȒ"eB9H $ҝ.v@ %T.Y3H{92$2Os?5(1r;lS\..bbOi$VJHs `,-9dP`|<`U[j.3q.t 4CfEzu?|#4rx]$5Eq@(?ҫoL$m}?q)ľ$:ј2qV9-|uAT$8>\S|KE PkF &z,w(gs%{ P7 &@]$Mqs&dqጜ3rS6{3T16gˀd-k /61JBǥLEX7}lK?|ҏ P!žlOÚ26zuA GPdv/~XչғEQFK|FY6:bd%p(]{[uV@]Dxsme?@Y)m{[vꢊIFDK Q!c.XXLb#oMRBHeU~31([=w~|o?FHmV]yE^+CFHsJrvڬRb*{=-ƃD0]3US@:kweT@aho2vY3 1^^1:Ӫ|:Gql)٥e@G&V95i' 2K[YN{4M˵6?ţQ >[_ :-2<"\#pb߯x޳.1ú a吓]vA8G ڦQd[ XSs$gò=)^[/k¬DӔ)%i}% .ܣJ漣1i !IfuK'rƲ}lW_n P/(ꖎ+ˏܺdY3-TQwVK: 5#?~`x;ź:tCmfkWCa8d&Svsɘn[/p0}_9)iQ^9`5 I g͝-MڼN8!r \f׻0k>116hy,d+JXӈj,]sCIi¤l>6D6k6o]f tnjuyKADRg- FTn0{@G_!fZ^0W?^;97ojs\on Uo{. } ȳϿ[ 6i +q ^nT!"86<1nD"´ d]$pۯ(34'l2Q/}PqD$U[8#/?r#Q y&O#&d%a1z<"ĴFu}N:~z8!"Vv\wy{lC2 9"n$b8jjL~3Flŧu,ƾ}g-|pDD)6Ew%ZD/,HcR{ 4&Hz`mÖX()W]K+vl[GtHY7 "e:@g޲V_( ''(-pCBV%e%/y62 ?$ڲ5 R:vRIp9Ȍ#-P(ϼs%@B o}O5yTڳ;_|cw 8$.-0^!=Ֆ䱵Nw Z}Q :F N[$ꊕ[Ϛ[h`!G>H߿fұ_ [{6c#~޵&]ufIZ H0g~r)`71ΓJQg@)Hf{2ҮҶ@Q7EJ֩ ̝NWuBt "&=yř';@yMsG6i>kT~_.Mf\U[|-K%a8:%8Q$IĺNU>ԪsmRšuǍHODb"Al5|hZ} ,aĬmto=qn??9I'wA(Ç;Շ޽ ۃVHȈL`-`w&4vx:98چ=ҧt躸;r8*pFC2p`IL $[jRZ^MaD5VBzrOU;Ƶ!9sWTP|zה_xqjCB K.-llӾֆP0O0hֵ :8\J2>S c>>HC0A[yX/pVnۅ`߬|Rth;OK$sD{:4~dڳw?`fS;<_2#Ǭtgr1]e8sdNC""T SV8>?v hB->)GfJWO)¡JC Θ[0ojN~"؁s uP,cZ]F Xpa\EE<yTwE)  ])5~c1_dLMObt:z믗wU(hTH-S 7!x;9[R?uFӿ;_AyɢNvZb 8&uY[ p F j]Dl2['P֌j`]ZDL7[zgg@lRCeåR@h3QWU~8CiFM3DV2Gz"xwC=QS(L$ˬEf6 S,1 )3s_#[NHs[CPwKi9 iX `Kq$gȄ}/t9@@ engF"O]R uӔ^'(Iv_cNMmo>b~2#>%u-;؀TɜGE>" d҂؄97Aq z !?<^;DhBWݱMםRh<. ۏOV A[NH;#mK2&3YbS`0wR䑩 ^]콏*TtڑpS1!tF !ppbu} ŭ ]aN i)l2^8*`}a33ߐK+b`DN8:?y P5DE Q`%ZѸC*q˔Ry58J )E$@ 3.8Yje]'0U/u{2fd-Zϝ[!@#pȡwA3f]`Ĭa9.|m ^[]s}Gm m?0O1"3LH^fDU| \2?sN>E<}\fl"DZُ8T϶ )Ӟ4ET?<ΡvQgqiA{ k1I Pf򏮛*%!~lι*}àṧ=W1kBj{%3$&h { ^O?h[YqɅ{"f '쬹Eu+ >!?O\Jܢd> G\~f]bD쬹V?E0LMON_to.($7Tt #ŊmߺdLOs-]hM?jj7\cO3NΉ =N:"(lwYK0b1`AǷ 2ڶ O*t9^8OkGś]q2@Ӑ\ oݣq f9A-P{n` +o to 6@fijIi3Š uE q8h(G<ԎqF|CD!uB1SlFG3fz2ܠq`LE\{${ãc]?<Yբ64 Vy @aNҍJ2p>*{o? +|aV1/.=]$~ͭ3qLDUG$ٶokqapx_we;cWj8~"זm]a/բ=)bژic2 J b\`tdmS蝵H 0cyoH_|(z+RڐlΕA[>X!~W5QÉA@c Bm佉rkIG bbPa,XQB @]jƩ+N !2ٽOn tsqd`.S~vw=c,:dѶ^5=Iٜ"3<%? "ց*ps`_Egus83<3ǥJɑ~dy)Um$2KHr=7?tDJ _;m(1| NC+ < ^p.9;ntb(Gh 6аyV+1TmMxha}#r[y6Qo8Y'LvO2XZƵK}dL6KD"Z4;33C:ؠ9x+7iJF0t0)NE}! vix7X`'vJFz:@xv%sFe89v"1 b bv/ 1k3QF+pъD`nɤZ6uM_&.0P®;<? tرÒ n(>îq%ƌ! !cvǿW⓱i A0,ٽ=ȀDVϡk(d$KRiJڂVU6ߘL"rHmRs?TIufR`\\Jh$k tlWuuBU޺#.O"ƽͻwց"ezN }OŽ $Ʈ8xDI&Et@Z:e5G7kL}dGD=$S//EVt&0TUk B}hcאCn;O?{(q? LB 4GOJsG;SsBB(}5b9!:ChÍ5/T70E8(! ?P-t4t~ /3qvrk!.6P:i2hqt}=XP &EOk*Qbc3&J#qt!'qph4Y 9\?oka/rqB/^[wܿM9Zo*.nu>!G3L8Z p~&>Ny\D^/s^oCW7l7A#M5sZǜ2}!tgD(3_CUNjU܊B:1:Zq S}7p],k5w7۝6hH_B@ !6ǩx~I'P>AX;63FC)@d:b$lh{ P;&]lI]D}z$ "z_<4FA-ʉ]!="⽪#m߽gC a`q{磭(yu H}gPDFW2_ Mo;Y"𳻤3"ܘ<^tL"zuc@8krڀ3 .MtF[ @H9=nҀ™9yY=G®5DEVSXgsGߴhfYt] {gu域e}2B7b#܉N3:w_VT₆[aU܃F8`3yT R쳯 !2 EcMiװ+}}ee)RFz ~p`2f&._T6vD<Q|¹s x J 1`ғ+]Q@8F [Bw4*GH001&Ѱk#@FJ1 M_#zD33b#5,ešλ@ըV*:7ng5B1SՠAԋl1<~dMM04zLָ4s/E/Fh:0rGuSGl :mw~Ai?Ƭ'?60&#~FtPQyU4 70Q&?{|c=$"*Gl &F~6 ƀq oW5Dx>/?! :6Sb5QULȗF!1 Ahdaa+{MD:Z6\@$4/>͓ q`0Xz)"ѼJGw>%YG Ȭ ]l+EeLoW'%An@P3e{ !۳N=*M ajÆW|ӎPc􏟝r<ȈnhEߤ" S*1}+Nk7u lAC.~`>}V EMq}7_<dF qx~oFΨ08Tu/{W3z];o?~@Lk7V''Ć{jdLfapU ?X#om&nl"C,ᲰpT?66Sm>P[KmkqpH۶5-kw6 +dݷV}嶷׮SN{lNY6V@oC:0Aږ`8ʻ2̡6eg[' >*cES[@BѨMɯ̛.\@a`Gחo9=n} ɓf;ĪuMguzQDATw=V,[[ Ufo9Ý^]^GR -%RpK5U3E:mv.XI}J'{- *bԟsSCQ4&OHUif㙲{7Dr~~ 2 䌃(Y:•~8ٻxQk\hą "-)rV8 }B`G5pT`M--~DF ak[gBKG( FhHsU*22kfc%tUf}b?|wj`,%׏OX"!fowP,U1EZ}as]y\D5GxyY~s/o?a!q8j}9׽r;q*@+1uxr;=R3D0B=:J*;#Ȭ1b8QD$G~pyAӉs pn Ewnڴpv=\c^*t}$ /S]<%O~IL6=S~Qp _{!h g 1c۷wŠ9>=+'m߹t\:W*(|OA1]8ƪ/35GG IK}q0uC/N=2*Y G+F Lyg`:t@6y~ܻ5ޟYyӻp|qz@hm(5E[g涣_ 3S !GŊ/5wjd(XE@e3Uה4:Br_Ȑ2{j >r7}Iמ;&'v(l4Ecz Vyz+kaIi1mi!Hp;&"#G|$IWtA`q$}8l[2%V,x ۚB@Pڴޚ9.㛗?%'mw9$ GMl;whNq,=o̝_Qˈ'nlVIذK&0ˡ4ʎw%:?7iEI fySy@;b ?(۲-oV9!׻/}ߓ;4БK$+{v|ky^+3>V6NT@"wTDoxNVbd,]jW=P۰U+f.HKƩ>d|Wclܜ~fSea'L ]y$e{k,!r팓~Mv7; !8lcL;)cҋr.,N<QTv~˪j# 4<㐅YF"k/4t"s`2tin}Z}Q6b]%EI\ D"8'~Hzᭃp`Ŧ{l"ۈ!~O>1u%9D*-UztǮ,ji?wƽw80'9cXB1gN l3_hV]@n[kj@QۖA/7=# ZzA)ٻvqg&]whf(7^r?uhg lpH_jE)R`fޤnhW$ R9Dcz4=WWsNF) Ik5@a@ ~qZ.Z8,?ÕHpW+6bnWHX{X[շki d5dΜOe[DG#78mM g={QVv FW\mY0=yEF&ymE&0*1Uovu5mmA`N.fGc01llކpqu&%_v>/z,4TκmHkq@hȓ"I 1ZFnrŲ+=NHG`:3wSD++ {͜9iTZQ!GZoݷ Bp('|I_0ڴzµdfŖHe?7oX2?8j|9-?+zsV~쭃}hǞ- OWx٣ Ov;$"KX\y4EPq&d2$i m׶n{ tF@2<3&~suS{N~}-?(ӻ@ @_}Sfdm,c=,EV$/gV@Ms:pVF;às#(I9hfj%ȘtHv}Ҽ wKG.k{+~v:駎խSyI7Ԟ@L$(4 s,oVsD~pb.-gmrF}̰5*(osu,-9?1vc9Xc|lNJw8+s&ً <^G/vHTw_x`y9[s1Mm3֮M54s~|%Nd+r?z3?+=jL=Iƥ04#@ 1j^\zljh W uGZ,9]csR(cddly*hIaEISƤ߶t9yƊPog/{ sؔ;9s޴\R# 3AkpZ$G}eu>`@3gNy\qV$ ]1 5`'wۘ+[<5WBdY)24Z{|U55x֜.TMw"4!`8ە-;7SY/MוuC-?PcȰ(:H.JVg|ys,k^N% 6YKIRP(`k*8Sm D_VT$:(:a9a9sz̑#R(5< ɨqq xmy,g\1o=]k@"@)Htg{֎pUci\]%W7td4qe5/i#b9:pIDP$Ā0^ZiPi?6xYg~:oep?z?&{y:}քl^5mI㊓ 4_zqV?᪚Π1dWk[Bp$3ŝⱏ)Ʃsl#;Z3WpHiua.A 5@b9H.x\B&Yf.Rіmeu@F@Ns` @'%bRj 3$c#/XP@!(kZ c].pJc[UcaDnI.(C# ?44U5B"K$K)6E=PİkŘđnBqISK2$I _S7>&Adt"'o_yۡj_Cs>$Elv,cV2<)/=85#ny]UaL&+ֵdɕT.uԖ9SuMxV'#փ"P$kG%ƕ4NF$^}M?!:(#Q..LIKh΋Q6jʲDvꌩ38:'lT<.s>99m1p٤d$a(G01Q:"(. 9w8جYk La2I2fucJGz]NDH7HEFB5FLhCk&K$\KRh/ t8q,)Jl=uӽEynB6큈$)5ɑlk:$qĴ|wɠ ` I=k8ǐK,TBuN:RqnbZ:uMaCf+ Ju3 c1=ʁPDoqdD5@bF%MNVhjvd%d03pJ5A"c-QѴVUnę@:HLLszJn0ݵ!Hg^"PXn  j<5uUMoi:sU.TCj1nst_oG["A"AOmʡ ǝpdF&;l F 6tH<^aUDc\%YQW[C"3Ibe# PxTTGvscJ)ũnR6Ua(!l,+%1 jm> P bd 'Pd;"*+G32vSQ2adR f JxlBiOU,,Ks[IMRtZ;"ᘮr|HQ# kF32AHE$[nK@妋+W5|Ѻ@}k*1Ɋr2]YI"@s{3&1df';jzS[FF3P5!,LpP4ʫNeSRlHXBs"(v61oJpD#2ai+1qÎ@)XY:/JD(cKG$P'Ef# I{N3;5 \BnPI<5:͆!0bs:_ïIpNs2IHdjs""D 3-saTA ]bYQ$Pu0gwbt6tQ.0T$Ŭ7'6".ko{5N@?P-(QSA;g0?c<e(Eٗ֕=ŹK1@ph(='076F}ۡ 2<ytl_'W>v8@і#FưU9x? J6(TZYK%s^K%pt_uI\3};n<ǚ3j$H})ubRo&ɄA6 UWdWQ h@jhnQLYBbϗkܦ0[GϹbD|1JJpĽAn$qKQ:w"@1$#@O! o"33q>" $|P p⍵ ^ Rbć 2 y4yha`I~ue[օNn} ':77xdЛ)bB/1[ked±.ÅBr٬ܑA|cclDʡ&H<7?3(kdbvE#}qInJG{]b{#0H$m 8Nfc- W(x.D.wvX d\''j5d-Z?㘐7iD%# MԅȘNGf('}m,9?C<Ǔq-;݂t*FX\\z͍"`qMG7qyvEO=_dwl D9WȠ!: a{X/hLјOd1&ix%io0'M3TtaQ^x'kA q.(L&"YES'IČ,8Fg'(!wZG'8t>Caꪸԭ`h@_g'$! IHB$$! I IHB$$! IHNHB$$! IHB~vB$$! IHB$$! IHB$$$! IHB$$g'$! IHB$$! I IHB$$! IHNHB$$! IHB~vB$$! IHB$$! IHB$$$! IHB$$g'$! IHB$$! ?K)1UoF#i陙Y6Y!"D."jmmHĦN#//nu1?u$Ib1a}݀*55%)) .(s9$ xosE),,$)##vc96xXpXf\ֶp8TPP>_`^|rEQQHw88D$IuD9DD1]C[dY>Juq~[[+%%%e$x҆rz8Ĺ .; 55^ϛ H BNo dYlC98:ֶʶԬlY?wz@["'cǧ/66C$zIb}u]evuyCÇ>\QiǪ2qWo@籩I=z'lI 9$Ilp+>mx7kpX˗.]"6Ė੧-z^kmmw\.sҒteE>={,[F$MJJbuy+"%%ukiƤ9 ciZ[[edfǮ -蚕+WqΓrŕjUU|+Vl,-V<=f^aa~/wᄡ4ásD+rر^v]]3<Ԕm}>q_K_4;F>͛7⑝uW޲eZڲ{L8xDaaa*ᲊ#U5j,r9g[g;;;痿;ēO)-##7 n7o޼O0g::::;:SRM'{`DdRR\rȽi(3f̘1S[[{5W $yŗw1rdGqܜ8466TVV:tHEeUUq8}\ejvѢE-z~YƤI'H hYhQumC G0|VUk֌;f7o޼yz뽗_~9ySLXLmjjlBkp}sN6o999 m@uV&Ϙ>m(9Eڵkw(>rY1ϿbŊ7xns3椓 >,##CtDCU8rd]}3fL~v}kuuZ [n?a$yŗ2Nrގ\K/^}e㖛o9s@>>_~}ٛL 'MDDDZ~`@ 0ڲe˖͚5k…Fbu+V\jϩ*(..wHvYbg.>vߊO4iҤI֭'Ñk7M>u0.,/Y/y׬](cƎ% `nv[|lhwիX~ӱ .Xp믿/(6[rg?Inn>-Vt#F "0wUUp8 vuBH,_ {nAO][n:v_wrү | gXrʋ/ꫯHH2eҽs߲n݆yĦ(W\t޼yOV}lݺZ[W }g̘SO#W?.kOi Gl6fIU {իWBH$i *w+gY|F\ti55;;>ZWV\\ԲYV6$Ñ'JQ8qB7ub-f|Ï.W~u ׮koo]R%ܼy˪U㊖j 6SL%r$7}.67vksԩ=*8az'N菎Ò۶sO4‹.[oS]]͸ toXJo}pC)'jǏYTXdtYZZZ45vm<6awY:o3999.۷^&].WIɨҲrIG{M 1}.(?!ϝ/u;i{999µ֛>u1oYzͣ>t:o|+gdӾzU))15O]J$K2 ۲{4f̘nQD6ezzk49Nsqݺ <_o?\NWg̘~7]NI ՘&k[6r9U. nguu6Oo޾vzN`04`۳l5Ms1ia'N\ryt0f%\|mߞ=kͦTVU>˗9ͦ됔t;c΁:MM<={/[nr/~Y3g .4MdxApDT}Ud2qԁW\aSlD\պ#G0i`$ٶmG(db ~Mʘ9bEq: SSur99'Ƙͦ~nq@OѣG7fSr+lvܸq \Fuy6y?Oȧ2-ޫjs)S5CCdjozEG_6'gw۩>aP;eʤS'àBU?\rIJJF͞5+v=z^˹~B&Y @ n1J~g∈^ǮT6MLVTyW_ ,c=}9?zJKK:ckQQٳdYfs~iFw8k(I%=n}[?pѢE]?=5t.u`"^8("lN(mF,ˡpwSRR)^}}qvjo؉ɂ\1Էe߲> c@p87 -X0_]ןyٕ+W84NyU[u%F-:}a5mqqqӟ2"z;` H6mݺuuu}K(޳giZ4t.Ncėyy vy.7n,CР6gtXrͩw9閤dofff6;э"$(/?uqrNG|ᆆriGiH+`dvxD"`H?V& EŏA1uK1 û% ⏻Ur8@z0-[gΘ`|Mݳ{ Tb̻s~&If;s?mrr@L& ) qR RmRR,3߿~GLȮ]40{p!BfNٟhh۟--[}̷l۶L8q@o5jT5<=]ttxp+O%Ytɒ\|>='_Dj0Y8nwIɨ7??P^ =gj X,:mԒQ%ݱ}GUU5nu0\rUvVֹ瞫(隦 1thc("[vjٚCpSO?D+$b=v@yye=|LUž `?o t?ηmݖ:|Lܿ`kk$; HٟC?;,~xYg"$|SO? C ėZ0=]ZXDk'O>C=tc8uWWÇK#'I,+;cw=;]>\u3<#=-BPG{ 茶8qℴ4]睝OJ;;;% Dq'2Z0&IDTTXx 7$6=/RR{L bE9kFrsz葖BzhNCB]vkp<._|p'+RZ^~ᄓ-H0g 6sƌbEQ/_yEOilllkoeYA=<>\VYY9kmmS2./) DmO>TMMmo: "A0xu6Jc+W~C6e٦Ϙ߻w_YYyb,裏>iļu=l&G1)9aU}kR_TXiO,q]UU$&N :yf`W]uȲ,߰GkecAîٴi*D4y NʲnիEB] 9RU^~HyyEyyEEEEy#t"ee{|#Gٳflw]@_j'QմʪZ+**͇~$Oeeu[[[泿tL +W]]Uy^]  !q4gg@"׭WMp8v-7z0TDo|WeeeUMC=ݔm9Sc>YY l6QdkkkLpϵeuJ̐ɲ @4eE|\HVE͚5^M6/]z>'.={/b10sUv3$IK}> vGEő\s͌ӾHY="z}}O7\Nk?\*S3\*;;JJJ7v̶lrg!15+V"} G_|Ur:\s "[bb_wWg̘>8tR3QE ruvl6GjjUi鬬믻_OKk[UUC=r3 N72 @8%-6'MQ$7 Dp8#sOzO[|;vv)99t믿?bY3[bh,^ fKzBNQ-$''}:THӴO1wp{cW? œ33u@NcϞ%J 3hE9k֖ۃ~6wSLQUog۾c't KcKWMMI{ʾ@࿏=a'MHqC`K{-Hq.IlϚՕ9pk>8;Rȑ#ok>psSső'xꖛot{ܖM\iUu]eG!F+jG| ֏t?3YςJ>3y͛w9{pi9srs].cRk{Hhd~?ȣ'?;se9==Sz4s.N:G9tg孷Q7V"x   _{beyUlʍ7XPXk˂ qę3BqԨ|De]Agh挩^SOw ֮YORR8yݞ$7 \SF D$rAA^VGNG%˰!rMYrE_UMa@ 8OJz^G=F%4N#"pl] PpcǎR`m}1) OQ$XyyE,HKC55R\.566+~2{$f孭 o(rg[?LMI!H(2c(@D~Te֬CoD~R+0$y̕t Wpii?5O7O?;wFnϗ^RUUeobJɊ}ԅ 2DgjrJy zgC,>D!nn[>5%%y44ݻ1m]{='&Ir]]}YY-x# c|+]4 ;%ϢsςZE斏>Z1ÓېAsg4ǧJE={vNN ]K'0~ɒ$Iox=8}rq~ccЃ/laaiU0t\^pMZZZ֬Yg}L>M?EHII$) C!w%r+臘%V¾/#QPd0SIȲi:~:+C+ݜH$Zt?q?/_z9g%Mŕ+W[ʁsCD] 6ygœ:iٲ,564[2 f"L2~Af_z钯uYgug}Y]|yssnЁԏu 9WϬKRAc=yK/c h˖y%%5%3#-[wU8NαX&Z/ΉX[m.XpK/u8l[bK/,zT19H5|X,ck#3P,˂;j]]]#zg)FD<9i+ۍM63,#` ~{\g&!>n}`IRjjG?͖t:h׮]AwtlSɜ24Mu*I.lɼy'G`0K/o۾ǐㄋTCIG\{UMvH|z 6{;8s.\xŧ/^|E-X0)(,Ţud{Ȏل5$~>y`S:̄'Nt\o:1d' ].W'h/]t:ٲeo"EQqc0y2Їr ~$:x\NgWWbAAhۼeԩ@0 #C\O4r'Yhq#e}Ӹ>|Xaa~,Nwxd]@(XiYٳg{D ΃sɤIO555wtt$CQGr&''?"~iFF+_#J+^(sUߔ)S wb)5vvvԈKډ.HwZNDkjj ~i_~agƛoZZ%#d7n X$S_zC?Qa_$Ц&]׏'6oiiiݸqSSSy#I8 6DPX,F]F>dC ';w4tI|{ff3c[H?@M*++;::tiuS7m39{ ͚5sjlhLMM<u|> .̙=KڗEԇVQ^Qz|ĉi=~)S"莝;#Ƞq ƭ㵥g4_4mkk:ӟ^}_}p8 =9Ib#==e_ ].ͦlݺ_д~y{\c}߉iNE]@ι; o.;V?66Xp-S E\+BˏDN0-ss>EQv^<SV9E[2EUSggg2ZRO)BRht)+lRaO1;寞>ȧ49(F"h$Rp(?cuZUW_#{ՕZ]Yכݳ< ۯks(>P7?zp.zO=gR/NLMM=_k]l+>#k`:zu&sWt\JM6կ[w׫RJ?xRi#(PZB. K+`0ۗJ*@pP}e'VVcwIII0,hI)@vV*==/4LR}9=Vv0P[vDs)$_!XY*\"k}[}Gϗƫx?*CgVfi2v^32"2l΀=ȵK9_.բu,ڗ*R i6binY?5Cee׾=]zJOR%{H8,tK?<99aXΞ=l1驩ߝ6'B.+ pXӔ{_^-{G bXEt1oE +EйݳҬV/թZ4f/|ؘa-mmB58~ȗ>žeol0^o8m_׿pkwom\^QQ\T‘9q%c_̥\[0i!iO~^ xBQ<㩯[i5>_UU>ifoo_;aiH$K!''^M2sommu.,ZYMzz^_^ͦiZ:mg}nttlgGۆ(<9)E*xVqX< Ki&P(p AyⱸŢ;~۶fUUaBcǎر#3RVg={Bu Õ,MRʺ۶>t?~⩧Z^^oe,FE">UZZ*\B}fx5xVD*B|>l/ߢƔ¢˗Ιe{b Øjf<֙폫BwH_OzH$[lXPhŲG> ޲$<ɩ驫iӰm 7yΙx<^SS{Oÿoy.jhΝ;v[W---+mJ.8G|>jD"~fe%={GswoP'zzzΙ CWVTݻjUUUKgxg^y/{]˵8#jښ%%%ah$b_y'VM0GIy뭷G.]W*V!.[J''|[Ԡ L&xq]w}ݛ6m\}˗.?73-unG@PYg۷4={VxQ|gΜxg&\3%ťBH4@4|鱣GȞ;Ν?yx"!bhcÆ&nhR9J$7tvؽe4I)N 4;:t(1ӧ;?5uujjV_ƢZBsKvܹ'oŋNf ;6nfw=y=r;\p8F 3ukk떖͛?ٹS ~x<V=O__79U\T6~XJaco?T*Ǐ;D6mֶF*++8uɓ'/͜iwlںa}EEE'x1:22(*[lٸ}W'ԙ3gq5NLkXݞ&&.ظ*֭[::vww﫪Zϟy-VK hmұs`ooؐÑ52 Gcj4! F*O?Cy=V0޾ #i޶um[v}WX|x||ԩ!p8B흝EE￿fi>{3c鴑ғ[l߾h+?PܜrWWWmڴiǎ] |B|.A?_I|{’^F[=hU;?M Xtܨ\*Ynʔ%P֚oMq%u>ސju8+-p/Ӯͼe9f唏%!ZLbK!5нϊ9F/7 r6@@99 gll r6@@99 glM9 g gl r6r6@9 g gl r6@&gl r6@@99 gll r6@@9 g gl r6r6@9 g gl r6r6@99 gll r6@@99 gll r6@9 g gl r6r6@-G3IENDB`g$$If!vh#v$:V t,5$/ / >2 p EDdg  dA?EU LogoPicture 2EU LogobiF("XlvtiٹE~3n=F("XlvtiٹPNG  IHDRkI:1 pHYs&s&slu gAMA|Q cHRMz%u0`:o_FIDATx]?LFT C5|9ޯ^@&6Z=0*uM`WCz׶U>uFJڵj5l{.jt~' TbT9.PG>!ZԄ5qzl5Y]"ٚ/`\sPPp۾d7=LZ˴Nb E{baR{=\q  4D86 YnpB#pCMAM1)l:KYɘ$JBB1Y½ X?HⰤR{)l^횐c΢`^O/+[a,F SligDQ°{,*RMA`ngOL.MSu͐INPp1p!K]鴕:: $Ёxd=.[Q m{/3YY@,M\d@@%cg T%,Dtpvgg*= udTJ!˻' $iF\k<"Zb\q exקJBr|5=Pd\R3 !dP$aL-j®l -24U% W088Y,h֚T` T醪ӷ#)WT^MPL.t f@nY16+D3޿+A/~٪\ Cz^sKO + hK %s;t;t2BBU+":([aL.޷o,0*~=H~/@&6ғ*తb ler\n|'7:`dVx*_z Yt-t!F௵?v֧bFߤZtDә-;9˪0y ˽n ^zoLꙶ{ f,a"$Q [j2<}Mt;hy]s7,Ujl 2%HDͮ..ձukny|=Q&5r3>g=sjMS-jhm׻.]r._ 3vaqʳ}_e #YGfਃdq88Y1ox?UCI=IENDB`$IfK$L$!vh#v #v:V 44 t++,5 5/ ?2pTl$IfK$L$!vh#v #v:V 4 t++5 5pTo$$If!vh#v>#v :V 4: t+,5>5 2 po$IfK$L$!vh#vH#vp#v#v :V : t,5H5p55 4 E$IfK$L$!vh#v]:V : t,5]4 o$$If!vh#v>#v :V 4 t+,5>5 2 pK$$If!vh#v$:V t,5$2 p K$$If!vh#v$:V t,5$2 p b 666666666vvv66>6666666666666666666666666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~PJ_HmH nH sH tH P`P  .Normal(CJOJQJ^J_HaJmH nHsH tHB@ABY Heading 1  F@& mHnHu8Q8 Y Heading 2  & F@&8a8 Y Heading 3  & F@&8q8 Y Heading 4  & F@&^@^ Y Heading 5$ & F@&56KH PJ\^JtH 88 Y Heading 6  & F@&88 Y Heading 7  & F@&88 Y Heading 8  & F@&8 8 Y Heading 9 & F@&DA D Default Paragraph FontRi@R 0 Table Normal4 l4a (k`( 0No List ROAR kyHeading centred (Agency)$a$L @L YFooter 9r CJOJPJQJaJtH .). Y Page NumberTO"T >Footer (Agency)B*CJPJaJphmoqtH `O2` >Footer blue (Agency)5B* CJ PJaJph3tH OC YFooter table (Agency){:Vjg OJQJ5CJOJ QJ loQl >Footer (Agency) Char Char!B*CJOJPJQJ^JaJphmoqlOl YPage number (Agency)$5&a$B*CJPJaJphmoqtH voqv YPage number (Agency) Char Char!B*CJOJPJQJ^JaJphmoqxox >Footer blue (Agency) Char Char$5B* CJ OJPJQJ^JaJph38B8 Y Body Text dROR VYBody text (Agency) dPJtH ::YBullets (Agency)tOt YDisclaimer (Agency)!dj9B*CJ PJhaJ phmoqtH `O` YDoc subtitle (Agency) dhCJPJaJtH dOd YDoc title (Agency) dhB* CJ PJaJ ph3tH xOx YDrafting Notes (Agency) d$6B*CJOJPJQJ^Jph3ftH F*`F YEndnote Reference H*OJQJXoX YEndnote reference (Agency) H*OJQJD+@"D Y Endnote Text"CJPJaJtH RO2R YEndnote text (Agency)# CJPJtH @@ YFigure (Agency)$$a$ZBZ YFigure heading (Agency)%$ FxH&`aH YFootnote Reference H*OJQJboqb YFootnote reference (Agency)B*H*OJQJphF@F XY Footnote Text(CJPJaJtH TOT bYFootnote text (Agency)) CJPJtH :O!: 6Header (Agency)*pOp qYHeading 1 (Agency)+$ F@&5CJKH PJ\^JaJtH xOx uYHeading 2 (Agency),$ & F@&!56CJKH PJ\^JaJtH tOt vYHeading 3 (Agency)-$ & F@&5CJKH PJ\^JaJtH ROR YHeading 4 (Agency). &@& 6CJaJJOJ YHeading 5 (Agency)/ &@&6FF YHeading 6 (Agency)0 &@&FF YHeading 7 (Agency)1 &@&FF YHeading 8 (Agency)2 &@&F!F YHeading 9 (Agency)3 &@&zOz YNo-num heading 1 (Agency)4$@&5CJKH PJ\^JaJtH ~O~ YNo-num heading 2 (Agency)5$@&!56CJKH PJ\^JaJtH VOV YNo-num heading 3 (Agency) 6 & FVOV YNo-num heading 4 (Agency) 7 & FVV YNo-num heading 5 (Agency) 8 & FRR YNo-num heading 6 (Agency)9@&RR YNo-num heading 7 (Agency):@&RR YNo-num heading 8 (Agency);@&RR YNo-num heading 9 (Agency)<@&bob YNormal (Agency)=(CJOJPJQJ^J_HaJmH sH tH rOr YNo-TOC heading (Agency) >$5CJKH PJ^JaJtH FFYNumber list (Agency)? FFOF Y Ref. (Agency)@CJPJ^JtH XOX YTable first row (Agency)A$5PJO# rbTable grid (Agency):VB0jj 34 B'CJOJQJ56CJOJ QJ aJ&O#3& YTable grid (Agency) black:VC0jj 4 C$!56B*CJOJ QJ aJphOC YTable grid (Agency) blank~:VDjj 4 D0CJOJQJ!56B*CJOJ QJ aJphXOX YTable heading (Agency)E$ Fx^Ob^ YTable heading rows (Agency)F$5PJVOrV oYTable text rows (Agency)GdPJfOf YTable/Figure note (Agency)Hd<CJaJ^@^BxpTOC 1I$$ d95CJPJaJmHnHtH uP@PYpTOC 2J$ d9CJPJmHnHtH uP@PYpTOC 3K$ d9CJPJmHnHtH uH@HYTOC 4L$ d9CJmHnHuH@HYTOC 5M$ d9CJmHnHu4@4 YTOC 6 Nd9PJ4@4 YTOC 7 Od9PJ4@4 YTOC 8 Pd9PJ4@4 YTOC 9 Qd9PJzoz kySpecial comment (Agency)R-B*CJOJPJQJ_HaJmH phsH tH @1@l2Bullets (Agency)1S FH@BH U, Balloon TextTCJOJ QJ ^J aJVoQV T,Balloon Text CharCJOJ QJ ^J aJnHtH^oa^ HBody text (Agency) CharCJOJPJQJ^JaJ\Oqr\ cStyle Table text rows (Agency)WCJPoP ({Footnote Text CharCJOJPJQJ^JB'`B 0Comment ReferenceCJaJ<@< [ Comment TextZCJaJNoN ZComment Text CharOJQJ^JnHtH@j@@ ]Comment Subject\5\ZoZ \Comment Subject Char5OJQJ\^JnHtHO Rp TOC Heading1^$d@& 8B*CJKHOJ PJ QJ ^JaJmH nHph6_sH tHu|o|e0Colorful Shading - Accent 11_(CJOJQJ^J_HaJmH nHsH tHJg`J HTML TypewriterCJOJQJ^JaJ@n@@&VArticle / Sectiona Ffo!f )&VFootnote text (Agency) CharCJOJPJQJ^JaJ$L$ YDatecZY@BZ Y Document Mapd-D M CJOJ QJ ^J aJ<[R< YE-mail Signaturee.X`a. YEmphasis6]r$@rr YEnvelope Address$g@ &#$+D/^@ CJOJQJ^JaJN%@N YEnvelope ReturnhCJOJQJ^JaJFV`F YFollowedHyperlink >*B* ph44 lHeader j!bOb /0Tablek$((CJOJPJQJ^JaJmH nHsH tHJoJ j[3 Header CharCJOJQJ^JaJnHtH`O` EKBBody text (EMA) mdCJOJPJQJ^JaJtH VOV Defaultn7$8$%B*CJOJPJQJ^JaJphtH ror GTable text rows (Agency) Char CJOJPJQJ^JaJnHtHoD0Frgad skuggning - dekorfrg 11p(CJOJQJ^J_HaJmH nHsH tHhoh +-rHeading 1 (Agency) Char"5CJKH OJPJQJ\^JaJ@# 9tTable 3D effects 1m:Vrj#j#j#j#j.j.j.j. r-5\5B* \ph B* phl@3l 9tTable 3D effects 3:Vsj.@j j j#j9jj44s2 B*ph B*ph5\5\6U`A6 Y0 Hyperlink >*B*phloQl ,\Heading 2 (Agency) Char%56CJKH OJPJQJ\^JaJroar -uHeading 3 (Agency) Char Char"5CJKH OJPJQJ\^JaJLoqL >Page Number (Agency) CJOJQJHCH y^Body Text Indentxx^^o^ x^Body Text Indent CharCJOJQJ^JaJnHtHVoVC0 Revision1z(CJOJQJ^J_HaJmH nHsH tHFQ@F |%K Body Text 3{xCJ^JaJtH HoH {%KBody Text 3 CharCJOJQJaJ~@ + Table Grid 1z:V}0jj }6]6]VOV +P  Liststycke1 ~^CJOJPJQJ^JaJtH .(. Y Line NumbertOt C$ENCePP comment textx7$8$H$1$!B*CJPJaJmH phsH tH JJ C$ENCePP comment header$O" C$ENCePP table 10 text&@((7$8$H$1$^@`!B*CJPJaJmH phsH tH T`2T%S0Revision(CJOJQJ^J_HaJmH nHsH tHO  .p TOC Heading2$ Fd@& 8B*CJKHOJ PJ QJ ^JaJmH nHph6_sH tHu\@R\  . List Paragraph ^CJOJPJQJ^JaJtH p-`bp Y Macro Text"  ` @  OJQJ^J_HmH nHsH tHH^@rH Y Normal (Web)CJOJQJ^JaJDZ@D Y Plain TextCJOJQJ^JaJ0K0 Y Salutation*W`* YStrong5\jj Y Table Grid7:V0T,T YTable of AuthoritiesL^`L<#< YTable of FiguresP.@P Y TOA Headingx5CJOJQJ\^JaJo kyDoc category heading (Agency)$7&dP45B* CJOJPJQJ^J_HaJmH ph3sH tH o O0Frgad skuggning - dekorfrg 12(CJOJQJ^J_HaJmH nHsH tHVO V O  Liststycke2 ^CJOJPJQJ^JaJtH o" +f0Frgad skuggning - dekorfrg 13(CJOJQJ^J_HaJmH nHsH tHVO2 V +f  Liststycke3 ^CJOJPJQJ^JaJtH oB 0Frgad skuggning - dekorfrg 1(CJOJQJ^J_HaJmH nHsH tHTOR T   Liststycke ^CJOJPJQJ^JaJtH PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] #&JKnqSq@ױt]f^G0yi j m f"$ 03l  (+3;!t#g&I'+#.1.2p34 678W:;<>8?E@AnBDEFDH:J:KcLMNcPRVZ[\^9aceBikk/optwxb{|}~69?k=?*2p5DTv{)*pe b'vxPW y`F ] ZX- 9"#+%&),9-.1357t89;W<=AACEHQJLQMPRTWXY{Z[\o^`ckrOstvx4z{.}d'9އ|4:6ȒǔInҝmc0äeZЪjɵ;>{+b6fhV      %(*,1345789:;=>?@BCLR`ktz{}~  "#$%'()+-/02345678:;?ADFIKMNPQRSTVXZ\_acefghiklmnoqstuwx{|~s!.^:FG+II;JJJJxKHLA?AAcCfCCCuEEGEGkHJQMMNNPPPPQQ*RSXx[\aIsy{|Rsc@K|eiϪʬXZ;OoS8V[!"#$&')+-./026<ADEFGHIJKMNOPQSTUVWXYZ[\]^_abcdefghijlmnopqrsuvwxy|    !&*,.19<=>@BCEGHJLOUWY[]^`bdjprvyz}HXe) * *-*?*[*]*^*`********/+K+N+O+Q+q+++++++(,D,G,H,J,j,,,,,,,E-a-d-e-g------.!....... /%/(/)/+/K/m///////000 0@0w00000011 1!1#1C1111111<2X2[2\2^2~2222222H3d3g3h3j33333333'4C4F4G4I4i4444444#5?5B5C5E5e5555556@6\6_6`6b66666666777:7;7=7]777777788"8#8%8E8f888888888889X9t9w9x9z9999999:,:H:K:L:N:n:::::::6;R;U;V;X;x;;;;;;<T<p<s<t<v<<<<<<<=u=======>>>>:>~>>>>>.0fUU X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X% I;L3CTd3  UU!C\s2gwGY*EI.2\w{k h m XXXXXXXXXXXXXXX8@0(  B S  ?iHead BodyBlank _Toc421005529 _Toc421710578 _Toc464653135 _Toc468365825 _Toc528579154 _Toc464653136 _Toc468365826 _Toc528579155 _Toc464653137 _Toc468365827 _Toc528579156 _Toc464653138 _Toc468365828 _Toc528579157 _Toc464653139 _Toc468365829 _Toc528579158 _Toc464653140 _Toc468365830 _Toc528579159 _Toc464653141 _Toc468365831 _Toc528579160 _Toc464653142 _Toc468365832 _Toc528579161 _Toc464653143 _Toc468365833 _Toc528579162 _Toc464653144 _Toc468365834 _Toc528579163 _Toc422210829 _Toc464653145 _Toc468365835 _Toc528579164 _Toc464653146 _Toc468365836 _Toc528579165 _Toc464653147 _Toc468365837 _Toc528579166 _Toc464653148 _Toc468365838 _Toc528579167 _Toc464653149 _Toc468365839 _Toc528579168 _Toc464653150 _Toc468365840 _Toc528579169 _Toc421005578 _Toc421016770 _Toc421005579 _Toc421016771 _Toc421005580 _Toc421016772 _Toc421005581 _Toc421016773 _Toc421005582 _Toc421016774 _Toc464653151 _Toc468365841 _Toc528579170 _Toc464653152 _Toc468365842 _Toc528579171 _Toc464653153 _Toc468365843 _Toc528579172 _Toc263433116 _Toc464653154 _Toc468365844 _Toc528579173 _Toc464653155 _Toc468365845 _Toc528579174 _Toc464653156 _Toc468365846 _Toc528579175 _Toc464653157 _Toc468365847 _Toc528579176 _Toc464653158 _Toc468365848 _Toc528579177 _Toc464653159 _Toc468365849 _Toc528579178 _Toc464653160 _Toc468365850 _Toc528579179 _Toc464653161 _Toc468365851 _Toc528579180 _Toc332296643 _Toc332297430 _Toc332298251 _Toc332298727 _Toc332299012 _Toc332299291 _Toc332299572 _Toc332299851 _Toc332296651 _Toc332297438 _Toc332298259 _Toc332298735 _Toc332299020 _Toc332299299 _Toc332299580 _Toc332299859 _Toc332298319 _Toc332298795 _Toc332299080 _Toc332299359 _Toc332299640 _Toc332299919 _Toc332298326 _Toc332298802 _Toc332299087 _Toc332299366 _Toc332299647 _Toc332299926 _Toc332298334 _Toc332298810 _Toc332299095 _Toc332299374 _Toc332299655 _Toc332299934 _Toc332298335 _Toc332298811 _Toc332299096 _Toc332299375 _Toc332299656 _Toc332299935 _Toc332298336 _Toc332298812 _Toc332299097 _Toc332299376 _Toc332299657 _Toc332299936 _Toc332298337 _Toc332298813 _Toc332299098 _Toc332299377 _Toc332299658 _Toc332299937 _Toc332298339 _Toc332298815 _Toc332299100 _Toc332299379 _Toc332299660 _Toc332299939 _Toc332298347 _Toc332298823 _Toc332299108 _Toc332299387 _Toc332299668 _Toc332299947 _Toc332298352 _Toc332298828 _Toc332299113 _Toc332299392 _Toc332299673 _Toc332299952 _Toc332298353 _Toc332298829 _Toc332299114 _Toc332299393 _Toc332299674 _Toc332299953 _Toc332298354 _Toc332298830 _Toc332299115 _Toc332299394 _Toc332299675 _Toc332299954 _Toc332298357 _Toc332298833 _Toc332299118 _Toc332299397 _Toc332299678 _Toc332299957 _Toc332298359 _Toc332298835 _Toc332299120 _Toc332299399 _Toc332299680 _Toc332299959 _Toc332298361 _Toc332298837 _Toc332299122 _Toc332299401 _Toc332299682 _Toc332299961 _Toc332298368 _Toc332298844 _Toc332299129 _Toc332299408 _Toc332299689 _Toc332299968 _Toc332298376 _Toc332298852 _Toc332299137 _Toc332299416 _Toc332299697 _Toc332299976 _Toc332298377 _Toc332298853 _Toc332299138 _Toc332299417 _Toc332299698 _Toc332299977 _Toc332298378 _Toc332298854 _Toc332299139 _Toc332299418 _Toc332299699 _Toc332299978 _Toc332298379 _Toc332298855 _Toc332299140 _Toc332299419 _Toc332299700 _Toc332299979 _Toc332298381 _Toc332298857 _Toc332299142 _Toc332299421 _Toc332299702 _Toc332299981 _Toc332298390 _Toc332298866 _Toc332299151 _Toc332299430 _Toc332299711 _Toc332299990 _Toc332298395 _Toc332298871 _Toc332299156 _Toc332299435 _Toc332299716 _Toc332299995 _Toc332298396 _Toc332298872 _Toc332299157 _Toc332299436 _Toc332299717 _Toc332299996 _Toc332298397 _Toc332298873 _Toc332299158 _Toc332299437 _Toc332299718 _Toc332299997 _Toc332298398 _Toc332298874 _Toc332299159 _Toc332299438 _Toc332299719 _Toc332299998 _Toc332298401 _Toc332298877 _Toc332299162 _Toc332299441 _Toc332299722 _Toc332300001 _Toc332298403 _Toc332298879 _Toc332299164 _Toc332299443 _Toc332299724 _Toc332300003 _Toc325387326 _Toc325387449 _Toc325390289 _Toc332298405 _Toc332298881 _Toc332299166 _Toc332299445 _Toc332299726 _Toc332300005 _Toc325387331 _Toc325387454 _Toc325390294 _Toc332298410 _Toc332298886 _Toc332299171 _Toc332299450 _Toc332299731 _Toc332300010 _Toc325387334 _Toc325387457 _Toc325390297 _Toc332298413 _Toc332298889 _Toc332299174 _Toc332299453 _Toc332299734 _Toc332300013 _Toc325387339 _Toc325387462 _Toc325390302 _Toc332298418 _Toc332298894 _Toc332299179 _Toc332299458 _Toc332299739 _Toc332300018 _Toc325387342 _Toc325387465 _Toc325390305 _Toc332298421 _Toc332298897 _Toc332299182 _Toc332299461 _Toc332299742 _Toc332300021 _Toc325387347 _Toc325387470 _Toc325390310 _Toc332298426 _Toc332298902 _Toc332299187 _Toc332299466 _Toc332299747 _Toc332300026 _Toc325387350 _Toc325387473 _Toc325390313 _Toc332298429 _Toc332298905 _Toc332299190 _Toc332299469 _Toc332299750 _Toc332300029 _Toc325387355 _Toc325387478 _Toc325390318 _Toc332298434 _Toc332298910 _Toc332299195 _Toc332299474 _Toc332299755 _Toc332300034 _Toc325387358 _Toc325387481 _Toc325390321 _Toc332298437 _Toc332298913 _Toc332299198 _Toc332299477 _Toc332299758 _Toc332300037 _Toc325387363 _Toc325387486 _Toc325390326 _Toc332298442 _Toc332298918 _Toc332299203 _Toc332299482 _Toc332299763 _Toc332300042 _Toc325387366 _Toc325387489 _Toc325390329 _Toc332298445 _Toc332298921 _Toc332299206 _Toc332299485 _Toc332299766 _Toc332300045 _Toc325387371 _Toc325387494 _Toc325390334 _Toc332298450 _Toc332298926 _Toc332299211 _Toc332299490 _Toc332299771 _Toc332300050 _Toc325387374 _Toc325387497 _Toc325390337 _Toc332298453 _Toc332298929 _Toc332299214 _Toc332299493 _Toc332299774 _Toc332300053 _Toc325387380 _Toc325387503 _Toc325390343 _Toc332298459 _Toc332298935 _Toc332299220 _Toc332299499 _Toc332299780 _Toc332300059 _Toc325387383 _Toc325387506 _Toc325390346 _Toc332298462 _Toc332298938 _Toc332299223 _Toc332299502 _Toc332299783 _Toc332300062 _Toc325387386 _Toc325387509 _Toc325390349 _Toc332298465 _Toc332298941 _Toc332299226 _Toc332299505 _Toc332299786 _Toc332300065 _Toc325387389 _Toc325387512 _Toc325390352 _Toc332298468 _Toc332298944 _Toc332299229 _Toc332299508 _Toc332299789 _Toc332300068 _Toc325387394 _Toc325387517 _Toc325390357 _Toc332298473 _Toc332298949 _Toc332299234 _Toc332299513 _Toc332299794 _Toc332300073 _Toc332298476 _Toc332298952 _Toc332299237 _Toc332299516 _Toc332299797 _Toc332300076 _Toc332298480 _Toc332298956 _Toc332299241 _Toc332299520 _Toc332299801 _Toc332300080 _Toc332298484 _Toc332298960 _Toc332299245 _Toc332299524 _Toc332299805 _Toc332300084 _Toc332298486 _Toc332298962 _Toc332299247 _Toc332299526 _Toc332299807 _Toc332300086 _Toc332298490 _Toc332298966 _Toc332299251 _Toc332299530 _Toc332299811 _Toc332300090 _Toc332298494 _Toc332298970 _Toc332299255 _Toc332299534 _Toc332299815 _Toc332300094 _Toc332298495 _Toc332298971 _Toc332299256 _Toc332299535 _Toc332299816 _Toc332300095 _Toc332298498 _Toc332298974 _Toc332299259 _Toc332299538 _Toc332299819 _Toc332300098 _Toc325387398 _Toc325387521 _Toc325390360 _Toc332296711 _Toc332297497 _Toc332298499 _Toc332298975 _Toc332299260 _Toc332299539 _Toc332299820 _Toc332300099 _Toc325387402 _Toc325387525 _Toc325390364 _Toc332296715 _Toc332297501 _Toc332298503 _Toc332298979 _Toc332299264 _Toc332299543 _Toc332299824 _Toc332300103 _Toc325387405 _Toc325387528 _Toc325390367 _Toc332296718 _Toc332297504 _Toc332298506 _Toc332298982 _Toc332299267 _Toc332299546 _Toc332299827 _Toc332300106 _Toc325387408 _Toc325387531 _Toc325390370 _Toc332296721 _Toc332297507 _Toc332298509 _Toc332298985 _Toc332299270 _Toc332299549 _Toc332299830 _Toc332300109 _Toc325387411 _Toc325387534 _Toc325390373 _Toc332296724 _Toc332297510 _Toc332298512 _Toc332298988 _Toc332299273 _Toc332299552 _Toc332299833 _Toc332300112 _Toc325387416 _Toc325387539 _Toc325390378 _Toc332296729 _Toc332297515 _Toc332298517 _Toc332298993 _Toc332299278 _Toc332299557 _Toc332299838 _Toc332300117 _Toc325387417 _Toc325387540 _Toc325390379 _Toc332296730 _Toc332297516 _Toc332298518 _Toc332298994 _Toc332299279 _Toc332299558 _Toc332299839 _Toc332300118 _Toc467844139 _Toc468294642 _Toc468365852 _Toc476237866 _Toc477774604 _Toc478109873 _Toc528579181 _Toc464653162 _Toc468365854 _Toc464653163 _Toc468365855 _Toc528579182 _Toc464653165 _Toc468365857 _Toc528579183 _Toc464653166 _Toc468365858 _Toc528579184 _Toc464653167 _Toc468365859 _Toc528579185 _Toc464653168 _Toc468365860 _Toc528579186 _Toc340066922 _Toc464653169 _Toc468365861 _Toc528579187 _Toc464653170 _Toc468365862 _Toc340066928 _Toc528579188 _Toc464653171 _Toc468365863 _Toc340066929 _Toc528579189 _Toc340066930 _Toc464653172 _Toc468365864 _Toc528579190 _Toc340066931 _Toc464653173 _Toc468365865 _Toc528579191 _Toc340066933 _Toc464653174 _Toc468365866 _Toc528579192 _Toc340066935 _Toc464653175 _Toc468365867 _Toc528579193 _Toc464653176 _Toc468365868 _Toc528579194)))))>>>NNN[[[!i!i!ixxx```ppp@@@ppppqqq~~~ҵҵҵ\\\             %%%<<<FFFIKIKIKQQQiiiqqqBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtrrrrrrrww999   uuuuͫOOOOhhhhKKKg  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOQPRSUTVWXYZ[\]^_`abcdefgh)))))>>>$O$O$O-\-\-\OiOiOiyyyrrr)))             666]%%%1=1=1=(G(G(GpKpKpKBQBQBQiiiDqDqDqBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtBtrrrrrrXXX۔۔۔ՙՙՙ֙SSSTgg4Gg4Gg"V30Ty~mtM_*.Vk ^{ jEz=0[ zw%O*.n`)%-<tpTT+(d:vv6!J#[Z#= y&B``/^?2#  S=3+`086e< B?n|UBN\M;WF>lYwnHJe4q.JF3QWL+,-./0123(SxKU^UфH!W^ex013Y:}Ievv;piP~KrȢ7}628^8`OJQJ^Jo(hHo^`OJQJ^Jo(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJQJ^Jo(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH"ee^e`B* CJOJQJo(ph3hH^`B* OJQJo(ph3hH- ^`o(hH ^`o(hH ^`o(hH ^`o(hH ^`o(hH ^`o(hH ^`o(hH^`OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH ^ `OJQJo(hHT^T`OJQJ^Jo(hHo$^$`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH#^`56CJOJQJaJo(hH Table .  8^`o(hH Section . P^`Po(hH() `p`^``po(hH() P^`Po(hH) P^`Po(hH) ^`o(hH) P^`Po(hH. 0p0^0`po(hH.^`OJQJo(hH^`OJPJQJ^Jo(hH" p^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH,P^`P56B*CJOJQJaJo(phhH Figure .  @@^@`o(hH. 0^`0o(hH.. ``^``o(hH... ^`o(hH .... ^`o(hH ..... ^`o(hH ......  `^``o(hH.......  00^0`o(hH........ hH hH hH hH hH hH hH hH hH^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hHJ^`56789;<>*B* XTCJH*OJQJS*aJo(phI}hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH>hh^h`567;<>*B*CJH*OJQJS*aJo(phhH.>^`567;<>*B*CJH*OJQJS*aJo(phhH.. ^`o(hH ^`o(hH ^`o(hH ^`o(hH ^`o(hH ^`o(hH ^`o(hH^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH^`OJQJo(hH" ^`OJQJo(hH" pp^p`OJQJo(hH" @ @ ^@ `OJQJo(hH" ^`OJQJo(hH" ^`OJQJo(hH" ^`OJQJo(hH" ^`OJQJo(hH" PP^P`OJQJo(hH" OJQJo(hH hH hH hH hH hH hH hH hH ^`hH Article . ^`hH Section . P^`PhH() `p`^``phH() P^`PhH) P^`PhH) ^`hH) P^`PhH. 0p0^0`phH.^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hHh^h`OJQJo(hH8^8`OJQJ^Jo(hHo^`OJ QJ o(hH ^ `OJQJo(hH ^ `OJQJ^Jo(hHox^x`OJ QJ o(hHH^H`OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH^`OJ QJ o(hH^`OJ QJ o(hHpp^p`OJ QJ o(hH@ @ ^@ `OJ QJ o(hH^`OJ QJ o(hH^`OJ QJ o(hH^`OJ QJ o(hH^`OJ QJ o(hHPP^P`OJ QJ o(hH^`OJ QJ o(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH ^`o(hH.  ^`o(hH..  ^`o(hH...  ^`o(hH ....   ^`o(hH .....   ^`o(hH ......   ^`o(hH.......   ^`o(hH........   ^`o(hH......... Z^Z`OJQJo(hH*^*`OJQJ^Jo(hHo^`OJ QJ o(hH ^ `OJQJo(hH^`OJQJ^Jo(hHoj^j`OJ QJ o(hH:^:`OJQJo(hH ^ `OJQJ^Jo(hHo^`OJ QJ o(hHOJQJo(hH hH hH hH hH hH hH hH hH^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hHZ^Z`OJQJo(hH*^*`OJQJ^Jo(hHo^`OJ QJ o(hH ^ `OJQJo(hH^`OJQJ^Jo(hHoj^j`OJ QJ o(hH:^:`OJQJo(hH ^ `OJQJ^Jo(hHo^`OJ QJ o(hH ^`o(hH) ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hH"tM_ z3Q+(d{ O?2UVk .J%-<V386e<S=3(Sz=TyB?}Iev;pi}6M;WFH!WxKU`/wnH013Y6!KrpnUBy&[Z#""hw~  [?D @5D%VJ9$NpNaB ^i6dR=j6J'`g6A0{7~7NpJ9g0hR; h;rI?% tC`% tC[?D?*FYQOdPqjb_AQi6dUbQ0-QYQg0=Q=RpU[?D U]Wi6drOX6Y[?D )=Zg0@s[:x]^NpW^i6dc`Npar$ag0WaqjbE^sdh2h@Wh,_ijk&|llvvn>:nNpXpNppg0)rwPtSQvavNp)[\wapzv=N{`k|r|7|i6d |r$ahS@s[jRM ,n0E4:ACGR[[eSlllz{nP  & ,#6FCUUYghSns\{B}!540:::BCZKMO~UU`episw|$e %++:G&\h !U, CYmbecpH +,6V@GGW[_%b*%256 @^ANOUm]eo:>TBSFH1NYadsfx`E]I}MULVkn r ^0 _H J N 8P S U V ^ f i k mp xq     $ !Z r q  q  ) , 8 'K yW p y  *' ( T4 E OH 5T Z D] d i 2~ q  d   z+ = ]  "$/EZIQL\C`b?cg?hhjkoN %6*j*a/SXcfte J*o6 ?@EABqCEFK=MmMndp|"!)\247Q?TG[RJZZ[e] dfjo %%>A@FqQ@[\_dm!z8C   x).0J5DUZab*i{w m%5?77BfGHL|~   Ac88kDG3OS!UKZ\\D]ew<*{56L"O!UoZ[Ak%R&&B9o:;AL:\\]gikk0{  BUE}JoRKT4kl!llmv 3 7CO]^ gk#@#pA#wI#MQ#X#X#sf#i#q#t#%z#$$}$R $ $C$,$d-$2$ 9$=$"K$T$T$W$d$d$q$%%% %%%]%%y*%5%F?%R%W%ef%n%=s%t% x%cy%}%%=&&/&&&&?&W1&B&E&bO&V&>h&@j&u&|&' ''' '!'x#'>$'.'3'xJ'4a'i'"l'( .(,1(I(L(^T(W(z()))N*)0.)QC)D)P)l)zo)* ***$#*A*C*D*b*@m*m*Mu* v*++;+v+@-+.+7+N+^+f+n+s+,, ,,],*,",$,P4,<,SG,K,\,_,f,Fl,o,q,(-j-0(-.-2-K-S-l-l-u-u-{- ..M.]+.=.xU.X.\.v].g.j.\k.w.z.C{..(////] /$/x-/h1/l5/I9/n;/X/u]/0S0) 00_*010M0N0^Q0Lf0uk0l0 n0Lz0v1H11 1!1@&1I1O1Q1V14Y1[1 _1$_1c1n1s1Wx1x1z1A}1~12O222!2 %2&2-'2V/2H2;L2N2O2Z2a2Db2fb2Jc2Sx2y2y23-33s3k3'3)363tC33R3LX3[3ib3d3g3g3p3Ty3}34h444E4I4N4_T4X4K]47c4Cd4 e4n4Iv4z4x5)5p55.5 5#5%5+5D5b5~c55h6o6Q 6R6%6&616C6H6J6:\62|6}7 77R7$7c77"7'7(7.707G7J7V7>%>/>G4>@>c>h>i>z>z>??b3?=?/??B?M?P?KQ?vS?U?2]?_?g?q?{?@#@&@b'@"0@4@7@ 9@:@?@M@ T@V@`@Az@{@|{@Z A A0 AA1AA$A(A;AXAkAkAkA|AByBH"B1BeHBEKBTB]BaBdB7fBFkB7qBsBxB8zBCzC C C%C%C;CdnC{CDDD&D1D4DdHDMDRD\DeDtsDtD^xDMzD E E< EE_E=ELE_EjEmErEtEtEF|Fi F+FF!F+@FCFuEF^LFLF&UF}ZFbFmF1tFuFF G!G(Gw/G1G8GH:GMG$NGNGNG UGUGVGZG'hGKpGx{GH Ho HHH%Hi9H=H>HTHXH^HAMKM&LMNMQMbRM]M kM}M'N NvN#NG/NZBNBNDNKNKN\NzmNsNHzNN O*OOOMOSFSOSPS]Ss^SeStSvS%TT TBTT!T$T,T@THTENTTTXTjYTYT^TkTCkTyTf{TZTOU U U9 UrUUU#Ud*U+U0U22U7U;UBUDUHUJU.KUTOUHQU ^UfU0oUyUQVaV Vy VV V#V&V )Vm-VQ6V6VYFY}FY>LYLY4OYQYRYvWYhYoYZlZZ"Z,Z3Zp;ZHZ;HZzOZhZSmZpZyZC~Z[t[,[7-[2[=[?[V[%[[l[[.c[Pc[qj[k[\ \\h(\(\*\x,\1\X6\J\ K\Q\3S\Y\a\n\u\x\{\ ]2]]|]^](]{3]@][D]J]K]Q]T]h]Zz]^:^^^8^*^*^J-^<^Z^[^d^t^Lz^c_"____%$_%_V1_B_G_fa_l_Q`*`J `B+`0`O5`D`O`Q`R`[`_```e`dk`#s`{` a:aa4a5aGaMahOaraZsa6zaaY b bbbJ$b3*b6bHbeJbPbVbcc cc/c0c1c4cqAcfchc*kclclc-d d#d,dr.d4d4dL8dVOdSd[d\d,xd(}d,}dveKeKe_Se#[e]efe oewewexze|e~e frf+fff5fKfzPf\[f \f^f gf#lfktfuffgy gggagOgPgPg_Ug*]gbgugh h{hFhhhhq#h#h$hj(h$2hNhXUhWh8\h_hBbhcmh~h iii_3izIibTiViWiCgijiKoiyritiQzijjjj%j'jv)j-j4jFjBRjUjVj.Yj2djujpwj(|j~jekk>kkn$k%k0k::kDkVPkSkck?dkZ{k{ku}kll l l l19lAlZlpltlwl?m1m02m6m7m=m>mOmVmYmK\m.dm1lmn nYnX)n/n9n#:nrmrurrsnsSs s$s.s8s9sFsvCvBDvMvVOv!PvPvvXvosv\|v~vwww=2wU:w\CwmGwRwTwUwbwrw|w ~w)x2x;xBx*Gx2IxOJxfKxZxexixUpxuxvx{xyyAyVIyhyky!uywyz; zzzdz'z-z6z`9z=zOzRzVzgzkzmznz2qz;tzCtz {{{{Z{{>8{:{;K{LR{Qn{s{u{z{S|| |g |||n'|.|":|=|H>|H|lR|[|-\|m|?m|4w|z|} } } }}>}}?}G}W}_}z`}f}f}j}h}}~ ~t ~r~a~~ ~.~?~PC~W~X~]~c~n{~~~C}#935O8<KIhLNRp+w}+2|8^>EIKKSlqr{ f>("(O4ZMWU^_cggrC r(/576:NI`i$lXs]vv 1%'N+UUScTNUZ `lz8 ">''<EIKUKXOZP-Th qqr{5?FCC)QUkdouxA( "C0[7;;J>CFNoauk}m)147BTClGS&bgGr 0.5P6=>S1TEZ`pV a14H68~=\>CD"JMMZX^`fnAotq9K)X[cchkinqpx}4,7PVdkq I (V F!t!%"L%E'7;=@BDR[`fihz}~MX  V58'9p99Y:PS^as:(-2 3f78uKKS1ddRuAxSx zv}t+,R0H3y69_>5?EBNpPco;r#tvh q/:)BSIPWXq y+69:>A+Brb6ejp{.`/\5BD3OTb+{C^.WXY^lry>.()=/4;;=S^^_Ig~U" w=!T'RpWfuhmnznippu}K g!i!'-/7.FPMe]]nFt!$%'#,/58*<<7>DNmtu?3^3<GH)QUYaeg (z+2-9UX;nw~`2wZZ ^ `ejloqz He5&'k/8:yAF?KKK U8Zr[]cZilktw;mQ o#5$)r*5BajOl 3!.83;4e;T>BLE4FaIIKUVWw\x &3>>@nK>WZ\cLgh+prtw z~=S0DEIeIkKqWemx: B!&.=//1JKU\cdgJtw. T#'-1l;%QNS^jw^{} `(9{>9@fyq1 $$ &(6DF _ho prvyIzQ ..0(JO^SX`gFI_JTTT.Xxs|)G0=DMY[cdns{}||)0|13O9hDF LoQ `jo }B,46DaEYfgin oyf %x>>EHKiabfjB \8~>fAHU`[]BDjG\JPS;qDruAxs x-v1N[OfuvD  '4/g3ILN OQ[ce{|}~{ *+,IQJOSgIqt.4J U$+ 0<CGN"gikl|9$1$''++0==;@XXdhp & IF&#+A+7DHPS\acdfmrz.& w.:;M=KDG{c'~} S0PRYace.lu -?h $5.12?BD"FNXllm'osyXzj l5c:<EI XX[cilz $y,-1,@]BByHIWY[bfgktA~~^)5?KyWmx} bg!,#,%@(S*L.y/>DH|NPVb`hyu:\{""3(p,@@B|_R j sDg'*-t.>|MuUZbdf{|RT g1*1,=CV3d %F(09>\O_s`Miw>z|E<AEVOQ,bee]w}y![-:EGIRW X[^`ns~Ta'))4*566GG8RSDT[V] cikvlw{v* :*>AK[y{r(-.01'49dL^ey~*6E==DTtT\`mzj 5#|%M*X/p>DL.RU[pn$'*AF7VY kSz"Q}$%)C1 59'>YC>Q^e`wb}R$YAS*a^jry~- t x(/=BYLjpr\3 u =BJL*P_Zkke F'<A@DL.V>X)_D`Fiov} $q)80;AFrKLeST8_f}kwQ b )*+. 38< PTgpApy|FNPSY[1c2hGijz|~'~~&30gEKQ?V`lY!#c*+.HWY[dk^kc|),4x7.92>XELWUcbxp,sr{"6B8:~TZagdi~ms" !.40055@ACCFKNOQTkn3s|B 5+z1O4E<XKKKfWZ^agp  w**x45S69]:w<<=@hJMU"W\_gjm e~R -$g$>2OTuWQ^SaiXmx|rADBsKV\^gupux ^G5ARX6[^`q.v{ u"&$(JK$LNWhku M'*'2WXMaa$hy}~ Q>+%27=DWM\jYky}} %X/>>BKNwehCjzl )#g4t?@F3MbMof:Y@+FsSZTV:YZefo.w7ymZ(H# q zAHegoyS}'15'57C@AB*N_ghl*ou|{?816y;>RZH[o{ t?()<?HHJ>_qu6l",@-6/j1381:oNgPVWardefys i PAATUzV0qxD @"%/mS`acn v??(HTIJSbXla`m,8x>IMPQa}demv [` 21:?PW(#6>/ADLS\hhv/x~)+(-3~jx}X~TemplateVersion February2010@op~~~f@x@L@@\@ @8 @UnknownG*Ax Times New Roman5Symbol3. *Cx Arial?= *Cx Courier New7.[ @Verdana7.@CalibriG=  jMS Mincho-3 fg;(SimSun[SOWTimesNewRomanMS Mincho5..[`)Tahoma7@CambriaK=   jMS Gothic-3 0000;WingdingsA$BCambria Math"13kG3kGED3MED3MZ4NX  6! xx RMP template 2.0.1 draft"  S      ?   a               ! Oh+'0X     ,8@HPRMP template 2.0.1 draftBE75F9E.dotm1Microsoft Office Word@@@tsu@tsu3ED՜.+,D՜.+,d  `hpx  M RMP template 2.0.1 draftRMP template 2.0.1 draft TitleTitelX`$0@\x     0T\ht _PID_HLINKS DM_Author DM_CategoryDM_Creation_DateDM_Creator_Name DM_DocRefIdDM_emea_doc_ref_id DM_Keywords DM_Language DM_Modifer_Name DM_Modified_Date DM_Modifier_NameDM_Modify_DateDM_NameDM_Path DM_Status DM_Subject DM_TitleDM_Type DM_VersionAP;_Toc528579194;_Toc528579193;_Toc528579192;_Toc528579191;_Toc528579190;_Toc528579189;_Toc528579188;_Toc528579187;_Toc528579186;_Toc528579185;_Toc528579184;_Toc528579183;_Toc528579182;_Toc528579181;_Toc528579180;_Toc528579179;_Toc528579178;_Toc528579177;_Toc528579176;_Toc528579175;_Toc528579174;}_Toc528579173;w_Toc528579172;q_Toc528579171;k_Toc528579170;e_Toc528579169;__Toc528579168;Y_Toc528579167;S_Toc528579166;M_Toc528579165;G_Toc528579164;A_Toc528579163;;_Toc528579162;5_Toc528579161;/_Toc528579160;)_Toc528579159;#_Toc528579158;_Toc528579157;_Toc528579156;_Toc528579155; _Toc528579154=a*whttp://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000683.jsp&mid=WC0b01ac058067a113ch'http://www.hma.eu/464.htmlch$http://www.hma.eu/464.html@*!khttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124chhttp://www.hma.eu/464.html http://www.ema.europa.eu/ http://www.ema.europa.eu/ http://www.ema.europa.eu/ http://www.ema.europa.eu/ciwhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000429.jsp&mid=WC0b01ac0580029590  http://www.ema.europa.eu/ch http://www.hma.eu/464.html@*khttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124 http://www.ema.europa.eu/ http://www.ema.europa.eu/General31/10/2018 14:03:34Semis-Costa NuriaEMA/164014/2018EMA/164014/2018Semis-Costa Nuria31/10/2018 14:03:34Semis-Costa Nuria31/10/2018 14:03:34RMP template 2.0.1 draft/13. Programmes and Projects/zz. Closed projects 2004-2014/00305 - Implementation of the new legislative proposal on pharmacovigilance/Project Organisational Structure/Initial governance structure/Subproject Teams/5. Committees subproject team/Deliverableemea_document1.15,CURRENT  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ACDEFGHIKLMNOPQRSTUVWXcdgRoot Entry F,R%ufData 1TablegWordDocument ;$SummaryInformation(BDocumentSummaryInformation8JMsoDataStoreO%uQ%u21UFAKIAA==2O%uQ%uItem  PropertiesUCompObj r   F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q